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Fve is a 12.7 kDa fungal protein isolated from the Flammulina velutipes mushroom 
and it has previously been reported to trigger immunological responses in both 
mouse and human lymphocytes. In the present study, the immunomodulatory effects 
of Fve on the T cells and dendritic cells (DCs) were investigated. In addition, the 
potential application as an adjuvant for tumor immunotherapy was explored. In vitro 
cell culture experiments showed that Fve stimulated full activation of both purified 
CD4+ and CD8+ T cells to proliferate and secrete high levels of IL-2, IFN-γ, and 
IL-6 accompanied by up-regulation of CD69, OX-40 and 4-1BB in the presence of 
accessory cells such as DCs and B cells. Trans-well studies showed that accessory 
cell-T cell direct interaction was important for T cell’s full activation. Moreover, in 
vitro experiments showed that Fve failed to drive bone marrow-derived dendritic 
cell’s (BM-DC) phenotypic maturation. In contrast, in vivo studies revealed that 
intraveneously injected Fve could drive splenic DC phenotypic and functional 
maturation as indicated by the up-regulation of MHC class II (MHC II) molecules 
and CD86 expression on DCs and the DC’s capabilities of priming both the 
antigen-specific Th1-skewed CD4+ cells and CD8+ T cells. Notably, it was found 
that Fve-activated T cells could provide accessory help to induce phenotypic 
maturation of DC in cell contact-dependent manner. Taken together, these data 
demonstrated that Fve was capable of driving enhanced Th1-skewed polarization 
and CD8+ T cells activity in antigen-specific manner. In view of this, it was 
hypothesized that Fve could act as a vaccine adjuvant to enhance the 
  x
immunogenicity of co-administered antigens. The proof of concept in vitro and in 
vivo studies were carried out with HPV type 16 E7 protein as a model antigen in 
tumor animal model induced by the cervical cancer related E7-expressing TC-1 
tumor cells. 
The results revealed that mice co-immunized with HPV-16 E7 and Fve showed 
increased production of HPV-16 E7-specific antibodies as well as enhanced 
expansion of HPV-16 E7-specific IFN-γ-producing CD4+ and CD8+ T cells as 
compared to mice immunized with HPV-16 E7 alone. Tumor protection assays 
showed that 60% as compared to 20% of mice co-immunized with HPV-16 E7 plus 
Fve or immunized with HPV-16 E7 respectively remained tumor free for up to 167 
days after the tumor cells challenge. Tumor therapeutic assays showed that HPV-16 
E7 plus Fve treatments significantly prolonged the survival of tumor bearing mice as 
compared to those treated by HPV-16 E7. In vivo cell depletion and adoptive T cell 
transfer assays illustrated that CD4+, CD8+ T cells and IFN-γ played critical roles in 
conferring the anti-tumor effects. Therefore, I conclude that the pleiotropic 
immunostimulatory effects of Fve on innate and adaptive immune cells leading to 
enhanced polarization of antigen –specific CD4+ and CD8+ cells can be exploited to 
develop effective adjuvant for anti-cancer and anti-viral vaccines.   
(467 words) 
  xi
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The immune system can discriminate a range of stimuli, allowing some to provoke 
immune responses, which lead to immunity, or preventing some from doing so, 
which we call tolerance. In tumor immunology, tumor immunity or tumor tolerance 
refers to the success or failure of the immune system against tumors, respectively.  
The origin of tumor immunology dates to 1863, when Rudolf Virchow observed 
leukocyte infiltration of tumors and for the first time suggested a possible 
relationship between inflammatory infiltrates and malignant growth. In 1909, Paul 
Ehrhich predicted that the immune system could repress the growth of carcinoma1. 
However, the hypothesis could not be tested experimentally because of a lack of 
quatititative in vitro techniques and the limited availability of molecular tools. Fifty 
years later, Burnet and Thomas proposed a new concept: “immune surveillance.” 
They believed that tumor cell-specific antigens could provoke an effective 
immunologic reaction that would eliminate developing cancers2,3. Despite 
subsequent challenges to this hypothesis over the next several decades4-9, cancer 
immunosurveillance was validated in a series of studies10-12. These studies found 
that antibodies and immune T lymphocytes can be detected in patients with 
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tumors13-22; tumors that have severe lymphocyte infiltration have a better prognosis 
than those that do not23-38; immunodeficient patients have an increased incidence of 
primary and secondary malignancies39-47; and tumor immunity can be demonstrated 
in experimental animal models48,49. 
However, spontaneous tumor eradication was rare. It originally was thought that 
inefficiency of tumor-associated antigen (TAA) specific immunity is due only to 
intrinsic cause: tumors do not represent enough tumor associated antigens; tumor 
antigens have low immunogenecities; antigen-presenting-cells (APCs) do not have 
sufficient stimulatory capacity; or there are not enough effective T cells or B cells.  
Recent work recognized that pathological interactions between cancer cells and 
host immune cells in the tumor environment can create an immune suppressive 
network that promotes tumor growth, protect tumor from immune attack, and thus 
attenuate immunotherapeutic efficacy11,50,51. In the tumor-associated antigen-based 
immunotherapy, poor antigen-specific immunity is not due simply to the failure of 
TAAs passively recognized by adaptive immunity. There is an active process of 
“tolerization” taking place in the tumor microenvironment. These finding have led 
to the development of the cancer immunoediting hypothesis, a refinement of 
immunosurveillance that takes a broader view of immune system–tumor interaction 
that compass both potential host-protecting and tumor-sculpting actions of the 
immune systems throughout tumor development.   
Therefore, successful tumor immunotherapy aims to enhance the TAA’s specific 
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immune response not only by boosting components of the immune system that 
produce an effective immune response intrinsically but also by inhibiting 
components that may induce tolerance. Besides, tumorogenesis is a slow process 
that can occur over several years. Thus, how to generate an immune memory to 
provide long-term protection against tumors also is a key point in tumor 
immunotherapy. 
In this chapter, I first provide evidences to support the existence of the tumor 
immunosurveillance as it occurs in mice and humans and three phases of 
immunoediting process, elimination, equilibriation, and escape. Secondly, I 
summarize recent work on tumor immunotherapy, including vaccination and T cell 
adoptive transfer. Thirdly, I review some adjuvants used in clinic trial, and finally, I 
summarize the objective and significance of my thesis study. 
1.2 Tumor immunology 
1.2.1 Historical Perspective of tumor immunosurveillance 
The validity of the tumor immunosurveillance hypothesis has emerged only 
recently after proposed by Macfarlane Burnet and Lewis Thomas. In 1957, Burnet 
stated52 that small accumulations of tumor cells may develop and provoke an 
effective immunological reaction with regression of the tumor. Almost at the same 
time, Thomas suggested that the primary function of cellular immunity was, in fact, 
to protect from neoplastic disease and maintain tissue homeostasis in a complex 
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multicellular organism2. Later on, several groups of investigators demonstrated: a) 
that the immune system of inbred mice and rats can recognize antigens expressed 
by tumor cells induced by chemical carcinogens; b) that such recognition results in 
rejection of a subsequent challenge of the same tumor in previously immunized 
animals; and c) that immune cells but not antibodies can mediate this reaction53-55. 
Based on these findings, Burnet defined the concept of tumor immunosurveillance 
in 1970 as follows3. In large, long-lived animals, like most of the warm-blooded 
vertebrates, inheritable genetic changes must be common in somatic cells and a 
proportion of these changes will present a step toward malignancy. It is an 
evolutionary necessity that there should be some mechanisms for eliminating or 
inactivating such potentially mutant cells and it is postulated that one of the 
mechanisms is of immunological character.  
The proposal of the immunosurveillance hypothesis quickly was challenged by 
subsequent experimental tests using athymic nude mice4,9. They found that CBA/H 
strain nude mice did not form more spontaneous or chemically induced tumors, nor 
did they show a shortened tumor latency period compared with wild type 
control5-8,56. For example, in an experiment by Stutman, nude mice or control were 
injected subcutaneously with 0.1 mg of the chemical carcinogen MCA at birth and 
were monitored for tumor incidence7. After 120 days, five of 27 nude mice formed 
tumors at the injection site with a mean time to tumor appearance of 90 days. Of 
the control mice tested, seven of 39 formed tumors with a mean time to tumor 
appearance of 95 days. There wase no significant difference between nude mice 
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and their counterpart control when using different doses of carcinogen or mice with 
different age8. Moreover, these observations were supported by studies of Rygaard 
that showed no differences in spontaneous tumor formation in 10,800 nude mice 
over a study period of three to seven months5,6. Due to the limited understanding of 
immunologic defects in the nude mice at that time, these results were highly 
convincing and thus resulted in the abandonment of the immunosurveillence 
hypothesis.  
We know now that there are several important caveats to these experiments that 
could not have been appreciated at the time. Firstly, nude mice have natural killer 
(NK) cells that may provide some tumor immunosurveillance capacity57. Secondly, 
the nude mouse now is recognized to be an imperfect model of immunodeficiency. 
These mice produce low but detectable numbers of functional populations of αβ T 
cells and therefore can manifest at least some degree of protective immunity58,59. 
Thirdly, the CBA/H strain mice used in Stutman’s MCA carcinogenesis 
experiments express the highly active isoform of the aryl hydroxylase enzyme that 
is required to metabolize MCA into its carcinogenic form60,61. Therefore, it is 
conceivable that MCA-induced cellular transformation in CBA/H strain mice 
occurred so efficiently that it masked any protective effect that immunity could 
provide. Nevertheless, the Stutman experiments were considered to be so 
convincing at that time. 
From the 1990s, several key findings invigorated interest in the process of tumor 
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immunosurveillence with the development of technologic advances in mouse 
genetics and monoclonal antibody (mAb) production. Firstly, endogenously 
produced IFN-γ was shown to protect the host against the growth of transplanted 
tumors and the formation of primary chemically induced and spontaneous 
tumors48,62-67 Secondly, mice lacking perforin (pfp-/-) were found to be more 
susceptible to MCA-induced and spontaneous tumor formation compared with their 
wild type64,65,68-71. Thirdly, gene-targeted mice that lack the recombinase activating 
gene (RAG)-2 definitely validated that lymphocytes play a key role in the tumor 
immunosurveillance48,72. Moreover, there was evidence showing that the IFN-γ and 
lymphocyte-dependent extrinsic tumor suppressor mechanisms were heavily 
overlapping48.  
These data, therefore, showed that components of the immune system were 
involved in controlling primary tumor development and overwhelmingly support 
the existence of an effective cancer-immunosurveillance process in mice. 
1.2.2 Components of the Immmunosurveillance Network 
1.2.2.1 IFN-γ in tumor immunosurveillance 
IFN-γ originally was recognized for its capacity to protect naive cells against 
microorganism infection, but now it is known to have a critical role in protecting 
the host from the development of neoplasia and thus has been regarded as an 
obligate component in tumor immunosurveillance. In one work from Dighe, 
Chapter 1 Literature review 
 
 7
LPS-induced tumor rejection was abrogated by injecting neutralizing monoclonal 
antibodies specific for IFN-γ into transplanted Mech A tumors (which are 
MCA-induced fibrosarcoma cells of BALB/c mice)62. In addition, the sarcoma 
induced by MCA grew more aggressively when transplanted into naive mice that 
had been treated with neutralizing IFN-γ-specific monoclonal antibodies. In 
another experiment, a similar result was found in overexpression of 
dominant-negative IFNGR1 mutant to Meth A tumor cells63. These observations 
then were confirmed by a primary tumor formation model. IFN-γ-insensitive mice 
129/Sv mice — lacking either the IFNGR1 subunit of the IFN-γ receptor or the 
STAT1, which is a transcription factor responsible for mediating much of IFN-γ 
biological effects on cells — developed MCA-induced sarcomas at a higher rate 
and three-to-fivefold more frequently than did their wild-type controls66. In 
addition, mice lacking the p53 tumor suppressor gene and either IFNGR1 or 
STAT1 formed a tumors more rapidly than did IFN-γ-sensitive p53-deficient mice, 
and these mice also developed a broader range of tumor types66. A similar result 
was found in an independent experiment by using C57BL/6 mice lacking the gene 
encoding IFN-γ itself64. Furthermore, another study showed that mice deficient in 
GM-CSF, IFN-γ, and IL-3 developed cancer more rapidly than did mice deficient 
in GM-CSF alone, both GM-CSF and IL-3, or IFN-γ alone. This data indicates that 
IFN-γ may cooperate with other cytokines to protect the host from tumor 
formation67.  
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Subsequent studies focused on possible mechanisms of the effects of IFN-γ in 
preventing tumor formation or promoting tumor elimination. In one study, the 
researchers found that highly immunogenic and poorly tumorigenic sarcoma from 
RAG2-deficient mice48 were converted into highly tumorigenic tumor cells with 
poorly immunogenic when there was overexpression of IFNGR1 in the tumors73. 
Moreover, IFNGR1 deficient sarcomas (poorly immunogenic and highly 
tumorigenic) can be rendered highly immunogenic and were rejected when their 
IFN-γ sensitivity was restored by enforced expression of IFNGR174,75. Together, 
these results indicate that the sensitivity to IFN-γ may affect tumor immunogenicity 
in antitumor immune response. Additional work from Shankaran’s lab showed that 
the ability of IFN-γ to promote tumor rejection is mediated, at least in part, through 
its capacity to upregulate the major histocompatibility complex (MHC) class I 
pathway of antigen processing and presentation in tumor cells. The researchers 
chose IFN-γ-insensitive sarcomas (RAD.gR.28) derived from IFNGR1-/- 129/SvEv 
mice for their studies. These tumor cell lines that express low but detectable 
amounts of TAP1 and H-2Kb protein (H-2Kb) were stably transfected with 
expression plasmids encoding the 129/SvEv haplotypes of TAP1 or H-2Kb, and 
clones were selected that expressed high protein levels comparable to those 
expressed in IFN-γ-treated, IFN-γ-responsive cells. Parental RAD.gR28 cells, 
empty vector-transfected RAD.gR28.neo cells, and 2/2 clones of H-2Kb-transfected 
RAD.gR28.Kb cells grew progressively in immunocompetent mice. In contrast, 
TAP1-transfected RAD.gR28.TAP1 cells formed small subcutaneous masses that 
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expanded for the first 5–10 days but then disappeared two weeks after inoculation. 
Subsequent work showed that selective overexpression of TAP1 or H2-Db 
increased the susceptibility of RAD–gR.28 cells to in vitro killing by 
RAD–gR.28-specific CTLs73. These findings indicate that augmented expression of 
components of the MHC class I pathway is sufficient to induce the rejection of an 
otherwise IFN-γ-insensitive tumor. 
1.2.2.2 Perforin in tumor immunosurveillance 
Perforin is a component of the cytolytic granules of cytotoxic T cells and NK cells 
that play an important role in mediating lymphocyte-dependent killing49. It is the 
second key factor in the renaissance of the concept of tumor immunosurveillance. 
In 1994, Kagi et al. found that perforin-deficient (perforin-/-) mice have a reduced 
ability to control the growth of synthetic MC57G fibrosarcoma tumor cells in 
vitro68. Subsequent work showed that perforin-/- C57BL/6 mice were more prone to 
MCA-induced and spontaneous tumor formation compared with wild-type mice in 
vivo64,69-71. Moreover, BALB/c mice lacking perforin also showed a higher 
incidence of spontaneous lung adenocarcinomas, which was not observed in 
wild-type mice65.  
Taken together, these observations demonstrated that deficiencies in key 
immunologic molecules enhanced host susceptibility to both chemically induced 
and spontanesous tumors. Thus, the next question is: what immune cells protect the 
host from tumor development?  
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1.2.2.3 Effector cells in tumor immunosurveillance 
The definitive studies supporting the existence of a tumor immunosurveillance 
process came through the use of gene-targeted mice lacking the recombinase 
activating gene-2 (RAG-2)48. RAG-2 expression is limited to cells of the lymphoid 
system, and its major function is to repair the breaks of double-stranded DNA. 
Mice lacking RAG-2 cannot rearrange lymphocytes antigen receptors and thus 
cannot produce peripheral T, B and NK T cells72. In contrast, the absence of RAG-2 
does not affect DNA damage repair pathways in nonimmune cells. Thus, RAG-2-/- 
mice provide an appropriate model to exclusively study the effects of host 
lymphocyte on tumor development.  
In the MCA-induced tumor system, 129/SvEv and C57BL/6 RAG-2-/- mice 
developed sarcoma more rapidly than stain matched wild-type mice48,76. In addition, 
helicobacter-negative RAG-2-/- 129/SvEv mice developed significantly more 
spontateous epithelial tumors than did wild type control. Specifically, 26/26 
RAG-2-/- mice ranging in age from 13–24 months developed spontaneous 
neoplasia whereas only 5/20 wild-type mice developed spontaneous neoplasia, 
which was predominately benign. Thus, lymphocytes protect mice against both 
chemically-induced and spontaneous tumor formation. 
Subsequent works have extended these findings by identifying which of the 
possible subsets of lymphocytes are involved in host antitumor defense. Girardi et 
al. found in 2001 that lack of either αβ T cells or γδ T cells increase susceptibility 
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to MCA-induced tumor formation in comparison to strain match wild type 
control77-79. Using a carcinogenesis model involving initiation with DMBA and 
TPA, 67 percent of T cell recepter (TCR)δ -/- mice were tumor-bearing versus 16 
percent of wild-type mice at seven weeks. By contrast, TCRβ-/- mice and wild-type 
mice were equally susceptible to DMBA/TPA carcinogenesis77. Interestingly, 
TCRβ-/- × δ -/- mice were more susceptible to DMBA/TPA induced tumor formation 
than TCRβ-/- mice, indicating host-protective role of αβ T cells in the setting of γδ 
T cells79. Thus, different subsets of T cells make distinct contributions to the 
regulation of tumor growth.  
NK and NK T cells also participated in the tumor immunosurveillance. NK cells 
first were shown to effectively eliminate tumor cells from the circulation of 
mice80,81. Subsequent studies showed that NK cells protected the host against the 
initiation and metastasis of MHC-I-deficient tumor cells in an IL-12 and T cell 
independent manner70,82-86. The direct evidence that NK cells protect mice against 
tumors was that NK1.1 depleted mice were more susceptible to MCA-induced 
tumor formation than wild type mice. The roles for NK T cells in the tumor 
immunosurveillance were shown when Jα281-/- mice, which lack a large 
population of Vα14Jα281-expressing invariant NK T cells, were found to develop 
MCA-induced sarcomas at a higher incidence than their wild-type control in an 
IL-12 dependent manner70. Moreover, mice treated with the NK T cell-activating 
ligand α-galactosylceramide (α-GalCer) exhibited a reduced incidence of 
MCA-induced tumors and displayed a longer latency period to tumor formation 
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than control mice87.  
Additional study also showed the overlap between the IFN-γ- and 
lymphocyte-dependent tumor suppressor pathways. Shankaran et al. found that four 
lines of gene-targeted mice formed three times more similar tumors than syngeneic 
wild-type control when injected with a single 100 ug of MCA by comparing tumor 
formation in 129/SvEv mice lacking either IFN-γ responsiveness (IFNGR1-/- or 
STAT1-/- mice), lymphocytes (RAG-2 -/- mice), or both RAG-2 and STAT[RAG-2-/- 
X STAT1-/- RkSk mice]48. No significant differences were detected among any of 
the gene-targeted mice. This indicates that the IFN-γ /STAT1 and 
lymphocyte-dependent tumor suppressor mechanisms overlapped heavily. However, 
RkSk mice also developed spontaneous breast tumors that were not observed in 
wild-type or RAG-2-/- mice, therefore demonstrating that the overlap between the 
two pathways was not complete.  
In summary, using a variety of well-characterized gene-targeted mice, specific 
immune system activators, and blocking monoclonal antibodies highly specific for 
distinct immunologic components, a large body of work overwhelmingly supports 
the basic tenets of the tumor immunosurveillance concept and highlights important 
roles for lymphocytes and cytokines in the tumor immunosuveillance in mice.  
1.2.3 Tumor immunosurveillance in human 
Given that there is significant evidence supporting the existence of a cancer 
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immunosurveillance process in mice, does a similar process exist in humans? Three 
lines of evidence suggest that cancer immunosurveillance indeed occurs in humans: 
(a) Specific antibodies and T lymphocytes can be detected in patients with tumors; 
(b) tumors that have severe lymphocyte infiltration have a better prognosis than 
those that do not; (c) immunodeficient or immunosuppressed patients have an 
greater incidence of primary and secondary malignancies than age-matched 
immunocompetent control populations.  
1.2.3.1 Tumor Recognition by lymphocytes in humans 
In order for the immune system to react against a tumor, the latter must have 
antigens that are recognized as foreign. Chemically induced or spontaneous tumors 
in mice, when transplanted from one syngeneic animal to another, express unique 
tumor-associated antigens. The TAAs of chemically induced tumors are discrete for 
each tumor, whereas those induced by oncogenic viruses are virus specific. TAAs 
are defined functionally by their ability to reject a tumor in preimmunized 
syngeneic mice.  
In humans, the presence of Abs to TAAs and of specific14-19 as well as nonspecific 
effector cells in the peripheral circulation of patients with cancer has been reported 
often. This implies that immune cells and Abs potentially capable of tumor 
rejection exist in these patients. Since the first human tumor antigen was identified 
in 199113, a large array of immunogenic human tumor antigens has been 
identified20-22. These can be classified into six groups: class I HLA-restricted 
Chapter 1 Literature review 
 
 14
cancer/testis antigen; class I HLA-restricted differentiation antigens, e.g., 
melanocyte differentiation antigens, Melan-A/MART-1, tyrosinase, gp-100; class I 
HLA-restricted over expressed antigen, e.g., HER-2/neu; class I HLA-restricted 
mutational antigens, e.g., abnormal forms of P53; viral antigens, e.g., EBV and 
HPV; and Class II HLA-restricted antigens. T lymphocytes (CD4+, CD8+ αβ T 
cells) expressing a unique TCR recognize tumor epitopes in the context of the 
MHC molecules. These T cells, together with B cells producing tumor-specific Abs 
and dendritic cells (DCs) processing and presenting tumor epitopes, are responsible 
for adaptive immunity against tumors. 
In addition to the tumor antigen presented on MHC molecules, transformed cells 
may overexpress other molecules that can function as recognition targets in the 
immunosurveillance process. Several studies have cited the human MHC class I 
chain-related proteins A and B (MICA/B) that are expressed differentially on tumor 
cells and function as ligands for two receptors expressed on cells of the innate 
immune system: NKG2D and the T cell receptor on Vα1 γδ T cells. MICA 
expression was found only on gastrointestinal epithelium of the stomach and large 
and small intestines. However, MICA/B gene expression could be induced in 
certain nontransformed cell lines by heat shock or viral infection88,89. Constitutive 
MICA/B expression has been documented in a high percentage of primary 
carcinomas of the lung, breast, kidney, ovary, prostate, and colon90, melanomas91, 
and hepatocellular carcinomas. Tumor cells expressing MICA/B are killed by 
effector cells with functional NKG2D receptors, and lysis can be inhibited by 
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pretreating the effector cell with blocking NKG2D mAb92. Moreover, Vα1 γδ T 
cells lysed the MICA-expressing target tumor cell by direct MCA binding to the 
γδ TCR93.  
Taken together, these observations indicate that human cancer patients indeed 
develop immune responses to the tumors and, in some cases, these responses may 
eliminate tumor from formation. 
1.2.3.2 Tumor-infiltrating lymphocytes correlates with patient prognosis 
In addition to the supporting data described above, there is accumulating evidence 
showing a positive correlation between the presence of tumor infiltrating 
lymphocytes (TILs) in a cancer patient’s tumor and improved clinical outcome.   
For example, Clemente et al. reviewed 285 primary cuteneous melanoma patients, 
which previously have been divided into three groups (brisk, nonbrisk, and absent, 
according to lymphocytic infiltrates) by Clark24, to verify the relationship between 
TILs and survival. The results showed that brisk patients had higher five and, 
ten-year survival rates than those of nonbrisk as well as absent patients, indicating 
that tumor infiltrating lymphocytes are significant positive histologic prognostic 
factors25. Similar correlation between the presence of TIL and patient survival also 
have been made in patients with cancers of the colon26, breast27, bladder28, 
prostate29, ovary30, rectum31, esophagus32, and neuroblastoma23. Moreover, other 
cases examined the prognostic significance of individual T-cell subsets that 
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infiltrate tumors32-35. Piras et al. reported that CD8+ T cells considered as 
independent, favorable prognostic factors in melanoma and CD4+ T cells also had 
similar distribution34. Finally, NK cell has been reported as a positive prognostic 
factor in breast cancer33, gastric carcinoma36, squamous cell lung carcinoma37, and 
colorectal cancer38.  
1.2.3.3 Immunodeficient or immunosuppressed patients display increased 
incidences of malignancies 
The third line of evidence that tumor immunosurveillance process exists in human 
comes from the findings in patients with primary (congenital) or acquired 
immunodeficiencies, since some of them live long enough to allow tumor 
development39. In some of these patients, the risk of developing cancer is increased 
up to 100-fold. Also, this group develops neoplasms that mostly involve the 
lymphoid system, including NHL, leukemia, and Hodgkin’s lymphoma. Gastric 
carcinoma is the most frequent epithelial cancer reported in these patients. In HIV- 
infected individuals, several types of malignancies may occur and most of them are 
virus-associtated cancers. Kaposi’s sarcoma (KS) and NHL are two most common 
neoplasms46,47. Human papillomavirus (HPV)-related cancers are another type of 
AIDS-related malignancy. There are likely to be two mechanisms by which 
papillomaviruses induce neoplasia — by altering the tumor microenvironment, and 
by directly disrupting cell differentiation, to induce cell proliferation.  
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Other cases are from organ transplant patients undergoing chronic 
immunosuppressive therapy to prevent transplant rejection. Israel Penn et al. found 
that transplant recipients have increased risk in virus-associated neoplasm, in 
pariticular B-cell derived lymphoma, skin cancer, cervical cancer, and Kaposi’s 
sarcoma42.  
Besides, they and other groups of researchers found that increased relative risk 
ratios have been observed in these patients for a broad subset of tumors that have 
no apparent viral origin. Transplant patients were two or three times more likely to 
develop melanoma or non-Kaposi’s sarcomas43,44. Furthermore, analysis of 5,692 
patients who received renal transplants from 1964–1982 in Finland, Denmark, 
Norway, and Sweden exhibited an increased cancer incidence ratio for 
development of a variety of cancers, including those of lung, colon, bladder, kidney, 
ureter, and endocrine tumors compared to the general population41. In Australia and 
New Zealand, assessment of 925 renal transplant patients from 1965 to 1998 
showed increased risk ratios for lung, colon, pancreas, and endocrine tumors, as 
well as melanomas45. Finally, when tumor incidence was examined in 608 cardiac 
transplant patients between 1980 and 1993 at the University of Pittsburgh, the 
prevalence of lung tumors was 25-fold higher than in the general population40. 
Thus, immunodeficiency and immunosuppressed individuals displayed an 
increased probability of developing a variety of cancers. This indicates that the 
immune system appears to be able to give protective immunity in preventing 
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human tumors.  
Thus, after a century of controversy, substantial amounts of direct experimental 
data from mice, coupled with correlative data from humans, show that innate and 
adaptive immunity function together to protect the host against neoplastic disease 
and thereby converge on the original conviction of Burnet and Thomas: 
immunosurveillance exists. 
1.2.4 Tumor immunoediting – refining tumor immunosurveillance 
Based on the data review above, host immune responses should efficiently 
eliminate tumors. However, spontaneous tumor eradication was rare. More and 
more work realized that although the immune system constrains tumor growth, the 
tumor cell might escape this immune pressure. This concept evolved from the 
observation that tumors from immunocompetent hosts and immunodeficient hosts 
have different immunogenicities48,75,94,95. Specifically, tumors formed in the 
absence of an intact immune system could be more immunogenic when 
transplanted into wild type hosts than tumors that arise in immunocompetent hosts. 
This indicates that the immunogenicity of a tumor might be sculpted or edited by 
the microenviroment of the immune systems from which it was derived. In other 
words, the immune systems exert host-protecting as well as tumor promoting 
effects on developing tumors. Because of this dual opposing function of immunity, 
the term tumor immunosurveillance may no longer be appropriate to describe the 
process accurately. Thus, Dunn et al. proposed a broader and more comprehensive 
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hypothesis, “cancer immunoediting,” to replace the original “tumor 
immunosurveillance”12,51.  
In this hypothesis, cancer immunoediting emcompasses three phases: elimination 
(original concept of immunosurveillance), equilibrium (persistence), and escape 
(progression).  
1.2.4.1 Elimination 
Elimination represents the original concepts of cancer immunosurveillance. During 
this phase, innate immunity received the “danger” signal from the developing 
tumor after transformed cells have circumvented the intrinsic tumor suppressor 
mechanism. Macrophage, NK, NK T cells, and γδ T cells are recruited to the tumor 
site. NK cells and NK T cells recognize developing tumors via TCR interaction 
with either NKG2D ligands expressed on tumor cells, whereas γδ T cells interact 
with tumors cells using glycolipid-CD1 complexes. These events lead to IFN-γ 
production that is critical for the progression of the anti-tumor response. 
Specifically, IFN-γ at the tumor site induces the chemokine productions, which in 
turn attract more cells in the innate immune system to the tumor sites and further 
amplify the innate immune response to attack developing tumors. This positive 
feedback also could be seen in the macrophages which secrete low amounts of 
IL-12. IL-12 induces NK cells to secrete more IFN-γ, which can activate 
macrophage leading to a large amount of production of IL-12. Moreover, the 
production of IFN-γ can kill the tumor through antiproliferative, proapoptotic, and 
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antiangiostatic effects. In addition, NK cells can kill the tumor cells via 
perforin-dependent or TRAIL-dependent mechanisms. As a result of this process, 
tumor antigens released from the dead tumor cells can be recognized by DCs in the 
tumor sites. Antigen bearing DCs activated by cytokines and NK cells can migrate 
from the tumor sites to draining lymph nodes, where they activate the adaptive 
immunity by inducing specific CD4+ T cells and CD8+ T cells activation through 
the interaction of MHC-peptide complex and TCR. Activated tumor specific CD8+ 
and CD4+ T cells home to the tumor site, where they participate in the killing of 
tumor cells through direct or IFN-γ dependent mechanisms.  
If the elimination phase is successful in deleting the developing tumor, it will 
represent a complete immunoediting process and won’t proceed to the subsequent 
phase. If not, immunoediting will proceed to the dynamic equilibrium phase in 
which a continuous sculpting of tumor cells produces cells resistant to immune 
effector cells. 
1.2.4.2 Equilibrium 
In the equilibrium phase, tumor cells persist but are “equilibrated” by the immune 
system. This process leads to the immune selection of tumor cells with reduced 
immunogenicity. The evidence comes from studies in which spontaneous or 
chemically induced sarcomas in IFN-γ-receptor-deficient, nude, SCID mice are 
more highly immunogenic than tumors from immunocompetent mice48,70,95-97. 
These findings suggest that the process of host immune selection leads to 
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elimination of   highly immunogenic tumor cells, whereas tumors with decreased 
immunogenicity and non-immunogenic tumor cells still grow.   
Two other test results may support the existence of an equilibration phase. One 
comes from a mouse experiment showing that wild-type mice were tumor free after 
low-dose MCA administration. However, when these mice were depleted of CD4+ 
and CD8+ T cells at day 200 after administration, they rapidly developed sarcomas 
that have unusual growth characteristics when transplanted into naive recipients98. 
More evidence comes from clinical studies in which cancers could be transmitted 
from donor to transplant recipient. Specifically, two renal transplanted recipients 
grew metastatic melanomas one to two years after they received kidneys from the 
same donor99. Upon analysis, it was found that the donor had been treated for 
primary melanoma 16 years before her kidneys were donated but was considered 
tumor free at the time of her death. These observations suggest that the tumors that 
grow rapidly and progressively in an immune deficient or suppression environment 
had previously been maintained in the equilibrium phase by the host or the donor’s 
competent immune system.  
1.2.4.3 Escape 
The final phase of immunoediting is termed escape in which tumor cells actively 
escape from attack of the innate and adaptive antitumor immune response through 
multiple immunoevasive strategies.   
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These include tumor-induced impairment of the antigen presentation machinery, 
activation of negative costimulatory signals in the tumor microenvironment 
(CTLA-4/B7, PD-1/PD-L1, Fas/ FasL), elaboration of immunosuppressive factors 
(IL-10, TGF-β, galectin-1, gangliosides, PGE2), and overexpression of indoleamine 
2,3 dioxygenase (IDO). In addition, cancer cells may promote the expansion and/or 
recruitment of regulatory cell populations that different regulatory cell populations 
contribute to this immunosuppressive network, including CD4+CD25+ regulatory 
T-cells (Tregs) and inducible T regulatory (Tr1) cells that impact negatively on the 
fate of effector T cells. Tumors can directly or indirectly impede the development 
of antitumor immune responses, either through the elaboration of 
immunosuppressive cytokines (such as TGF-β and IL-10) or via mechanisms 
involving T cells with immunosuppressive activities (i.e., regulatory T cells).  
1.3 Tumor immunotherapy  
Tumor immunotherapy is an anticancer approach in which the patient’s immune 
system is stimulated to fight tumors. Over time, our understanding of the immune 
system and tumor immunology has increased. and his has enabled scientists to 
develop specific immunotherapies to enhance the immune response of a particular 
patient against unique targets.  
The earliest reported efforts about cancer immunotherapy date back to 1893, when 
the New York surgeon William Coley noted the regression of sarcomas in patients 
with tumors with attack of erysipelas100. He felt that some of the beneficial effects 
Chapter 1 Literature review 
 
 23
of erysipelas were due to the toxic products produced by the infections. In 1909, he 
reported on 24 patients with sarcoma, eight with carcinoma, and three with 
undefined histology but probably carcinoma or sarcoma: five sarcomas were cured 
and the others had a marked improvement. The results set the scene for similar 
clinical studies over the next four decades. Tumor regression and clinical 
improvement occasionally were seen; cures were very rare.  
Now, the prevailing techniques of tumor immunotherapy can be divided into two 
broad groups called nonspecific and antigen-specific therapies. The latter can be 
attained either by vaccination or adoptive transfer. Vaccination means the 
administration of a particular antigen to induce a specific immune response. 
Adoptive transfer involves the physician transferring direcinto the patient the actual 
components of the immune system that already are capable of producing a specific 
immune response. Nonspecific immunotherapy refers to therapies that can 
stimulate the immune system by using a substance that activates or enhances 
immune cell function regardless of their antigen specificity. In the early days of 
immunotherapy, many nonspecific immunostimulants were tested as antitumor 
reagents in their own right, but today their use in this way has declined. The 
majority of these substances now is recognized for the supporting roles they play, 
such as enhancing cellular communication between immune cells, and therefore are 
being tested for use in combination with antigen-specific immune stimulation. I 
will review the adjuvant effects of nonspecific immunotherapeutic reagents in 
section 1.4. Next, I will focus on the specific immunotherapy.  
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1.3.1 Tumor cell-based immunotherapy 
Vaccination for protection against infectious agents has been one of the most 
successful interventions in medicine101. Twenty-six infectious diseases are 
preventable through vaccination. However, cancer now is outstripping infectious 
diseases as a cause of death in developed countries, and there is an urgent need for 
effective ways to prevent it. In this section, a few examples of anticancer 
vaccination methods, including tumor-based, protein or peptide-based, DC-based, 
and gene-based vaccination, will be reviewed. 
Before the identification of human cancer antigens, cancer vaccine approaches 
depended on immunization with whole cancer cells (both autologous and 
allogeneic preparations) or cancer cell extracts. Autologous tumor cell-based 
vaccine uses cells from the patient’s own tumor that have been treated so that they 
no longer can replicate in vivo.  
Tumor antigens that are not of a viral nature probably will be self-antigen, to which 
the patient would be expected to have higher levels of tolerance. Therefore, 
successful immunization relies on the ability of the vaccine to break tumor-specific 
tolerance. The basis of autologous tumor challenge is, therefore, to generate an 
effective immune response against what is naturally a less immunogenic cancer in 
vivo. Hence, the relevant autologous vaccine should be combined with an adjuvant. 
In one of the earliest trials, autologous irradiated tumor cells administered with 
BCG and pre-treatment low-dose cyclophosphamide to metastatic melanoma 
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patients showed a small but significant number of patients with responses to 
treatment102. Its clinical efficacy was improved by being conjugated to a hapten 
(dinitrophenyl, DNP)103. Later trials in clinics reported that 214 patients with 
clinical stage III melanoma (117 patients with stage IIIC and 97 with stage IIIB) 
treated with multiple intradermal injections of autologous, DNP-modified vaccine 
mixed with BCG had significantly longer durations of relapse-free survival and 
overall survival104,105. Based on these encouraging results, a phase I/II randomized, 
double-blind trial of this vaccine is ongoing106.  
Despite these successes, there also are clear technical disadvantages to this strategy. 
Patients must present with a resectable tumor that can be used to prepare the 
vaccine. Furthermore, it is not unusual for autologous tumor cells to be cultured for 
a period prior to use as a vaccine, often to increase the bulk of the cells. This has 
profound implications for patients whose disease may progress, as exemplified by a 
study from Dillman et al. in which a large proportion of the patients had clinical 
deterioration during the culture period and no longer met the inclusion criteria107.   
An alternative approach is to immunize with cells from allogeneic sources. This 
overcomes the requirement for tumor tissue from the patient and consequently the 
delay in preparation of vaccine, and provides unlimited material for vaccination.  
Knight et al. showed that, in a murine melanoma model, allogeneic cell vaccination 
with the melanoma cell line K1735-M2 prolonged survival compared to 
non-immunized controls. This effect was dose sensitive as 5 × 105 cells gave 20 
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percent long-term protection but 5 × 104 cells gave rise to 100 percent mortality108. 
However, a lung carcinoma cell line was not able to cross-protect against 
melanoma109. This indicates that vaccination with an allogeneic tumor of the same 
type can induce rejection of a tumor while treatment with cell lines of a different 
cancer background does not. Besides, allogeneic whole tumor cell vaccines 
typically consist of cells from more that one tumor line in order to maximaize the 
antigen expression. 
Specifically, a mixture of three cell lines plus a BCG named Canvaxin used to 
vaccinate metastatic melanoma patients showed encouraging results. Phase II trials 
of Canvaxin in stage IV melanoma demonstrated a five-year survival rate of 25 
percent of 157 patients treated with vaccine, compared with only 6 percent of 1,521 
historic controls treated with nonvaccine therapies110. Moreover, they also showed 
further immunological responsiveness in patients with DTH response111 and 
humoral responses112 correlating to clinical response. Another allogeneic vaccine, 
Onyvax-P, is composed of three cell lines (OnyCap23, LnCaP and P4E6) for the 
treatment of hormone-resistant prostate cancer113, and test results demonstrated that 
11 of the 26 patients vaccinated with Onyvax-P showed significant prolonged 
decreases in prostate-specific antigen (PSA) velocity. The median time to disease 
progression was 58 weeks, compared with historical control values of around 28 
weeks. In addition, an analysis of immunological results suggested that a positive 
clinical outcome was correlated with a Th1 cytokine profile in combination with 
the reduction in PSAV.  
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Although there clearly are encouraging results from studies using tumor-cell 
vaccines, none has yet proved to be effective enough for routine use in the clinic. 
Tumor cells generally are poorly immunogenic, at least partly due to heterogeneous 
expression of costimulatory molecules and MHC114. A phase III trial recently was 
stopped as there was no evidence that survival in the treatment arm was diverging 
from that of the control arm, which included the BCG without the allogeneic cell 
component of the vaccine, itself being better than expected115. Therefore, in order 
to prime antitumor immune responses efficiently, tumor cells have been modified 
to express costimulatory molecules such as CD80 and CD86. Preclinical animal 
studies showed that that CD80-transfected tumor cells can elicit CTL responses116 
and protect against tumor challenge in curative models117,118. These data indicate 
that CD80 modification of tumor cells might have some clinical efficacy in treating 
patients. In the clinic, Raez et al. treated 19 patients with relapsed metastatic 
non-small-cell lung cancer with a whole-cell vaccine composed of an allogeneic 
human lung adenocarcinoma cell line transfected with CD80 and either HLA-A1 or 
-A2. The result showed a 32 percent clinical response rate with a median overall 
survival of 18 months compared with a previously reported median survival of less 
than one year for metastatic lung cancer patients119. Besides, cytokine modified 
tumor-cell vaccines have been used clinically. Tumor-cell vaccines modified to 
secrete IL-2, IFN-γ, and GM-CSF have shown clinical effectiveness. A number of 
cytokine-secreting tumor vaccines have been investigated in mouse models but 
have not yet reached the clinic, including IL15120, IL-21121, IL-23122 and IL-27123. 
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1.3.2 Protein or peptide based immunotherapy 
The identification and molecular characterization of human TAAs has opened new 
approaches to the development of cancer vaccines. The first gene encoding a 
human TAA, the melanoma antigen-1 (MAGE-1) was reported in 199113. 
Subsequently, many human TAAs have been identified and characterized124. The 
TAAs can be classified into six groups: class I HLA-restricted cancer/testis 
antigens such as MAGE-3, BAGE, GAGE, and NY-ESO-1; class I HLA-restricted 
differentiation antigens, e.g., melanocyte differentiation antigens, 
Melan-A/MART-1, tyrosinase, gp-100; class I HLA-restricted over expressed 
antigen, e.g., HER-2/neu; class I HLA-restricted mutational antigens, e.g., 
abnormal forms of P53; Viral Antigens, e.g., EBV and HPV; and Class II 
HLA-restricted antigen. When bound to histocompatibility complex molecules, 
TAAs or their peptide can be recognized by T cells and subsequently induces T and 
B cell activation. Therefore, animal and clinical studies were initiated to assess the 
therapeutic potential of active immunization or vaccination with TAAs or peptides 
in patients with cancers. Of all the examples mentioned above, NY-ESO-1 
represents one of the most potent naturally occurring cancer antigens. With the 
exception of the testis, this protein is completely absent from normal tissues, hence 
its categorization as a CT antigen. NY-ESO-1 is found in about 30 percent of breast, 
prostate, and ovarian cancers as well as melanoma. These desirable features—that 
is, rarity in normal tissues, high immunogenecity, and significant presence in a 
relatively broad range of cancers—have made NY-ESO-1 a highly attractive target 
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for specific immunotherapy in certain cancer patients, especially those with 
metastatic melanoma125,126.  
Immunization with whole proteins has some advantages, as they potentially have 
multiple CTL epitopes and T helper cell epitopes not restricted to one HLA type. 
However, since most TAAs are self antigens, they have potential for induction of 
autoimmunity. Another disadvantage is that purified proteins elicit relatively poor 
immune responses on their own.  
Rationally designed peptide vaccines may be able to overcome some of the 
limitations of whole protein vaccination. The main advantage of a peptide-based 
vaccine is that it provides a method for monitoring a specific immune response for 
a particular antigen. Other advantages are as follows: firstly, it bypasses the need 
for antigen-presenting cells to process a whole cell before presenting the antigen to 
the immune system; secondly, administration of a peptide antigen minimizes the 
potential for induction of autoimmunity; and thirdly, the preparation of peptides is 
relatively easy and cost-affordable127. Several studies have utilized single epitope 
peptides in combination with various types of vaccine adjuvants for the therapy of 
tumors128-131. However, each peptide-based vaccine is limited to the number of 
epitopes presented within a peptide vaccine. Lee et al. reported a case of gp100 
peptide vaccination for treatment of a gp100-expressing melanoma132. After the 
vaccination, the patient was found to develop tumor progression that did not 
express the gp100-antigen. And, the tumor-infiltrating lymphocytes isolated from 
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these lesions were not reactive to gp100 but to MAGE-A12, which was not a 
component of the original vaccine. Besides, other important mechanisms of 
immune escape are equally problematic across peptide tumor vaccination strategy 
aimed at generating cellular immune response. Thus, multipeptide vaccines, 
together with MHC class II-restricted peptide133, with a variety of different 
adjuvants134-136, have been investigated in preclinical and clinical studies. 
1.3.3 APC-based immunotherapy 
In general, the success of vaccine strategies depends on the mode of antigen 
delivery, the choice of adjuvant, and the particular antigen being used. Both 
immunity and tolerance are controlled by a network of professional APCs, the most 
important of which are known as DCs 137,138. Tissue-resident DCs that capture 
pathogen-encoded antigens are activated by stimuli generated in the course of a 
pathogen-induced inflammatory response. Activation of DCs occurs in two phases, 
maturation and licensing, and is an essential step that enables the antigen-loaded 
DCs to migrate to the draining lymph nodes. There, the DCs present the peptide to 
naive T cells, thereby inducing a cellular immune response that involves both CD4+ 
T helper 1 (Th1) cells and cytolytic CD8+ T cells139,140. In addition, DCs are 
important in launching humoral immunity, through their capacity to activate naive 
and memory B cells141,142. DCs also can activate NK cells143 and NK T cells144. So, 
DCs can conduct all of the elements of the immune orchestra, and they therefore 
are a fundamental target and tool for vaccination.  
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In 1992, Inaba et al. found that mouse DCs can be cultured ex vivo from bone 
marrow precursors145. In a similar fashion, human DCs can be generated in culture 
from CD34+ hematopoietic progenitors and, more commonly, from peripheral 
blood–derived monocytes146,147. Now, ex vivo-generated, antigen-loaded DCs have 
been used as vaccines to improve immunity148. Numerous studies in mice have 
shown that DCs loaded with tumor antigens can induce therapeutic and protective 
antitumor immunity149. In clinical studies, Vieweg and colleagues showed that 
patients with prostate cancer vaccinated with DCs transfected with mRNA 
encoding tumor antigens such as PSA or TERT, and patients with renal cancer 
vaccinated with DCs transfected with unfractionated tumor-derived mRNA, 
developed tumor antigen–specific CD8+ T cell responses150-153. Banchereau et al. 
demonstrated that patients with metastatic melanoma who were vaccinated with 
DCs pulsed with several melanoma-derived peptides showed a better clinical 
outcome154. These works provided proof of the concept that using DCs as vaccines 
can work. Despite this, the efficacy of therapeutic vaccination against cancer has 
been questioned recently155 because of the undeniably limited rate of objective 
tumor regressions that have been observed in clinical studies so far. A phase III 
clinical trial in patients with stage IV melanoma failed to demonstrate that DC 
vaccination provided increased benefit compared with standard DTIC 
chemotherapy156. The overall response was low in both patient groups (DTIC, 5.5 
percent; DC vaccinated, 3.8 percent)156. However, the question is not whether DC 
vaccines work but how to orient further studies to refine the immunological and 
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clinical parameters of vaccination with DCs to improve its efficacy. It is 
conceivable that the suboptimal nature of the cytokine cocktail maturation protocol 
might have had an important role in the failure of the trial. Pathogen-mediated 
maturation of DCs is done mainly through the Toll-like receptors (TLRs) that are 
expressed on immature DCs and activated in response to distinct microbial 
compounds, PAMPs157. Cytokines, such as TNF-α, IL-1, and IL-6, also are capable 
of promoting DC maturation but cannot substitute for TLR stimulation158. The most 
widely used maturation protocol for human monocyte-derived DCs consist of four 
reagents, TNF-α, IL-1β, IL-6, and PGE2, also known as monocyte conditioned 
media mimic or cytokine cocktail, that were used in above mentioned clinical trial. 
The rationale for including PGE2 in the maturation protocol is to endow the ex 
vivo-generated DCs with the capacity to migrate159, but PGE2, in the context of the 
tumor microenvironment, can mediate Th2 polarization and promote the 
differentiation of DCs secreting the immunosuppressive cytokine IL-10160. 
Therefore, the key negative impact of PGE2 on the function of ex vivo-generated 
DCs probably is the primary reason for the failure. In addition, it is important to 
appreciate the fact that a DC vaccination protocol is a complex, multistep process 
and that a myriad of seemingly trivial steps such as how the cells are frozen and 
thawed, how long the cells are matured, at what speed they are centrifuged, the 
quantity and timing of antigen they load, the mechanics of their administration, and 
the time intervals between boostings can have a critical impact on the outcome of 
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the treatment. Therefore, the complexity of the DC system requires rational 
manipulation of DCs to achieve protective or therapeutic immunity.  
Improving the maturation protocol is a central challenge to improving the DC 
vaccine. Several rapid, two-day “fast-DC” protocols have been developed that 
generate DCs able to stimulate T cell responses in vitro as effectively as DCs 
generated by standard protocols, which usually require seven to nine days of 
culture161,162. In a recently published clinical trial, HER2/neu-positive breast cancer 
patients vaccinated with peptide-loaded DCs generated in a two-day culture of 
monocytes incubated with IFN-γ and LPS induced HER2/ neu-specific CD4+ and 
CD8+ T cell responses and measurable decreases in tumor volume163. Another 
alternative to optimizing the ex vivo DC maturation process is to inject 
antigen-loaded ex vivo-generated immature DCs into sites that have been pretreated 
with adjuvant to induce a local inflammatory reaction164. 
The forms of antigens presented by DCs also could be optimized. Traditionally, 
there are two forms of antigen loading to the DCs165. Firstly, antigens can be added 
exogenously, as peptides, whole proteins, tumor lysate, or apoptotic debris. 
Secondly, the DCs can be engineered to synthesize it endogenously by transfection 
with mRNA or cDNA encoding the antigen.  
Exogenous provision of short peptides presented by the MHC class I and MHC 
class II molecules used to be the favorite form of antigen to load DCs166. Such 
peptides are synthesized by chemical means and are readily available for clinical 
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use. However, the logistical advantage of using peptides is offset by the need to 
determine the MHC haplotype of the patient, the paucity of known tumor-specific 
peptides, and the limited persistence of peptide-MHC complexes on DCs165. Whole 
antigen is more useful because it is likely to contain peptides that can be presented 
effectively by most MHC molecules166. However, use of protein-based antigens to 
load DCs is limited by access to clinical grade reagents. Another approach is to use 
overlapping long (20–25 aa) peptides covering most, but not necessarily all, of the 
coding sequence of the tumor antigen. This approach should provide both MHC 
class I and MHC class II epitopes, does not require knowledge of an individual’s 
MHC haplotype, and seems to be highly effective167.  
The use of antigens encoded by nucleic acid, either cDNA or mRNA, also is 
attractive because their isolation and use in clinical settings is more straightforward 
than the use of exogenously provided peptides and proteins165. However, 
transfection of DCs with cDNA encoding antigen has not proven effective for 
loading DCs with the antigen168. By contrast, transfection of DCs with mRNA that 
encodes antigens has turned out to be an efficient method in both preclinical and 
phase I/II prostate cancer and renal cancer clinical trials169. One main drawback of 
transfection as an approach to expressing tumor-specific antigens in DCs is that the 
antigen is channeled primarily into the MHC class I presentation pathway, limiting 
the generation of effective CD4+ T cell responses170. One approach to rechannel 
cytoplasmic antigens into the MHC class II presentation pathway is to fuse the 
antigens with a lysosomal targeting signal171. This approach has been shown to 
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enhance CD4+ T cell stimulation in vitro172 and augmented the induction of CD4+ T 
cell responses in vaccinated patients151.  
In summary, DCs as APCs have been very well established and accepted in mice; 
multiple clinical trials have been carried out targeting different cancer using 
different methods of generating DCs, different antigens, and different 
antigen-loading techniques173. The ex vivo strategies should help to identify the 
parameters for in vivo targeting of DCs, which is the next step in the development 
of DC-based vaccination. In addition, DC is not the only professional APC to use 
in the setting of cancer vaccination with ex vivo-derived APC. A recent study has 
provided provocative evidence that monocytes loaded with antigens can do just 
about everything that DCs do — migrate to the lymph node and stimulate potent T 
cell immunity174. Even more intriguing are B cells. An increasing number of 
studies have shown that B cells loaded with antigens can stimulate robust T cell 
response in vitro and, more tellingly, in vivo in mice175. Human γδ T cells also have 
been shown to function as potent APCs in vitro176. A key advantage that B cell or 
γδ T cells–based APC has over DC and monocyte is that these two cell types can be 
expanded easily in vitro.  
1.3.4 DNA vaccine 
DNA vaccine based on simple vehicles for in vivo transfection and antigen 
production is a recently developed approach that has the potential to elicit strong 
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and long-lasting immunity while also having several practical advantages over 
other vaccines177-180.   
In the early 1990s, a number of animal model studies first indicated success in the 
delivery system and protein expression of vaccinating with DNA preparations181,182. 
Wolff et al. found that intramuscular injection of naked DNA led to the expression 
of the encoded gene by myofiber cells181. Subsequent study by Ulmer and 
colleagues demonstrated that intramuscular delivery of DNA encoding influenza 
protein nucleoprotein A antigen could elicit a CD8+ T cell immune response 
protective against infection183. This study provided the rationale to develop DNA 
vaccines for therapy of diseases, including cancer.  
With time, a number of murine systems have shown prophylactic and therapeutic 
successes in reducing the spread of cancer through DNA vaccines. And the major 
advantage of DNA vaccines is that both cellular (including CD4+ and CD8+ T cells) 
and humoral immune responses can be induced because the encoded antigen is 
processed through both endogenous and exogenous pathways, and peptide epitopes 
are presented by both MHC class I and class II complexes184.  
Amici et al. showed that DNA vaccine induced a Th1 skewed immune response in 
a transgenic FVB/neu mouse model185. Lindencrona et al. found that DNA vaccine 
encoding HER-2 and GM-CSF can induce Her-2 specific tumor immunity, the 
anti-tumor effect relied on by both CD4+ and CD8+ T cells. And IFN-γ were crucial 
cytokines during tumor rejection186. Kontani et al. showed that mice immunized 
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with a DNA vaccine encoding MUC1 polypeptide were able to reject a challenge 
with MUC1-transfected syngeneic tumor cells187. Vaccination against PSA using a 
DNA vaccine has been investigated as immunotherapy treatment of prostate cancer. 
Pavlenko et al. demonstrated that vaccination with plasmid vector carrying the PSA 
gene results in PSA-specific cellular responses and protection against tumor 
challenge188. Thus, a phase I trial of a PSA DNA vaccine was undertaken in 
patients with hormone-refractory prostate cancer. Among eight patients, a 
PSA-specific cellular immune response and a rise in anti-PSA IgG were detected in 
two patients after vaccination in the highest dose cohort.  
In addition, DNA vaccine encoding virus antigens, which are the cause of 
transformation in a number of tumors, also has been explored in preclinical and 
clinical trials. For example, Chen et al. showed that DNA vaccines encoding HPV 
virus oncogene E7 or E7 fused to LAMP-generated potent antitumor immunity in 
the liver and lung metastases models189. Another study showed that animals that 
received DNA expressing the L1 gene of HPV type 16 intramuscularly, 
subcutaneously, and orally developed systemic anti-L1 IgG antibodies. Specific 
IgA antibodies also were found in vaginal washes from immunized mice. CTL 
activity mediated by CD8+ cells also was achieved. Challenged with a melanoma 
cell line engineered to express the HPV16-L1 protein, mice showed a slower tumor 
growth rate and a longer survival time190. Other vaccines encoding E6 and E7 
epitopes or whole proteins have been used successfully prophylactically and 
therapeutically in animal models191,192. In a phase I clinical trial, a therapeutic 
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HPV16 DNA vaccine, ZYC101, was tested against anal dysplasia. This DNA 
vaccine encoded four multiple HLA-A*0201 epitopes from the E7 protein. Ten of 
twelve subjects demonstrated increased immune responses to the relevant 
epitopes193. A more comprehensive DNA vaccine ZYC101a subsequently was in a 
phase 2/3 clinical trial for cervical dysplasia194. This vaccine is composed of 
complete HPV-encoding sequences contained within ZYC101, in addition to 
regions encoding segments of HPV-16 and HPV-18 E6 and E7 viral proteins. The 
results showed that ZYC101a was well tolerated in all patients and can promote the 
resolution of CIN 2/3 in women younger than age 25. 
In summary, DNA vaccines hold considerable promise as a useful tool to prevent or 
treat tumorigenic growth and subsequent metastasis. However, several hurdles need 
to be overcome before DNA vaccines reach clinics widely. Firstly, it’s difficult to 
choose the proper antigen for DNA immunization. The oncogenic process normally 
is the result of tissue outgrowth with self-antigen over-expression such as CEA and 
MUC1. Cells producing these molecules as a result of transfection with the vaccine 
DNA, such as myocytes, keratinocytes, or DC, would be expected to produce these 
molecules in the form expressed on normal cells rather than the form produced by 
tumor cells and thus promote autoimmunity rather than tumor immunity. Secondly, 
tumor environment might be conducive to evade the immune attack by various 
mechanisms to lead finally to tumor evasion. Thus, in the future, additional tactics 
must be employed in order to achieve an optimum immune response to initiate 
effective long-lived immunity. 
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1.3.5 Adoptive transfer of T cells 
Adoptive T cell immunotherapy (ACT) is a treatment strategy for cancer in which 
T-cells derived from tumor-bearing hosts are activated and numerically expanded 
ex vivo, and then reinfused into the host with a goal of eliminating a tumor and 
preventing its recurrence195-199. Early attempts of ACT therapies using TILs and an 
immunoreplete patient met with some success. Pioneering investigation in the 
1970s by Chester Southam and colleagues demonstrated that subcutaneous growth 
of human tumor autografts to patients bearing advanced cancers was inhibited by 
the cotransfer of autologous leukocytes in about half of the patients200. This finding 
suggested that T lymphocytes with a specific inhibitory effect on the implantation 
and growth of cancer cells were present in many patients and could be used as 
potential candidates for adoptive immunotherapy. 
Later, adoptive T-cell therapy was established in murine models using ex 
vivo-expanded splenocytes as an effective antitumor strategy against syngeneic 
tumor. The antigen-specific CD8+ T cells were identified as an essential immune 
effector in several studies201-203. In some cases, CD4+ T cells also were found to 
play an important helper role204,205 or CD4+ T cells alone were sufficient to mediate 
an antitumor effect206,207. In the clinic, adoptive T cell therapy for cancer focuses 
mainly on therapy with CTLs, TILs, engineered T cells, and the use of adoptive T 
cell transfers to facilitate therapeutic cancer vaccines.  
At present, there is a plethora of suitable CTL targets for many tumors208. In one 
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clinical study, CTLs derived from PBLs were used to treat patients with refractory, 
metastatic melanoma, and eight of the 20 patients had antitumor immune 
responses209. Furthermore, the infusion of autologous melanoma-associated 
antigens recognized by T cells specific (MART-1–specific) CD8+ T cells into a 
patient with metastatic melanoma resulted in T cell infiltration into both the skin 
and tumor tissue210. These results were confirmed in an independent trial in which 
engraftment of the CTLs, which specifically bind tetramers loaded with MART-1 
peptides, was detectable up to two weeks after T cell transfer in all patients, with a 
maximal frequency of 2 percent of the total CD8+ T cells211. Despite this high level 
of engraftment in all patients, only three of 11 patients had clinical antitumor 
responses, and a selective loss of MART-1 expression in lymph node metastases in 
both of two evaluated patients was observed211. Therefore, perhaps the most 
worrisome issue revealed with CTL transfers is the emergence of antigen escape 
variants212,213. 
Another adoptive transfer therapy strategy is to transfer TILs isolated from fresh 
patient biopsy specimens. The adoptive transfer of these cells showed promise in 
preclinical models214, but clinical experiences almost uniformly were 
disappointing215-217. However, two recent studies suggest that prior host 
conditioning with chemotherapy increases the response to adoptive immunotherapy 
with TILs218,219. When 13 patients with progressive metastatic melanoma were 
given cyclophosphamide and fludarabine, a drug regimen that is 
immunosuppressive but does not have anti-melanoma efficacy, six of the patients 
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had objective clinical responses to treatment and four others demonstrated mixed 
responses, with significant shrinkage of one or more metastatic deposits218. This 
approximately 50 percent objective response rate was confirmed in a subsequent 
report from the same group219. Moreover, an alternative vaccine adoptive transfer 
approach may circumvent many of the limitations posed by adoptive transfer using 
TILs. Chang and coworkers carried out a phase I clinical trial in patients with either 
advanced melanoma or renal cell carcinoma220. Patients were vaccinated with 
irradiated autologous tumor cells together with adjuvant BCG. Seven days later, 
draining LNs were removed for activation with anti-CD3 mAb, followed by 
expansion in IL-2. Activated LN cells were administered intravenously with the 
concomitant administration of IL-2. Among the 11 patients with melanoma, one 
had a partial tumor regression, and among the 12 patients with renal cell carcinoma, 
there were two complete and two partial tumor regressions220, suggesting that there 
might be some clinical benefit to this adoptive transfer approach to boost the 
clinical efficacy of therapeutic cancer vaccines. 
Genetic modification of T cells to engineer improved antitumor effects is an 
attractive strategy in many settings221. Introduction of a chimeric antigen receptor 
composed of an antibody-based external receptor and the intracellular domains for 
T-cell signaling provides an efficient means of redirecting T-cell responses to 
surface tumor antigens. These constructs can function to retarget T cells in vitro in 
an MHC-unrestricted manner to attack the tumor while retaining MHC-restricted 
specificity for the endogenous TCR. Three pilot clinical trials recently have been 
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reported. The results showed that the approach was safe, but poor expression and 
persistence of the transgene encoding the T body receptor222 or poor persistence of 
the T cells was observed in vivo223. Methods to enhance survival of adoptively 
transferred T cells include the introduction of costimulatory molecules224 or 
chimeric cytokine receptors composed of an extracellular domain (e.g., GM-CSF 
receptor) and the intracellular signaling molecule for the IL-2 receptor to allow 
antigen-driven, helper-independent proliferation225. Besides, strategies to improve 
effector function may be achieved by countering inhibitory proteins expressed by T 
cells, such as CTLA-4, src homology phosphatase-1, suppressor of cytokine 
signaling, or cbl-b226. Thus, the means to transduce T cells efficiently and to 
maintain transgene function in T cells for adoptive transfer represent surmountable 
challenges, and several promising clinical studies already are under way to evaluate 
the use of genetically modified T cells in cancer.   
In summary, vaccine and adoptive T-cell therapy provides a rigorous means of 
dissecting the requirements for successful immunotherapy and is an increasingly 
feasible treatment modality for patients who have cancer. With recent scientific and 
technologic advances, lessons learned from murine models gradually are being 
translated into clinical trials. Although the majority of studies have been performed 
in patients who have advanced disease, immunotherapy is particularly well suited 
for prevention and for treatment of patients who have low tumor burden. The 
convergence of early disease detection and antigen-specific immunotherapy may 
lead to safe and effective strategies for long-term tumor immunoprotection. For the 
Chapter 1 Literature review 
 
 43
treatment of established tumors, the development of strategies to undermine tumor 
immune escape mechanisms and the integration of adoptively transferred 
antigen-specific T cells in combination with chemotherapy, anti-angiogenesis 
agents, or other targeted molecules will enhance the prospect of achieving and 
maintaining clinical responses in patients who have otherwise refractory disease.  
1.4 Adjuvants – strategies for optimizing vaccine for tumor 
immunotherapy  
Adjuvants (from the Latin, adjuvant = to help) are substances or formulations that 
have been used to improve vaccine efficacy from the early 1920s227,228. It has been 
proposed that adjuvants may act in one or more of five discrete ways229. A 
summary of these is given below230.  
(i) Immunomodulation describes the ability of an adjuvant to modify the cytokine 
network. A high degree of immunomodulation can result in a more rapid response, 
a quantitatively greater response (or less antigen to achieve an equivalent response), 
and the selection of a Th1 or Th2 response. 
(ii) Presentation describes the ability of an adjuvant to maintain the essential native 
configuration of an immunogen for presentation to B cells. A high level of 
presentation should result in an increased proportion of neutralizing antibody, that 
is, antibody that recognizes native epitopes. It is possible that the duration of the 
immune response also may be increased, as a result of an increased availability of 
Chapter 1 Literature review 
 
 44
native antigen to dendritic cells. 
(iii) Cytotoxic T-lymphocyte (CTL) induction describes the ability of an adjuvant 
to deliver antigen in sufficient quantity to the cell cytosol of an antigen-presenting 
cell to permit class 1 processing and subsequent induction of a cluster of 
differentiation of CTL responses. 
(iv) Targeting defines the ability of an adjuvant to deliver antigen more efficiently, 
and even selectively, to immune effector cells. There are many ways in which this 
can be achieved, including use of optimal particle size to achieve draining and 
trapping in lymph nodes, and targeting specific receptors, e.g., the mannose 
receptor on macrophages. 
(v) Depot generation describes the ability of an adjuvant to retain antigen at the 
dose site. Short-term depots usually release antigen over one to two weeks; 
long-term depots may retain antigen for months. Depots increase the efficiency of 
delivery of antigen to an APC by minimizing losses due to liver uptake and 
detoxification. 
Adjuvants can be classified according to their source, mechanism of action, or 
physicochemical properties. Alison231 classified adjuvants into three groups: (i) 
active immunostimulants, being substances that increase the immune response to 
the antigen; (ii) carriers, being immunogenic proteins that provide T-cell help; and 
(iii) vehicle adjuvants, being oil emulsions or liposomes that serve as a matrices for 
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antigens as well as stimulating the immune response. An alternative adjuvant 
classification divides adjuvants according to administration route, namely mucosal 
or parenteral. A third classification divides adjuvants into particulate or 
nonparticulate adjuvants229. A fourth, more recently proposed, system of 
classification divides adjuvants into the following groups: gel-based adjuvants, 
tensoactive agents, bacterial products, oil emulsions, particulated adjuvants, fusion 
proteins, or lipopeptides232. 
At present, there are only four adjuvants worldwide that are approved for clinical 
use: aluminum-based salt (alum), Imiquimod (Aldara), Incomplete Freunds (IFA) 
and a squalene oil–water emulsion (MF59). Although many other adjuvants have 
been proposed over the years and proved to be effective in animal models, these 
have failed to be successful in humans largely because of toxicity, stability, 
bioavailability, and cost.  
For the development of a vaccine for cancer immunotherapy, the prerequisites for 
an ideal cancer adjuvant differ from conventional adjuvants for many reasons. First, 
the tumor Ags usually are self-derived and therefore are poorly immunogenic. 
Second, the patients who will receive the vaccines are immuno-compromised 
because of, for example, impaired mechanisms of antigen presentation, 
non-responsiveness of activated T cells, and enhanced inhibition of self-reactivity 
by regulatory T cells. Third, tumors develop escape mechanisms to avoid the 
immune system. Thus, adjuvants for cancer vaccines, especially therapeutical 
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vaccines, need to be more potent than for conventional infectious vaccines. In 
summary, the ideal cancer adjuvant should rescue and increase the immune 
response against tumors in immuno-compromised patients, with acceptable profiles 
of toxicity and safety. Next, I will review some main adjuvants used currently in 
ongoing anticancer clinical trials. 
1.4.1 Aluminum compounds 
Aluminium adjuvants have been used in practical vaccination for more than half a 
century to induce early, high-titer, long-lasting protective immunity. In general, 
aluminium adjuvants are regarded as safe when used in accordance with current 
vaccination schedules233. Thus, they are the most widely used adjuvants in human 
vaccines.  
The adjuvant activity of aluminium compounds (aluminium phosphate or 
hydroxide) first was described by Glenny and colleagues in 1926. Glenny observed 
that injecting the diphtheria toxoid as an alum precipitate led to a significant 
increase in the immune response against the toxoid234,235. Vaccine preparations 
based on this approach are called alum-precipitated vaccines. However, one report 
from Holt found that such preparations could be highly heterogeneous, depending 
on which anions (such as bicarbonate, sulfate, or phosphate) were present at the 
time of precipitation236.   
In 1931, Maschmann found that aluminium-hydroxide hydrated gels have the 
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ability to adsorb protein antigens from an aqueous solution, and these gels can be 
preformed in a well-defined and standardized way237. Vaccine preparations based 
on this approach are called aluminium-adsorbed vaccines. In 1946, Ericsson 
devised a method by which diphtheria toxoid was coprecipitated into a matrix of 
aluminium phosphate238. Holt, shortly after, demonstrated that preformed 
aluminium phosphate, prepared from equimolar amounts of aluminium chloride 
and trisodium phosphate, acted as an adsorbant and was adjuvant active wisth 
diphtheria 239. At present, preformed hydroxide and aluminium phosphate gels has 
almost completely replaced the alum precipitation in vaccine preparations. 
Occasionally, the word “alum” is used to describe both aluminium hydroxide and 
aluminium phosphate gels.  
The immunostimulating effect of the aluminium adjuvants is highly complex and 
the mechanism is not very well understood. It now is generally accepted that 
aluminium adjuvants are Th2 stimulators because they mainly induce Th2-type 
immune response for many antigens, and are particularly effective in stimulating 
IgE and IgG1 production240. And they are not capable to induce cytotoxic T cells 
and are poor at enhancing delayed hypersensitivity reactions241. Thus, alum is not 
likely to protect against diseases for which Th1 immunity and MHC class I 
restricted CTL are essential for protection, e.g., cancer or tuberculosis. However, it 
is interesting to note that a complex between Al(OH)3 and IL-12 (Al(OH)3/IL-12) 
induced a Th1 response rather than a Th2 reponse when used as an adjuvant242, and 
the Th1-promoting effect of the Al(OH)3/IL-12 complex was augmented greatly by 
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the coadministration of exogenous IL-18243.  In a recent clinical trial, 60 patients 
with high-risk resected melanoma were randomized to receive antigen (melanoma 
peptides gp100, MART-1, and tyrosinase) with either IL-12/alum or 
IL-12/GM-CSF244. The result showed that alum with IL-12 induced sustained 
immune responses and the generation of functional IFN-γ–secreting CD8 T cells as 
compared to IL-12/GM-CSF244. Therefore, a combination of alum with other 
adjuvants might be a new promising strategy for future cancer immunotherapy. 
1.4.2 Mycobacterium bovis Bacillus Calmette-Guérin 
A variety of bacterial cells and their fractions have been used as adjuvants for the 
host stimulation against cancer in both preclinical and clinical situations. The 
mycobacterium bovis bacillus Calmette-Guérin (BCG) strain is a tuberculosis 
vaccine strain that is almost nonpathogenic, yet retains the immunogenic properties 
of tuberculosis245. Several reports have suggested that phagocytosis of BCG 
mycobacteria is a potent inducer of maturation of DCs. Infection of DC with BCG 
facilitated secretion of inflammatory cytokines, including TNF-α, IL-1β, and IL-12, 
and up-regulation of CD40, CD80, CD83, CD86, and MHC class I molecules. 
Immature dendritic cells (iDCs) exhibit potent antigen-presenting ability through 
uptake of BCG246,247. Thus, BCG mycobacteria may serve as an adjuvant in cancer 
therapy.   
In a clinical cancer study, patients were immunized with autologous 
colon-tumor/BCG vaccine or autologous colon tumor alone. PBL from 64 percent 
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of patients immunized with the autologous colon-tumor/BCG vaccine responded to 
the CTAA 28A32-32K antigen, which is a colon-associated tumor antigen, whereas 
only one responded to the CTAA28A32-32K antigen248. In another multicenter, 
randomized controlled phase III clinical trial, stages II and III colon cancer patients 
were randomized to receive either OncoVAX therapy (autologous tumor cells with 
BCG vaccine) or no therapy after surgical resection of the primary tumor. Analysis 
of prognostic benefit in the pivotal phase III trial, with a 5.8 year median follow-up, 
showed that a beneficial effect of OncoVAX is statistically significant for all 
endpoints, including recurrence-free interval, overall survival, and recurrence-free 
survival in Stage II colon cancer patients. For melanoma immunotherapy, Berd et al. 
treated 64 patients with metastatic melanoma using a melanoma vaccine (irradiated 
tumor cells mixed with BCG) preceded by low-dose cyclophosphamide, and 
monitored immunologic effects and antitumor activity. Of 40 assessable patients 
with measurable metastases, five had responses, four complete and one partial, 
with a median duration of 10 months249.  
Besides, intravesical BCG is an effective therapeutic option for patients with 
superficial bladder cancer. A number of randomized trials have been done to 
evaluate the benefit of adjuvant intravesical BCG in intermediate and high risk 
bladder cancer patients after transurethral resection (TUR). Several systematic 
reviews555,556 of these data indicated that BCG adjuvant following TUR 
significantly reduced the risk of recurrence in patients with superficial bladder 
cancer compared to TUR alone.  
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These studies support the idea that BCG may act as an effective adjuvant for the 
active immunotherapy of cancers. To further explore effective components of BCG 
that are responsible for antitumor immunity or the mechanisms by which BCG can 
potentiate the host immune system, it is recognized that the host immune responses 
are enhanced by complete Freund's adjuvant (CFA) containing dead mycobacterial 
cell wall. Azuma et al. reported that the active immunoadjuvant component in 
mycobacteria is cell-wall skeleton (CWS) and examined in detail the biochemical 
and immunologic properties of these CWS fractions250,251. The cell wall skeleton of 
BCG-CWS, consisting of a peptidoglycan covalently linked to arabinogalactan and 
mycolic acids, was identified as an agonist for TLR2 and TLR4252. Now, 
BCG-CWS has been used as an effective adjuvant for patients with various cancers, 
showing possible antitumor effects without any major adverse effects253,254.   
1.4.3 Toll-like receptor ligands 
1.4.3.1 Lipopolysaccharides and its derivate MPL 
Lipopolysaccharide (LPS), a major constituent of the Gram-negative bacterial outer 
membrane, can trigger a variety of inflammatory reactions, including the release of 
proinflammatory cytokines and other soluble factors. The LPS molecule is 
composed of a highly conserved lipid A, a core oligosaccharide, and O-antigen255. 
The lipid A moiety is responsible for the proinflammatory properties of LPS, and 
therefore is a target for the development of medical therapies for the treatment of 
cancer. Recognition of LPS occurs largely by the mammalian LPS receptor — the 
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TLR4–MD2–CD14 complex — which is present on many cell types, including 
macrophages and dendritic cells256. In vivo, LPS has been shown to induce the 
maturation and survival of dendritic cells257 and trigger the release of many 
proinflammatory cytokines, in particular TNF-α, IL-1β, and IL-6.  
In 1943, Shear et al. first demonstrated that LPS had an antitumor effect against 
mouse tumor258. Later, Parr et al. showed that Lipid A had a similar antitumor 
effect as whole endotoxin259. Since then, various types of Lipid A have been tested 
either alone or as adjuvant in therapeutic anticancer vaccine in clinical trials. 
Specifically, Mitchell demonstrated clinical responses in melanoma patients given 
subcutaneous injection of a melanoma vaccine consisting of allogeneic melanoma 
cell lysates plus DETOX adjuvant (consisting of MPL and purified mycobacterial 
cell-wall skeleton). Of the 106 evaluable patients, 20 had objective clinical 
regression of tumor masses, five with complete remission260. In another clinical 
trial, 38 patients with resected stage III melanoma were immunized with a 
polyvalent melanoma antigen vaccine mixed with DETOX. A non-randomized 
control group of 35 patients was treated similarly with vaccine plus alum. Although 
the antibody response rate was significantly higher in the DETOX group (79 
percent) compared with that in the alum group (21 percent), median disease-free 
(DF) survival for the DETOX group (17.8 months) was shorter than that in in the 
alum group (32.1 months).  
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1.4.3.2 TLR 9 agonist-unmethylated CpG dinucleotides 
Oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs directly 
stimulate B cells and DCs, thereby promoting the Th1 and pro-inflammatory 
cytokines and the maturation of professional antigen-presenting cells. Yamamoto et 
al. were the first to report that synthetic ODNs with sequences patterned after those 
found in bacterial DNA could activate NK cells to secrete IFN-γ261. Later, Krieg et 
al. found that specific sequence motifs present in bacterial DNA consisting of an 
unmethylated CpG dinucleotide flanked by two 5’ purines (optimally GpA) and 
two 3’ pyrimidines were responsible for triggering this “innate” immune 
response262,263. They further established that TLR9 in mice is responsible for the 
recognition of CpG motifs by immune cells264, a finding subsequently confirmed 
for humans265,266. TLR9 is narrowly expressed in human B cell and plasmacytoid 
DCs and broadly expressed in B cells, monocytes, and probably all DC subsets of 
mice264-267. It detects the unmethylated CpG dinucleotides that are prevalent in 
bacterial and viral genomic DNAs but are in vertebrate genomes. So far, at least 
three families of immune stimulatory CpG ODN with distinct structural and 
biological characteristics have been described268 — A-class CpG ODN (also known 
as D type), B-class CpG ODN (also known as K type), and C-class CpG ODN. 
Most studies of CpG activity utilize B-class CpG, which are strong B cell 
stimulators but induce relatively little pDC secretion of IFN-α. 
CpG enhances tumor-associated antigen-specific humoral and cellular responses to 
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a wide variety of antigens, including peptide or protein antigens, dendritic cell 
vaccines, and autologous cellular vaccines in both prophylactic and therapeutic 
vaccines in numerous animal models269-273. The mechanisms that contribute to the 
strong adjuvant activity of CpG ODN potentially include synergy between TLR9 
and the B-cell receptor, which preferentially stimulates antigen-specific B cells262; 
inhibition of B-cell apoptosis274; enhanced immunoglobulin G (IgG) class switch 
DNA recombination275,276; and dendritic cell maturation and differentiation, 
resulting in enhanced activation of Th1 cells and strong CTL generation. 
Conjugation of a CpG ODN directly to an antigen can enhance antigen uptake and 
reduce antigen requirements277. Comparisons of different adjuvants in mouse 
models have demonstrated CpG ODN to be unsurpassed at inducing Th1-type 
responses278,279. The Th1 bias induced by TLR9 stimulation is maintained even in 
the presence of vaccine adjuvants such as alum or IFA that normally promote a 
TH2 bias280,281. 
In humans, most types of immune cells do not express TLR9, and so are not 
activated directly by CpG DNA. All of the cellular immune effects of CpG ODN in 
humans are thought to result directly and indirectly from activating 
TLR9-expressing plasmacytoid DC and B cells. TLR9-stimulated B cells and pDCs 
show increased expression of costimulatory molecules (such as CD80 and CD86), 
resistance to apoptosis, upregulation of the chemokine receptor CCR7, and 
secretion of Th1-promoting chemokines and cytokines, such as monocyte 
inflammatory protein-1 (MIP-1), IFN-γ-inducible 10-kDa protein (IP-10) and other 
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IFN-inducible genes282. pDC activated through TLR9 secrete IFN-α, which drives 
the migration and clustering of pDC in the marginal zone and outer T-cell areas of 
the lymph node, where they are better able to stimulate adaptive immune 
responses283. Co-activation of naive, germinal center or memory B cells through 
the B-cell-antigen receptor and TLR9 induces their differentiation into plasma 
cells284; for memory B cells, activation through TLR9 alone is sufficient to drive 
differentiation to plasma cells285. Moreover, the efficiency of CpG-induced plasma 
cell differentiation could be enhanced by interactions with pDC, together with 
B-cell receptor crosslinking286.   
In clinical trials, CpG ODN has been used as adjuvant for hepatitis B vaccination 
either in combination with alum287 or alone288. In a randomized, double-blind 
controlled Phase I/II dose-escalation study, healthy individuals received three 
intramuscular injections of an alum-absorbed HBV vaccine either in saline or 
mixed with a B-class ODN, CPG 7909287. HBsAg-specific antibody responses 
appeared earlier and had higher titers at all time points from two weeks after the 
initial prime up to 48 weeks in CPG 7909 recipients compared with those 
individuals who received vaccine alone. Moreover, most of the subjects received 
CPG 7909 as adjuvant developed protective levels of anti-HBs IgG within just two 
weeks of the priming vaccine dose, compared with none of the subjects receiving 
the commercial vaccine alone287. In another small clinical trial, eight melanoma 
patients received four monthly vaccinations of low-dose CpG 7909 mixed with 
MART-1 analog peptide and IFA. All patients exhibited rapid and strong 
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antigen-specific T cell responses: the frequency of Melan-A-specific T cells was 
more than 3 percent of circulating CD8+ T cells, significantly higher than the 
frequency seen in eight control patients treated similarly but without CpG. The 
enhanced T cell populations consisted primarily of effector memory cells, which in 
part secreted IFN-γ and expressed granzyme B and perforin ex vivo289.  
Taken together, the results from animal studies and human clinical trials show that 
stimulation of TLR9-expressing cells is sufficient to induce strong and sustained 
humoral and cellular memory immune responses, offering several advantages over 
conventional vaccines. The adjuvant effect of CpG may have three components: a 
CpG-induced enhancement of APC function; a CpG-dependent induction of a 
cytokine/chemokine microenvironment supportive of antigen-specific immunity; 
and an improvement in antigen uptake mediated by DNA-binding receptors on 
APCs. 
1.4.4 Heat shock protein 
Heat shock proteins (HSPs) are ubiquitous soluble intracellular and highly 
conserved molecules that are present, and can be induced, in all eukaryotic and 
prokaryotic species, including plants. They were discovered in 1962 when Ritossa 
noted that temperature shock had induced odd puffing patterns and an unusual 
profile of gene expression in the polytene chromosomes of salivary glands in 
Drosophila melanogaster larva290. In 1974, the first products of these genes were 
identified and termed heat shock proteins291. Later, it became known that in 
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addition to raised temperature, exposure to oxidative stress, nutritional deficiencies, 
ultraviolet irradiation, chemicals, ethanol, viral infection, and 
ischaemia-reperfusion injury also can induce the expressions of these proteins292-297. 
Heat shock proteins are categorized into several families that are named on the 
basis of their approximate molecular weight (e.g., the 60 kDa Hsp60 family). They 
can exist in an unbound state or bound to specific client proteins. HSPs function as 
molecular chaperones in numerous processes, such as protein folding, assembly 
and transport, peptide trafficking, and antigen processing under physiologic and 
stress conditions.   
The immunological functions of HSPs began to emerge in the 1980s when 
Srivastava et al. found that homogeneous preparations of certain HSPs that were 
isolated from cancer cells elicited immunity to cancers, whereas corresponding 
preparations from normal tissues did not298. The protein that induced tumor 
protection has been shown to be the heat shock protein gp96. Later, the heat shock 
proteins calreticulin, Hsp70, Hsp90, and grp170 also were shown to elicit similar 
effects by similar mechanisms299-304. Now, HSPs have been demonstrated to 
activate CD8+ and CD4+ lymphocytes; induce innate immune response including 
NK cell activation and cytokine secretion; and induce maturation of dendritic 
cells305-307. 
Autologous heat shock protein-peptide complexes produced from each patient's 
tumor is a logical personalized strategy that may obviate the need to identify the 
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unique antigens contained in the individual vaccine. Clinical trials have been 
performed to define the safety and characterize immunologic responses of 
autologous HSPs in immunotherapy for cancer. Autologous HSP-based 
immunotherapy studies in humans started in 1995 in Berlin and 1997 in New 
York308. Now, the gp96 HSP-peptide complexes (HSPPC-96) have been evaluated 
in early trials of pancreatic cancer309, gastrointestinal tract cancers310, lymphoma311, 
chronic myelogenous leukemia, renal cell carcinoma312 and melanoma313. For 
example, in one clinical trial, two of 28 melanoma patients vaccinated with 
HSPPC-96 had a completed response and three had stable disease at the end of 
follow-up. ELISPOT assay with PBMCs of 23 subjects showed a significantly 
increased number of postvaccination melanoma-specific T-cell spots in 11 patients, 
with clinical responders displaying a high frequency of increased T-cell activity313. 
Similar immune response and related clinical significance also was found in 
vaccine treated patients with colorectal cancer310 and with pancreatic 
adenocarcinoma309. Recently, the results of a randomized, open-label, multicenter 
Phase III trial in patients with stage IV melanoma were announced314. In this trial, 
HSPPC-96 was given once weekly for the first four weeks and every other week 
after that. The control patients received the physician's choice, typically including 
IL-2 and/or dacarbazine/temozolomide, and/or tumor resection. Approximately 300 
patients were accrued and randomized 2:1 in favor of HSPPC-96 treatment. The 
results showed that the survival plots of vaccine-treated and control patients were 
quite similar. However, when the data were analyzed for the sub-stages of stage IV 
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melanoma, the patients in the M1α category in the vaccine treatment group 
survived an estimated median of 626 days as compared with 383 days in the 
control patients. In another clinical trial done by Wood557, patients who had 
nephrectomy were randomly assigned to receive either HSPPC-96 or observation 
alone. The results showed that patients with earlier stage (patients with T1, T2 and 
T3a diseases) of renal carcinoma drew clinical benefit from HSPPC-96 treatment 
with better prognosis whereas those with later stages did not. 
Another strategy is to transduce tumor cell lines with HSP. This approach could be 
particularly promising in tumors in which dominant antigens are poorly 
characterized or a single HSP-antigen complex is inadequate to confer protection. 
Wang et al. showed that CT26 colon carcinoma cells transduced with cDNA of 
Hsp110 had reduced tumor growth as compared to the wild-type CT26 tumor in 
immunocompetent mice315. Immunization of mice with inactivated CT26-HSP110 
cells significantly inhibited the growth of wild-type CT26 tumor315. Huang et al. 
demonstrated that vaccination with an engineered melanoma cell line expressing 
HSP 70 led to augmentation of NK and CTL activities and protection against tumor 
challenge in mice316.  
In summary, HSPs are potent inducers of immunity and have been harnessed as 
vaccine adjuvants targeted to cancers. HSP-based vaccine strategies — including 
vaccines derived from patient tumor material and from transduced tumor cells lines 
— are promising for immunotherapy. Advanced clinical studies using autologous 
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tumor-derived HSPs are underway. 
1.4.5 Cytokines 
1.4.5.1 IL-2 and its family members 
IL-2 is a 15,000-KDa a-helical cytokine produced predominantly by activated 
CD4+ and CD8+ T cells. It is produced rapidly and transiently upon engaging the 
TCR and costimulatory molecules such as CD28 on naive T cells. Activated DCs, 
NK cells, and NK T cells also produce IL-2. IL-2 stimulates the proliferation of 
activated T cells and facilitates the induction of CTLs. Moreover, it induces the 
proliferation of B cells that have been stimulated with IgM-specific antibody or 
CD40 ligand. IL-2 also stimulates the generation, proliferation, and activation of 
NK cells148.  
In 1985, IL-2 combined with autologous lymphokine-activated killer cells first was 
used to treat patients with metastatic cancer317. After that, a series of clinical trials 
that combined various cancer vaccines with IL-2 have been published. In an early 
randomized clinical trial558, IL-2 was administered alone or with LAK cell in 181 
patients, 97 had renal cell cancer and 54 had melanoma. There were 10 complete 
responses among the 85 assessable patients who received IL-2 plus LAK cells, 
compared with four among the 79 who received IL-2 alone. Complete response 
continues in seven patients at 50-66 months. Improved survival was seen for 
patients received IL-2 plus LAK cells compared with those who received IL-2 
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alone ((36-month survival: 31% versus17%).  
In another clinical trial done by Rosenberg, IL-2 could enhance the anti-tumor 
activity of the gp100 peptide vaccine318. Eight of 19 patients who received the 
peptide plus high dose IL-2 were seen with objective remissions, whereas no 
objective cancer regressions were seen in any of the 11 patients who received the 
peptide in incomplete Freund's adjuvant. In a recent phase II clinical trial559, A 
recombinant modified vaccinia virus Ankara (MVA) encoding human 5T4 
(MVA-5T4) combined with high dose IL-2 were given by intramuscular injection 
to 25 of patients with metastatic renal carcinoma. The results showed that the 
combination treatment induced higher levels of 5T4-specific humoral and cellular 
immunity as compared to the MVA-5T4 alone560. Twelve patients had stable 
disease, which was associated with increased effector T cells. 
Because high doses of IL-2 have toxicity317,319, subsequent trials tried to use low 
doses of IL-2 but got frustrating results134,320-322. Thus, there are no convincing data 
to support combining various vaccines with lower doses of IL-2 except for one 
report from Rosenberg’s study318. 
Much data now support an essential role for IL-2 for Treg production323,324. These 
ideas are much different from the early paradigm in which IL-2 is central for 
immune responses by promoting T cell growth and effector differentiation. For 
cancer patients, increasing Treg cells is likely to be detrimental by preventing 
induction of tumor-specific T cell responses and may explain the limited efficacy 
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of IL-2 in antitumor therapy. Now, two new family members, IL-15 and IL-21, 
have been indentified. They share some immune-stimulating activities with IL-2 
but are not primarily involved in immune-regulation, and have been proposed as 
alternative candidates for cancer immunotherapy325,326. 
1.4.5.2 IL-12 and its family members 
IL-12 is a heterodimeric protein composed of two covalently linked p35 and p40 
subunits and first was recovered from the supernatant of phorbol-ester-induced 
EBV-transformed B cell lines327,328. Its biological functions are mediated by the 
IL-12 receptor composed of two chains (ß1 and ß2)329. IL-12Rβ1 binds IL-12 p40, 
and it is associated with Tyk2, whereas IL-12Rβ2 recognizes either the heterodimer 
or the p35 chain and is associated with Jak2. Signaling through the IL-12 receptor 
complex induces phosphorylation, dimerization, and nuclear translocation of 
several STAT transcription factors (1, 3, 4, 5), but the predominant response and 
most of the biological responses to IL-12 are mediated by STAT4330. IL-12 is 
produced mostly by activated hematopoietic phagocytic cells (monocytes, 
macrophages, neutrophils) and dendritic cells. It is a potent inducer of IFN-γ 
production from T, NK, and other cell types, and it has been shown to be a potent 
inducer of differentiation of Th1 cells331.    
The antitumor and adjuvant activities of IL-12 have been shown extensively in 
murine models, including melanomas, mammary carcinomas, colon carcinoma, 
renal carcinoma, and sarcomas332. In clinic, it has been investigated in patients with 
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advanced solid tumors and hematologic malignancies, as either monotherapy or in 
combination with antigen-associated proteins as adjuvant. For example, Lee et al. 
immunized 48 patients with stage III or IV melanoma with two tumor peptides 
derived from gp100 and tyrosinase, with or without s.c. administration of IL-12. 
IL-12 augmented peptide-specific delayed-type hypersensitivity reactivity to the 
gp100 antigen in 34 of 40 patients333. Moreover, the treatment boosted the 
gp100-specific and tyrosinase-specific peripheral immune response, as measured 
by IFN-γ release in 37 of 42 patients333. In another trial done by Cebon et al.334, 
IL-12 was administered s.c. or i.v. in 21 of stage III or IV melanoma patients 
expressing Melan-A in their tumors. Melan-A peptides were administered 
intradermally. One patient achieved complete response and one had stable disease 
in the i.v. arm. One patient achieved partial response, and five had stable disease in 
the s.c. arm334. Peterson et al. reported a trial in which 20 advanced melanoma 
patients were immunized with PMBC loaded with Melan-A/Mart-1 peptide plus 
IL-12. The results showed that two complete responses, five minor or mixed 
responses, and four stabilizations of disease were achieved. The overall median 
survival was 12.25 months and seven patients remained alive at the time of data 
analysis, with all patients followed for more than 12 months335.    
Systemic administration of IL-12 in cancer patients is limited by toxicity. IL-12 
gene therapy might be an alternative strategy. Based on the promising results 
obtained in preclinical IL-12 gene therapy studies336, clinical trials have been 
designed with the aim of achieving production of the cytokine at the tumor site, 
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while maintaining low serum concentrations to reduce systemic toxicity. In one 
study conducted by Sun et al., patients with melanoma received s.c. injections at 
weekly intervals of autologous tumor cells transduced with IL-12337. Two patients 
developed delayed-type hypersensitivity reaction against their autologous 
melanoma cells and one had a minor clinical response337. 
In addition, two new family members, IL-23 and IL-27, have been discovered. 
Similar to IL-12, IL-23 and IL-27 are produced predominantly by macrophages and 
dendritic cells and affect IFN-γ production by T and NK cells338. All three 
cytokines (IL-12, IL-23, and IL-27) seem to play roles in the priming and 
reactivation of polarized T cell responses. In murine models, IL-23 as adjuvant has 
been used to treat tumors effectively339. Thus, further clinical studies could be 
developed by exploiting the antitumor effects of new IL-12 family members and 
combining IL-12 with its new members.   
1.4.5.3 GM-CSF 
GM-CSF has been shown to stimulate monocytes and neutrophils, reducing the risk 
for febrile neutropenia in patients with cancer. It also augments the numbers and 
activity of DCs, enhancing cellular immunity340. A number of clinical trials have 
utilized GM-CSF as an adjuvant for cancer vaccines. 
GM-CSF has been administered with irradiated autologous or allogeneic melanoma 
cells and transduced into these types of cells111,341 or combined with tumor peptides 
Chapter 1 Literature review 
 
 64
to enhance immune responses342,343. For example, in a study done by Weber et al.343, 
48 patients with resected stage IIA or IIB melanoma were immunized with gp100 
and tyrosine in IFA, with or without GM-CSF. Immune responses were seen in the 
majority of patients post-vaccination. There was a trend for GM-CSF to increase 
modestly the levels of immune activation as measured by all these assays. In 
another phase II clinical trial, 25 patients with melanoma were immunized with 
three melanoma HLA-A2-binding peptides344. Patients were randomized into three 
groups: (i) peptides with Montanide ISA-51; (ii) peptides + Montanide + GM-CSF 
10 μg; or (iii) peptides + Montanide + GM-CSF 50 μg. Nine patients showed a 
successful immune response, as measured by delayed-type hypersensitivity testing 
to gp100 peptides. There did not seem to be any evidence of an enhanced immune 
response by combining the vaccine with either of the low-dose GM-CSF regimens 
used. The authors concluded that higher doses of GM-CSF may be needed. This 
conclusion may be supported by a randomized phase I clinical trial345. Twenty 
staged IIB, III or IV melanoma patients were immunized with VACCIMEL (The 
vaccine VACCIMEL consisted of three irradiated allogeneic melanoma cell lines 
with BCG as an adjuvant). Besides, patients received local injections of placebo, 
GM-CSF 150, 300, 400, or 600 μg split into four doses. The result showed 
GM-CSF induced statistically significant increased DTH reactions, with the 
maximal effect occurring in the 400 μg high dose group. 
GM-CSF also has been fused with tumor-associated antigen and used to pulse 
antigen-presenting cells as a vaccine. A variety of tumor types, both hematological 
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cancers and solid tumors, have been shown in phase I/II studies to respond to 
adoptive therapy using antigen-primed DCs, including myeloma346, lymphoma347, 
prostate cancer348, melanoma154, and colon cancer349. Research by Small and 
colleagues, for example, evaluated immunotherapy of HRPC (hormone-refractory 
prostate cancer) with antigen-loaded DCs348. The DCs had been loaded ex vivo with 
a recombinant fusion protein composed of prostate-specific acid phosphatase (PAP) 
linked chemically to GM-CSF. Patients who had evidence of an immune response 
to PAP had a longer progression-free survival interval than patients with no 
evidence of immune response, suggesting that induction of immunity was 
associated with clinical response348. 
1.4.6 Costimulatory molecules 
For effective T cell immune response, recognition of antigen (signal 1) — 
interaction of CD3/TCR complex with peptide-MHC complex expressed on APCs 
— is not efficient. An additional signal from a costimulatory receptor (signal 2) is 
required for T cell activation. The costimulatory receptor can be divided into two 
main groups: the immunoglobulin superfamily, such as B7/CD28 (CD28 is a 
receptor for B7-1 and B7-2), and TNF/TNFR superfamily. 
1.4.6.1 B7/CD28 Family 
A CD28 signal is considered to be the primary costimulatory receptor that controls 
initial clonal expansion and provides early signals to augment expression of 
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anti-apoptotic members of the Bcl-2 family to prevent cell death350. It also 
regulates early cytokine production in particular IL-2, and IL-2R signals may 
provide additional early anti-apoptotic signals351. B7-1(CD80) and B7-2(CD86) 
have been used in various cancer therapies by fusing them with Ig352-354, 
overexpressing them on tumor cells355-358. When translating these findings into 
clinic for treatment with 12 metastatic melanoma patients, 50 percent of the 
injected lesions remained stable or regressed after vaccination, an objective clinical 
response was observed in one patient, and disease stabilization in two others359. 
Besides, Orabona C et al, found that CD28-Ig can induce DCs to secrete IL-6 and 
IFN-γ, thus eradicated a growing tumor in vivo360.  
The obstacle of using CD28 ligand as an adjuvant is that B7 also bind to another 
receptor CTLA-4 which has been shown to inhibit T cell response and regulate 
peripheral T cell tolerance361-364. A monoclonal antibody that blocks CTLA-4 
binding has been developed and has been studied extensively as a means to 
overcome immune checkpoints and break tolerance365. A CTLA-4 blockade has 
entered clinical trials for patients with a variety of tumors, including prostate, 
ovarian, breast, colon, renal carcinomas, and melanoma365,366.  
More recently, several new B7/CD28 family members have been identified that 
integrate into stimulatory or inhibitory activity for T-cells. The five new B7 family 
members, ICOS ligand, PD-L1, PD-L2, B7-H3, and B7-H4, mainly are expressed 
on APCs as well as on cells within lymphoid organs, providing new means for 
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regulating T cell activation and tolerance363,367. The new CD28 family members, 
ICOS, PD-1, and BTLA, are inducibly expressed on T cells and are important for 
regulating previously activated T cells363. Investigation of applications of these new 
costimulatory molecules in cancer therapy is underway368,369. 
1.4.6.2 TNF/TNFR Family 
Several members of the TNF/TNFR family function after initial T cell activation to 
sustain T cell division and promote T cell survival370. CD40/CD40L (CD154), 
OX-40L/OX-40 (CD134), 4-1BBL/ 4-1BB (CD137), LIGHT/HVEM, 
CD30L/CD30, CD70/CD27, GITR L/GITR, all can have costimulatory effects on 
T cells and thus can be potential targets for tumor immunotherapy.  
CD40 is expressed on a wide range of cells including APCs — such as DCs, 
macrophages and B cells — as well as on cells with high proliferative potential, 
including tumor cells371. Its ligand CD154 is up-regulated on T cells after CD28 
signaling371. Evidence for the role of the CD40–CD154 signaling in enhancing 
antitumor immunity came initially from studies that demonstrated that conferring 
CD154 expression to tumors is sufficient to promote regression of some 
transplantable murine tumors372,373. Thereafter, a soluble form of CD154 as well as 
an anti-CD40 antibody was proved to have antitumor effect in animal models374,375. 
A phase I clinical trial delivered recombinant human CD40L protein systemically 
to patients with advanced non-Hodgkin’s lymphoma or solid tumors376. Of the 32 
patients treated, one subject achieved a complete response, one a partial response, 
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and 12 achieved stable disease. And clinical trials with anti-CD40 monoclonal 
antibodies are ongoing377.  
OX-40 is expressed primarily on activated CD4+ T cells with some CD8+ T cells 
after TCR engagement. OX40 can costimulate some IL-2 production and blocking 
OX40 signaling suppresses the accumulation of effector T-cells370,378,379. 
Furthermore, OX40 costimulation appears to be most important in T-cell memory 
responses370,379. Another important function of OX-40 is to sustain the expression 
of anti-apoptotic Bcl-2 family members, hence promoting cell survival380. The 
potent biological effects observed following OX40-mediated signaling imply that 
OX40 might be an excellent target for cancer therapy. Stimulating OX40 on T-cells 
with an agonist monoclonal antibody results in therapeutic activity381. Consistently, 
another study has shown that engagement of OX40 during tumor-specific adoptive 
immunotherapy improves the ability of T cells to eradicate lung and brain 
metastases382. More recently, a phase I clinical trial of an agonistic anti-OX40 
monoclonal antibody has been initiated for patients with advanced cancers, such as 
melanoma, lung, breast, prostate, colon, and lymphoma, who have failed standard 
cancer treatments383.  
4-1BB (CD137) is expressed on the surface of activated T cells384, as well as on 
NK cells385, monocytes386, and DC387; its ligand 4-1BBL is expressed on B cells 
and macrophages. In vitro exposure to anti-CD137 mAbs can stimulate the 
proliferation of CD8+ T cells with CTL activity and production of Th1 cytokines 
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IFN-γ and TNF-α388. And 4-1BB signaling also can protect T cells against 
apoptosis389-391. Moreover, engagement of CD137 can induce proliferation of 
monocytes392 and facilitate their differentiation to DC. Initially, it was found that 
administration of anti-CD137 mAbs can break the tolerance and induce a 
tumor-destructive immune response in mouse models393,394. However, the clinical 
use of such MAbs may be problematic since they depress antibody formation and 
abrogate T cell-dependent humoral antibody responses395,396. The alternative 
approach is to transfect tumor cells to express the CD137 ligand (CD137L) and 
increase their immunogenicity397, but antitumor response by vaccinating with 
tumor cells transfected to express CD137 ligand is less effective than by injecting 
anti-CD137 mAb398,399. A more effective way to engage CD137 toward tumor 
destruction is to transfect tumor cells to express a cell-bound form of anti-CD137 
single-chain Fv fragments (scFv). For example, cells from sarcoma Ag104 became 
immunogenic when transfected to express anti-CD137 scFv3 but not when 
transfected to express CD137 ligand385. Ye et al. transfected cells from the M2 
clone of the K1735 mouse melanoma to express anti-CD137 scFv and showed 
therapeutic efficacy against small M2 tumors growing s.c. or in the lung400. 
Furthermore, a recent study showed that mammary carcinoma cells (MMC) 
transfected to stably express surface scFv completely eradicate the tumor growth in 
the neu-transgenic mouse breast cancer model401. Clinical trial with the CD137 
mAb is expected in the near future. 
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Taken together, costimulatory signals play a critical role in inducing and 
maintaining cell-mediated immune response and thus might be promising targets 
for helping to increase the safety and efficacy of tumor immunotherapy. However, 
some of these molecular pathways are very well characterized and require further 
investigation. 
In summary, adjuvants are crucial components of immunotherapy. However, the 
field of pharmacological adjuvants still is at a very early stage of development. 
Many components from mushrooms have been shown to be potential 
immunomodulatory activities. 
1.5 The history and immunobiology of fungal immunomodulatory 
proteins  
For centuries, mushrooms have been shown to contain abundant biologically active 
compounds for the promotion of good health and vitality, enhancement of the 
body’s adaptive capabilities, and treatment of various diseases worldwide, 
especially in Asian countries402-405. To the ancient Romans, they were “the foods of 
the gods” and to the early Egyptians they were “a gift from the God Osiris,” 
whereas the Chinese considered them as “the elixir of life.” The practice of using 
medicinal mushrooms in Chinese traditional medicine dates back into antiquity and 
has been recorded in ancient Chinese manuscripts406. More than 14,000 species of 
mushroom have been found and at least 270 species are known to possess various 
therapeutic properties402,407. In recent years, the ability of mushrooms to modulate 
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the immune system and inhibit tumor growth has been studied and 
investigated403,408-410. After early studies were conducted with whole mushrooms, 
some of the most effective components, such as polysaccharides, 
polysaccharopeptides, and polysaccharide-proteins, subsequently have been  
isolated and identified411. The major immunomodulating activity of these bioactive 
compounds includes their mitogenicity, potential stimulation of hematopoietic stem 
cells, and activation capacity of immune cells like NK cells, DCs, and T cells411-416.  
Historically, most medicinal mushroom species were relatively scarce and were 
collected from the forests where they grew on dead or living trees and forest litter. 
Nowadays, almost all important medicinal mushrooms have been subjected to 
large-scale artificial cultivation by solid substrate or low moisture fermentation, 
thus removing the historical scarcity factor and allowing large commercial 
operations to develop. Overall, the world production of cultivated edible and/or 
medicinal mushrooms was recorded as 4909 × 103 tons in 1994, increasing to 6158 
× 103 in 1997, with an estimated value in excess of US $14 billion417. Output yield 
of the leading 10 species cultivated made up about 92 percent of total world 
production and of these, six species —Agaricus bisporus, the white button 
mushroom (31.8 percent); Lentinula edodes (25.4 percent); Pleurotus spp. (14.2 
percent); Auricularia auricular (7.9 percent); Flammulina velutipes (4.6 percent); 
and Volvariella volvaceaea (7.9 percent) — made up 87 percent of the total 
production418.  
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Of these species, Flammulina velutipes (also called golden needle mushroom) 
possess immunomodulatory, anti-tumor, anti-viral, anti-fungal, and 
cholesterol-lowering activities419-422. Its major fruiting body protein, Fip-Fve, has 
been shown to play a significant role in the mushroom’s immunomoduatory effect 
423. The Fip-fve is classed as a new distinct family of fungal immunomodulatory 
proteins (Fips), which include LinZhi-8424,425, Fip-vvo426, Fip-gts416, Fip-vvl427, 
purified from Ganoderma lucidium, Volvariella volvacea, Ganoderma tsugae, and 
Volvariella volvacea, respectively. Fips exhibit a high homology in their amino acid 
sequences426, which comprise ~110 amino acid residues with a molecular mass of 
~13 kDa, and are significantly similar to the VH region of the immunoglobulin in 
both amino acid sequence and predicted secondary structure428. Fips are mitogens 
in vitro for human peripheral mononuclear cells (hPBMCs) and are mediated by 
active monocytes and T-lymphocytes to induce the production of cytokines, IL-2, 
IL-12, IFN-γ, and TNF-α414,424,429. 
Native Fve protein is an acetylated protein consisting of 114 amino acid residues 
with an estimated molecular weight of 12.7 kDa423. Its 3D structure determined by 
x-ray crystallography revealed that it is a non-covalently linked homodimer, and 
has a novel structure, wherein each subunit of the homodimer consists of an 
N-terminal alpha-helix followed by a fibronectin III (FN III)-type fold (appendix 4). 
Sugar-binding studies suggested that Fve could be a lectin with specificity for 
complex cell surface carbohydrates430. Fve has potent mitogenic stimulatory effects 
on both mouse splenocytes and hPBMCs and enhances IL-2, IFN-γ, and TNF-α 
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production415,423. The comparison of structures and their functions of different 
mitogens was shown in appendix 6. Besides the mitogenic effect, Hsu et al. 
reported that Fve can inhibit IL-5-mediated survival of eosinophils through the 
modulation of cytokine receptor expression and apoptotic signal protein production. 
Moreover, mice fed with Fve protein induced systemic production of IFN-γ, and 
coadministration of Fve with antigen could drive a strong Th1 skewed immune 
response431. Taken together, Fve has a characteristic ability to induce production of 
high levels IFN-γ by immune cells in vitro and in vivo, presumably through its 
mitogenic stimulatory effects on the immune response cells.  
1.6 Objectives and significance of the study  
To clarify further the immunomodulatory activity of Fve, the interactions of Fve 
with immune cells, T cells, DCs, and NK cells were explored. Also, the potential 
application of Fve in the development of tumor vaccine was investigated. The 
adjuvant effects of Fve in the clinical application and for immunotherapy of other 
diseases such as asthma were not examined in this study.      
The specific aims of the research were:                          
1. To elucidate the characteritics of Fve in the immune system. 
z The interaction between Fve and T cells was investigated. The surface 
markers staining, proliferation, and cytokine production of T cells was 
assayed in vitro.   
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z The interaction between Fve and antigen presenting cells DCs in innate 
immunity was investigated. The surface markers of DCs were examined 
after stimulation by Fve in vitro as well as in vivo using FACS analysis. 
The cytokine production by antigen-specific T cells was analyzed to 
evaluate the functional maturation of DCs in transgenic mice models. 
z The transwell experiments were assayed to elucidate the possible roles of 
T cells in the maturation of DCs by Fve. 
z The interaction between Fve and NK cells in innate immunity was 
investigated. The cytokine released by NK cells after stimulation by Fve 
were analyzed by ELISA  
2. To investigate the adjuvant effect of Fve in cervical cancer immunotherapy. 
z HPV type-16 E7 protein was used as the antigen model to evaluate the 
E7-specific humoral and cellular immune response in vitro. E7-specific 
antibodies and cytokine production from T cells was the read-out. 
z TC-1 tumor cell, which expresses E7 protein, was used as the animal 
tumor model to evaluate the ability of protection and therapeutics in vivo. 
The tumor size and survival rate were monitored in different groups. 
Results from the tumor model study may provide an alternative model to test the 
immunomodulatory functions of Fve in vivo. More importantly, clarification of the 
relationship between Fve and different immune cells could contribute to a better 
understanding of the molecular mechanism of immunomodulatory proteins in the 
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immune system. This should provide useful information on how to optimize the 
vaccine to prevent and treat HPV-related and other cancers in clinics in the future. 




Chapter 2   




The BALB/c, BALB/cJ and C57BL/6 mice were originally obtained from The 
Jackson Laboratory (Bar Harbor, Me, USA) and were bred in the Animal Holding 
Unit of National University of Singapore (NUS).   
Breeding pairs of OT-I, OT-II and DO11.10 mice having transgenic Vα2Vβ5 TCRs 
specific for OVA257−264 epitope in the context of H-2Kb, OVA323−339 epitope in the 
context of I-Ab and OVA323−339 epitope in the context of I-Ad respectively, were 
originally acquired from Jackson Laboratory (Bar Harbor, Me, USA) and were 
maintained and bred in the pathogen-free environment in the Animal Holding Unit 
of NUS. All animal procedures were performed according to approved protocols 
and in accordance with the Institutional Animal Care & Use Committee (IACUC) 
of NUS. 
Female mice (6-8 weeks old) were used to study function of Fve and to evaluate the 
potential clinical application of Fve in treatment of cancer.  
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2.1.2 Edible mushroom 
Flammulina velutipes (Golden needle mushroom) was purchased from Taiwan, 
Republic of China (Fig. 2.1). 
2.1.3 Bacterial strains 
Escherichia coli strain TG-1 [Genotype: supE hsd∆5 thi ∆ (lac-proAB) F’ (traD36 
proAB+ lacIq lacZ∆M15)] was used for the expression of recombinant protein. 
2.1.4 Bacteria culture media 
Chemical Recipe Company 
Bacto-tryptone Difco Laboratories (Detroit, MI, USA) 
Bacto-yeast extract Difco Laboratories (Detroit, MI, USA) 
Bacto-agar Difco Laboratories (Detroit, MI, USA) 
Glycerol Merck (Whitehouse station, NJ, USA) 
NaCl Sigma (St Louis, MO, USA) 
KH2PO4 and K2HPO4 Sigma (St Louis, MO, USA) 
Ampicillin Calbiochem (San Diego, CA, USA) 
IPTG Calbiochem (San Diego, CA, USA) 
Luria-Bertani (LB) medium composes of 10 g of bacto-tryptone, 5 g of bacto-yeast 
extract, and 10 g of NaCl in 1000 ml deionized H2O. 
2.1.5 Cell lines 
TC-1 tumor cell line was kindly provided by Dr TC Wu, Johns Hopkins University, 
USA and was used as HPV type-16 tumor model experiments. The maintenance of 
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TC-1 cells has been described previously432. HPV-16 E6, E7, and ras oncogene 
were used to transform primary C57BL/6 mice lung epithelial cells. The cells were 
grown in RPMI 1640, supplemented with 10% (v/v) FBS, 50 units/ml 
penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.4 
mg/ml G418 at 37 °C with 5% CO2. On the day of tumor challenge, TC-1 cells 
were harvested by trypsinization, washed three times with PBS, and the designated 
concentrations of cell number for tumor inoculation was re-suspended in 200 μl of 
PBS. 
Anti-CD4 (clone, GK1.5), anti-CD8 (clone, 2.43) and anti-IFN-γ (clone, R4-6A2) 
antibodies were purified from the supernatant of hybridoma cells (ATCC) by 
passage through a protein-G column (Amersham).  
2.1.6 Cell culture media and supplements 
Chemical Recipe Company 
Cell culture medium RPMI 1640 HyClone (Logan, UT, USA) 
L-glutamine HyClone (Logan, UT, USA) 
sodium pyruvate HyClone (Logan, UT, USA) 
sodium bicarbonate HyClone (Logan, UT, USA) 
HEPES HyClone (Logan, UT, USA) 
Hank’s balanced salt solution (HBSS) HyClone (Logan, UT, USA) 
fetal calf serum (FCS) HyClone (Logan, UT, USA) 
fetal bovine serum (FBS) StemCell Technologies (Vancouver, BC, 
Canada) 
2-mercaptoethanol Life Technologies (Grand Island, NY, USA)
penicillin and streptomycin solution  HyClone (Logan, UT, USA) 
Geneticin® selective antibiotic (G418) 
solution 
Life Technologies (GibcoBRL) (Grand 
Island, NY, USA) 
Trypsin solution Life Technologies (Grand Island, NY, USA)
[3H]-thymidine Amersham Pharmacia (Piscataway, NJ, 
USA) 
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2.1.7 Plasmids and reagents for gene cloning 
The pGEX is a glutathione S-transferase (GST) fusion protein expression system 
used extensively as a high yield expression and easy purification system. GST is a 
26 kDa tag to any recombinant protein, that it can be removed as an endopeptidase 
(thrombin, Factor Xa protease or enterokinase) cleavage site sequence which is 
incorporated between the tag and the protein. Elution of the purified protein is 
accomplished under mild, nondenaturing conditions. This prokaryotic expression 
plasmid was purchased from Pharmacia (Uppsala, Sweden). 
Pfu DNA polymerase, T4 DNA ligase, shrimp alkaline phosphatase, restriction 
enzymes such as Bam HI, Eco RI were purchased from Promega (Madison, WI, 
USA). Wizard® Plus SV minipreps DNA Purification System was purchased from 
Promega (Madison, WI, USA). DYEnamic™ ET Terminator Cycle Sequencing Kit 
were purchased from Amersham Pharmacia Biotech (Piscataway, NJ, USA).  
2.1.8 Reagents for protein purification and identification 
Protein purification resins such as Cynogen Bromide-activated Sepharose 4B, 
Sephadex G-25, Butyl Sepharose 4 Fast Flow, Q Sepharose Fast Flow, Hi-Trap 
Q-Sepharose, Hi-Trap SP-Sepharose, and the Fast Performance Liquid 
Chromatography (FPLC) system for protein chromatography were purchased from 
Pharmacia Amersham Biosciences AB (Uppsala, Sweden). Glutathione agarose, 
DNase, and lysozyme were purchased from Sigma (St. Louis, MO, USA). Protein 
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concentrator Amicon® Centricon Plus-20 (PL-10, PL-30) was purchased from 
Millipore (Bedford, MA, USA). 
Bio-Rad Protein Assay kit was purchased from Bio-Rad Laboratories (Richmond, 
CA, USA). Coomassie Plus Protein Assay Reagent and SuperSignal® West Pico 
Chemiluminescent were purchased from Pierce (Rockford, IL, USA). Coomassie 
blue R was purchased from Sigma (St Louis, MO, USA). BioMax film was 
purchased from EASTMAN KODAK Company (Rochester, NY, USA). 
2.1.9 Antibodies and microbeads 
All antibodies were purchased from BD PharMingen (San Diego, CA, USA) unless 
specified otherwise.  
For the detection of antigen-specific IgG1 in mouse sera, the rat anti-mouse Igκ 
light chain (clone 187.1) and biotin-conjugated rat anti-mouse IgG1 mAb (clone 
LO-MG1-2, Serotec Ltd., Oxford, England) were used. The purified mouse IgG1 
(clone 107.3) was used as the standard.  
For cytokine ELISA, mAbs of rat anti-mouse IFN-γ (clone R4-6A2), 
biotin-conjugated rat anti-mouse IFN-γ (clone XMG1.2), rat anti-mouse IL-2 
(clone JES6-IA20), biotin-conjugated rat anti-mouse IL-2 (clone JES6-5H4), rat 
anti-mouse IL-4 (clone BVD6-24G2), biotin-conjugated rat anti-mouse IL-4 (clone 
BVD4-1D11), rat anti-mouse IL-6 (clone MP5-20F3 ), biotin-conjugated rat 
anti-mouse IL-6 (clone MP5-32C11), rat anti-mouse TGF-β (clone, A75-2.1), 
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biotin-conjugated rat anti-mouse TGF-β (clone A75-3.1) were used. Rat anti-mouse 
TNF-α (clone AF-410-NA), biotinylated rat anti-mouse TNF-α (clone BAF410), rat 
anti-mouse IL-10 (clone JES052A5) and biotin-conjugated rat anti-mouse IL-10 
were purchased from R&D Systems (Minneapolis, MN, USA).  
Rat anti-mouse CD3ε (clone 145-2C11) and CD28 (clone 37.51) mAbs and 
recombinant mouse IL-2 were used for stimulation of T cells in vitro. 
Percp-conjugated rat anti-mouse CD3 (clone 17A2), FITC-conjugated rat 
anti-mouse CD8β (clone 53-5.8), biotin-conjugated rat anti-mouse CD4 (clone 
GK1.5), APC-conjugated rat-anti-mouse CD4 (clone RM4-5), PE-conjugated 
anti-mouse OX-40 (clone OX86, eBioscience San Diego, CA, USA), 
PE-conjugated anti-mouse 4-1BB (clone 17B5, eBioscience San Diego, CA, USA), 
biotin-conjugated hamster anti-mouse CD69 (clone H1.2F3 ), streptavidin-PerCP, 
were used for the surface marker staining of T cells. APC-conjugated 
rat-anti-mouse IFN-γ (clone XMG-2.1) was used for the intracellular cytokine 
staining of T cells. Rat anti-mouse CD16/CD32 (clone D34-485), biotin-conjugated 
rat anti-mouse CD8α (clone 53-6.7), APC-conjugated rat anti-mouse CD4 (clone 
RM4-5), PE-conjugated rat anti-mouse CD11c (clone HL3), FITC-conjugated 
anti-mouse I-Ab (clone AF6-120.1), FITC-conjugated anti-I-Ad (clone AF6-120.1) 
FITC-conjugated anti-CD86 (clone GL1), PE-conjugated rat anti-mouse CD40 
(clone 1C10), FITC-conjugated rat anti-mouse CD80 (clone 16-10A1), 
FITC-conjugated hamster anti-mouse CD54 (clone 3E2) and 
streptavidin-conjugated PerCP were used for surface marker staining of splenic 




Immune cell separation microBeads, which recognize CD4, CD8, CD19, CD11c, 
or NK1.1 were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).  
2.1.10 Reagents for immunoassay 
Anti-mouse Ig κ light chain, mouse IgG1, IgG2a,  recombinant IL-2, IL-6, IL-4, 
IL-10, IFN-γ, TNF-α, TGF-β were used as ELISA standards, and monoclonal 
antibodies for mouse cytokine ELISA were purchased from PharMingen (San 
Diego, CA, USA). Biotin-conjugated anti-mouse total immunoglobulins, 
ExtraAvidine Alkaline Phosphatase (AP), ExtraAvidin-Peroxidase conjugate, 
para-nitrophenyl phosphate (pNPP) substrate for AP, and 
2,2’-Azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) substrate for HRP 
were purchased from Sigma (St. Louis, MO, USA). Biotin conjugated anti-mouse, 
anti-rat IgG1 and IgG2a were purchased from Serotec (Oxford, England, UK).  
2.2 Methods 
2.2.1 Preparation of native Fve protein, recombinant E7 protein, and 
recombinant GST protein. 
2.2.1.1 Purification of Fve protein from Flammulina velutipes  
Two kilograms of Flammulina velutipes (golden needle mushroom) was purchased 
from Taiwan. The fresh fruit bodies of mushroom were homogenized with 2 L of 5 
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% acetic acid (v/v) in the presence of 0.1 % (v/v) 2-mercaptoetheanol. The 
homogenate was centrifuged for 20 min and soluble proteins in the supernatant 
were precipitated by addition of ammonium sulphate to 95 % saturation. After 
stirring for an overnight, the precipitate was collected by centrifuge for 20 min 
again. The pellet was then dissolved and dialyzed against 4.5 L of 10 mM Tris-HCl 
(pH 8.0) at 4 ˚C for 4 days with 6-9 changes of dialysis solution. The dialyzed 
solution was firstly applied to Q column, which had been pre-equilibrated with 10 
mM Tris-HCl (pH 8.0). The flows through fractions were then further purified by 
SP column, which was pre-equilibrated with 10 mM sodium acetate (pH 5.0). The 
column was washed with 10 mM equilibration buffer and then eluted with a linear 
gradient of 0-1 M NaCl in 10 mM sodium acetate (pH 5.0). The fractions were then 
further purified on a Q column (pH 8.0) and SP column (pH 5.0). Purified Fve was 
dialyzed with 2 L of 10 mM PBS (pH 7.4) and stores at -80˚C.  
2.2.1.2 Construction of plasmid DNA pGEX-E7 
The cDNA of HPV-16 E7 (A gift kindly given by Dr SW Chan, Institute of 
Molecular and Cellular Biology, ASTAR, Singapore) was subcloned into 
pGEX-4T1 expression vector. DNA fragment of E7 was amplified by polymerase 
chain reaction (PCR) using a set of primers: E7-F 
5’-TTGTTGGATCCCATGGAGATACACCTACATTG-3’ and E7-R 
5’-TTACTGAATTCTTATGGTTTCTGAGAACAGATG-3’. The primers were 
synthesized by QIAGEN Operon (Alameda, CA, USA). The PCR was performed 
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under standard conditions (94 oC for 1 min, 55 oC for 1 min and 72 oC for 2 min for 
25 cycles) using pfu DNA polymerase. The amplified products were separated on a 
1% of agarose gel. The band corresponding to the expected PCR product size was 
cut out and the DNA were purified by Wizard® Lamba Preps DNA purification 
system. The purified DNA was digested with Bam HI and Eco RI, and the resulting 
fragment was then cloned into the Bam HI and Eco RI sites of pGEX- 4T1 vector. 
Then the nucleotide sequencing was analyzed by the ABI 377 DNA Sequencer 
(Applied Biosystems, USA). The pGEX-E7 recombinant plasmid was transformed 
into Escherichia coli TG-1 for protein expression.  
2.2.1.3 Preparation of recombinant E7 protein 
E7 was expressed as GST-fusions protein from pGEX-4T1. Small scale of 
pGEX-E7 transformed TG-1 bacteria was seeded in LB medium. The overnight 
culture was transferred to 1L of LB medium containing ampicillin (100 µg/ml) in 1 
in 40 proportion and grown at 37 ◦C with 250 rpm vigorous shaking until the OD600 
reach to 0.6-0.8 (approximately 2-3 hrs). The recombinant protein was induced by 
IPTG at a final concentration of 0.1 mM and further incubation of 4-6 hrs at 30 ◦C 
in a shaker incubator at 200 rpm. Cells were harvested by centrifugation at 6000 
rpm for 10 minutes and the pellet was used for protein extraction. 
The pellet of E7 transformed bacteria was re-suspended in 250 ml ice-cold lysis 
buffer (TBS pH 7.5, 1 mM PMSF (Sigma, MO, USA), 20 µg/ml DNase I and 1 % 
Tween 20). The cell suspension was then sonicated at 4 ◦C for 50 seconds, 18 
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cycles with 30 seconds intervals. Total cell lysate was centrifuged at 16 000 rpm 
for 25 min at 4 ◦C. The supernatant was collected for further affinity purification on 
glutathione agarose beads. Initially, glutathione agarose beads (Sigma, MO, USA) 
was dispensed into a chromatography column and then washed with TBS (pH 7.5). 
Supernatant from the total cell lysate was then loaded onto the column and 
subsequently washed with TBS. GST-E7 was eluted with elution buffer 
(Glutathione 0.15 g, Tris-base in a total volume of 50 ml dH2O) and then analyzed 
by SDS-PAGE. Pure fractions of GST-E7 protein were pooled together and cleaved 
with thrombin. Purified E7 was dialyzed against PBS (pH 7.4) and used for further 
studies. 
2.2.1.4 Preparation of recombinant GST protein 
Glutathione S-transferase is the GST enzyme of Schistosoma japonicum worms 
which terms as Sj26. The expression and purification was described previously433. 
Briefly, vector pGEX4T-1 was transformed into E.coli strain TG-1 for expression 
of GST. The protein product was induced with 0.1 mM IPTG at 30 ◦C in a shaker 
incubator at 200 rpm for 1 hr. Recombinant GST protein was obtained by passing 
the cell lysate through glutathione agarose beads. 
2.2.1.5 SDS-PAGE and immunoblot analysis 
Protein samples were routinely loaded on 7.5 % SDS-PAGE tricine resolving and 
stacking gel for electrophoresis. Samples were mixed with 2 × sample buffer (100 
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mM DTT, 4 % SDS, 0.01 % Coomassie blue, 24 % glycerol, pH 6.8) to a 
concentration of 1 × and boiled for 15 minutes to denature the proteins before 
being loaded into the wells. SDS-PAGE molecular weight standards, broad range 
protein markers (Bio-Rad, CA, USA) were used. Electrophoresis was carried out 
with anode (0.2 M Tris, pH 8.9) and cathode buffers (0.1 M Tris, 0.1 % SDS, pH 
8.25) on a vertical electrophoresis apparatus (Hoefer, Pharmacia) at 50-100V. After 
electrophoresis has completed, the proteins in the gel were stained with Coomassie 
plus Reagent. For western blotting, the proteins were transferred from the gel to a 
bio-blot nitrocellulose membrane (Amersham, Piscataway, NJ) and probed with 
specific antibody. The membrane was pre-equilibrated with PBST solution 
containing 2 % BSA for 1 hr and then reacted with anti-E7 mAbs (Oncogene, 
Boston, MA) for overnight at 4 oC. After three washes with PBST, the membrane 
was incubated with anti-mouse IgG-HRP for 1 hr at room temperature. The 
immunoreactive protein bands were detected using the ECL detection reagents 
(Amersham). 
2.2.1.6 Determination of proteins concentration 
The concentrations of native Fve, and recombinant E7 protein, recombinant GST 
protein were analyzed by 7.5 % Tricine SDS-PAGE (Schagger and Von Jagow, 
1987) were determined by the Coomassie plus protein assay reagent (Pierce, 
Rockford, IL, USA) with bovine serum albumin as standards, and quantified by 
Bio-Rad Model GS-700 Imaging Densitometer (Bio-Rad Laboratories, Richmond, 
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CA, USA).  
2.2.1.7 Endotoxin removal  
Removal of LPS and LPS-associated molecules from Fve protein and GST protein 
using Polymyxin B-Agarose (Sigma-Aldrich) was performed according to 
manufacturer’s instruction. 10 mL of Polymyxin B-agarose were poured into 
disposable polypropylene columns (Pierce, Rockford, IL, USA) and washed three 
times in 20 mL of PBS. The Polymyxin B-agarose was then poured into a 50 mL 
polypropylene tube. Fve protein or GST protein at 1 mg/mL were added to 
Polymyxin B-agarose at a ratio of 5 mg protein to 10 mL Polymyxin B-agarose. 
The mixture was then preceded shaking for overnight at 4 ˚C. Next, the Polymyxin 
B-agarose was re-packed into the disposable polypropylene columns, washed with 
PBS until the absorbance at 280nm of the eluents dropped to baseline. The eluents 
containing the protein of interest, which were excluded from the Polymyxin 
B-agarose, were collected, concentrated by Amicon cell, and assayed for endotoxin 
levels using the Limulus Amebocyte Lysate (LAL) QCL-1000 (Cambrex Bio 
Science, USA). 
2.2.2 Preparation of immune cells 
2.2.2.1 Preparation of single splenocyte suspension 
Spleens were removed from mice and placed in Petri dishes in the presence of 10 
ml of HBSS. Single cell suspension was made by disrupting the tissues using two 
Chapter 2 Materials and methods 
 
 88
frosted-slides. Red blood cells (RBCs) were lyses by adding 1.5 ml of RBC lysis 
buffer (10 mM Tris, 0.83% NH4Cl, PH8.2-8.4) for 90 seconds. The cells were then 
washed three times with HBSS and cell number was determined using 
hematocytometer. The cells were re-suspended in complete RPMI-1640 medium 
for further use. 
2.2.2.2 Preparation of accessory cells/antigen presenting cells 
Mitomycin C-treated splenocytes, splenic DCs, B cells from naïve mice and 
BM-DCs from 5-days culture were used as accessory cells (ACs) or antigen 
presenting cells. Mitomycin C (Roche Diagnostics GmbH, Mannherim, Germany) 
was dissolved in PBS at a concentration of 0.5 mg/ml. Cells were washed twice 
with HBSS and suspended in PBS to a concentration of 50 μg/ml and the tube was 
wrap with aluminum foil. The tube was incubated in 37 oC water bath for 20 min. 
After that, cells were washed 3 times with large volume of HBSS and suspended in 
RPMI-1640 medium. 
2.2.2.3 Preparation of bone marrow-derived DCs 
The method for generating bone marrow-derived dendritic cells (BM-DCs) with 
GM-CSF was adapted from previous publication434. In brief, bone marrow cells 
were harvested from femurs and tibias of normal C57BL/6 mice and washed with 
PBS. 4-6 × 106 of cells were re-suspended in complete RPMI-1640 medium 
containing recombinant mouse GM-CSF (20 ng/ml, BD PharMingen) and cultured 
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in 100-mm diameter petri dishes. On day 3 half of the medium was replaced with 
fresh medium supplemented with GM-CSF (10 ng/ml). On day 5 or 6 of cultured 
bone marrow cells were harvested for dendritic cell purification. 
2.2.2.4 Preparation of splenic DCs 
The splenic DCs were purified as describe before435 with modifications. Spleens 
(from eight mice) were minced with scissors and digested in 10 ml HBSS (with 
Ca2+ and Mg2+) containing collagenase (400U/mL, Roche Molecular Biochemicals) 
for 30 min at 37 °C. Next, EDTA (1 ml, 0.1 M) was added at room temperature for 
5 min to disassociate the DCs from any complexes with T cells. The digested tissue 
samples were filtered through a 40 μm nylon mesh to remove undigested fibrous 
materials. All subsequent steps were performed at room temperature using a HBSS 
(without Ca2+ and Mg2+). Cells in the filtrate was recovered by centrifugation, the 
pellet was re-suspended in a 1.068 g/cm3 OptiPrep medium and centrifuged at 
600g for 15 min. The low-density fraction was collected (2-4% of the total) and 
re-suspended in the running buffer (PBS with 0.5% BSA and 2 mM EDTA).  
2.2.2.5 Lymphocytes purification using AutoMACS separator 
Magnetic microbeads of autoMACS separator (Miltenyi Biotec GmbH Bergisch 
Gladback, Germany) was employed to purify splenic CD90+ (Thy1.2+) T cells, 
CD4+ T cells, CD8+ T cells, CD11c+ splenic DCs, CD11c+ BM-DCs, CD19+ B cells, 
and NK1.1+ NK cells according to the manufacturer’s protocol. Briefly, every 107 
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single cells were re-suspended in 90 μL of staining buffer (0.5% bovine serum 
albumin (BSA, Sigma-Aldrich), 2 mM EDTA (1st BASE, Singapore) in PBS, pH 
7.4) and 10 μL of corresponding MicroBeads were added. After incubation for 20 
min at 4 °C and extensive washing with staining buffer, the cells were subjected to 
magnetic separation using AutoMACS. The purities of CD90+ T cells, CD4+ T cells, 
CD8+ T cells, CD11c+ splenic DCs, CD11c+ BM-DCs, CD19+ B cells, and NK1.1+ 
NK cells are above 97%, 95%，90%，97%，98%， 95% and 90%，respectivley.   
2.2.3 Cell aggregation assay 
CD4+ T cells, CD8+ T cells, NK1.1+ NK cells from spleen in C57BL/6 mice were 
purified by AutoMACS. CD11c+ BM-DCs were purified from GM-CSF cultured 
BM-cells at day 5. Purified CD11c+ BM-DCs, CD4+ T cells, CD8+ T cells and 
NK1.1+ NK cells were stimulated with 20 μg/ml of Fve for 24 hrs, respectively. 
The morphologies of the cells were examined by light microscopy at 24 hrs. 
Non-stimulated cells used as negative controls. 
2.2.4 Cell proliferation assay 
For splenocytes proliferation, spleen cells collected from C57BL/6 mice were 
re-suspended in the RPMI complete medium, and incubated in the presence of 
different doses of Fve in triplicate wells of a 96-well plate (5 × 105 cells/well). For 
T cell proliferation assay, CD90+ T cellls were purified from splenocyte of 
CD57BL/6 or BALB/c mice by AutoMACS. Mitomycin C-treated splenocytes (3 × 
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105 cells/well) or mitomycin C-treated B cells (3 × 105 cells/well) were co-cultured 
with purified CD90+ T cells (1 × 105 cells/well) with GST (20 μg/ml), or Fve (20 
μg/ml) for 72 hrs. For another set of experiment, mitomycin C-treated purified 
BM-DCs (2 × 104 cells/well) were co-cultured with purified CD90+ T cells (1 × 105 
cells/well) from C57BL/6 mice with PBS or Fve (20 μg/ml) for 72 hrs. The 
3H-thymidine was added 18 hrs before cell harvest and thymidine incorporation 
was measured by liquid scintillation counting after 72 hrs. 
2.2.5 In vitro cytokine production by Fve-stimulated T cells  
For cytokine profiling experiment, 2 × 106 of CD90+ T cells purified from the 
C57BL/6 mice spleens were seeded into a 6-well U-bottom plate together with 2 × 
105 of Mitomycin C-treated BM-DCs. Cells were treated with or without Fve (20 
μg/ml). The supernatants were collected after 24 hrs and the cytokine productions 
(IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α) by T cells were measured by ELISA. 
For cytokine kinetics experiment, CD90+ T cells (2 × 106 cells /ml) from the 
C57BL/6 mice spleens were incubated either alone (T cells) or with BM-DCs at a 
10:1 ratio (T cell/DC) in the presence or absence of 20 μg/ml of Fve for 24, 48, 72 
hrs. The transwell groups were also set up correspondingly. The supernatants were 
collected and cytokine production (IFN-γ, IL-2) by T cells was measured by 
ELISA. 
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2.2.6 Flow cytometry analysis  
2.2.6.1 Cell surface marker staining and flow cytometry analysis of the 
Fve-stimulated T subsets 
For T subsets population analysis, splenocytes from C57BL/6 were stimulated with 
or without 20 μg/ml in vitro. The cells were collected at 24, 48, 72 hrs time point. 
Then the cells were stained with rat anti-mouse CD3-PercP, CD8-FITC, CD4-APC 
monoclonal antibody or IgG isotype control. Flow cytometry was performed using 
FACSCalibur (Becton Dickinson immunocytometry systems, San Jose, CA). 
For T cell activation marker staining, CD90+ T cells purified from the splenocytes 
of C57BL/6 mice were incubated for 24 hrs either alone (T cells) or with BM-DCs 
at a 10:1 ratio (T cell:DC) in the presence or absence of 20 μg/ml of Fve. The cells 
were collected and suspended in the staining buffers. The mAbs (rat anti-mouse 
CD3-PercP, CD8-FITC, CD4-APC, OX-40-PE, 4-1BB-PE, hamster anti-mouse 
CD69-PE) were used to stain the cells and flow cytometry analysis was performed 
using FACSCalibur. 
2.2.6.2 Surface marker staining and flow cytometry analysis of the 
Fve-stimulated dendritic cells. 
For BM-DCs surface marker staining, day 5 GM-CSF-cultured Bone marrow cells 
were stimulated with different concentrations of Fve protein (10, 20, 100 μg/ml), or 
LPS (1 μg/ml) in vitro for 16-18 hrs. The cells were stained with rat anti-mouse 
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CD11c-APC, I-Ab-FITC, CD80-FITC, CD86-PE, or hamster anti-mouse 
CD54-FITC mAbs. For splenic DCs surface marker staining, C57BL/6 and 
BALB/c mice were intraveneously injected with PBS, Fve or LPS 12 hrs prior to 
cell harvest. DCs were enriched from spleen for staining of MHC class II and 
CD86. Rat anti-mouse CD11c-APC, I-Ab-FITC, or I-Ad-FITC, CD86-PE mAbs 
was used. Flow cytometry analysis was performed using FACSCalibur. 
2.2.6.3 Surface marker staining and flow cytometry analysis of the 
Fve-stimulated DCs with/without the help of T cells 
Transwell experiment was performed in six well plates with tissue culture inserts of 
0.4 μM pore size (Corning, NY). Purified BM-DCs (1 × 106 cells/well) were 
seeded at the bottom well and incubated alone, or with CD90+ T cells from the 
splenocytes of C57BL/6 mice at a T cell/ DC ratio of 10:1, or with CD90+ T cells 
(T cell:DC = 10:1) separated in trans-well (DC/T) in the presence or absence of 
Fve protein (20 μg/ml) for 24 hrs. For another experiment, CD90+ T cells were 
purified from the splenocytes of C57BL/6 mice and stimulated with/without Fve 
protein (20 μg/ml) for 24 hrs. Then the activated T cells or freshly purified T cells 
were cocultured with purified BM-DCs (T cell/DC ratio= 10:1) for 24 hrs. The 
surface markers were stained with Rat anti-mouse CD11c-APC, I-Ab-FITC, 
CD86-PE, CD40-FITC or CD80-FITC mAbs and analyzed by flow cytometry.  
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2.2.7 Analysis of DC-directed CD4+ and CD8+ T cells activities 
There are two set of experiments for this purpose. For the first set of experiment, 
BALB/c mice (n = 8 mice/group) were intraveneously injected with PBS or Fve. 
The DCs from the pool of eight spleens from each group of mice were isolated 12 
hrs later. Purified DCs were pulsed with 0.1 µM of OVA323-339 peptide for 2 hrs at 
37 °C and washed three times. Then splenic DCs (5 × 103 cells/well) were 
co-cultured with CD4+ T cells (2 × 104 cells/well) from DO 11.10 mice for 72 hrs. 
The 3H-thymidine was added 18 hrs before cell harvest and thymidine 
incorporation was measured by liquid scintillation counting after 72 hrs. 
Supernatants were collected and cytokine production was measured by ELISA.  
For the second set of experiment, C57BL/6 naive mice were intravenously injected 
with PBS, 100 μg of OVA, 20 μg of Fve, or 100 μg of OVA plus 20 μg of Fve 24 
hrs prior to CD11c+ DC harvest. Purified CD11c+ DCs were pulsed with 1 μM of 
OVA323-339 peptide or 1 μM of OVA257-264 peptide respectively (AnaSpec, Inc., San 
Jose, CA) for 2 hrs at 37 °C and washed extensively thereafter. Naïve CD4+ cells 
were purified from OT-II transgenic mice. Naive CD8+ cells were purified from 
OT-I transgenic mice. DC (5 × 103 cells) were incubated with 5 × 104 of CD4+ T 
cells or 5 × 104 of CD8+ T cells respectively in U-bottom 96-well plates in 200 μl 
of RPMI medium in triplicates for 72 hrs. Supernatants were collected and cytokine 
production was measured by ELISA. 
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2.2.8 Cytokine analysis of Fve-stimulated NK cells in vitro 
Different cell numbers of purified NK1.1+ NK cells from BALB/c mice were 
stimulated with/without 10 μg/ml Fve in vitro. After 24 hrs, supernatant were 
collected for cytokine assay using ELISA.  
2.2.9 Immunization protocol in the E7 model experiments 
For E7-specific B cell immune response, C57BL/6 and BALC/cJ mice were 
subcutaneously immunized with PBS, 20 µg of E7 or 20 μg of E7 plus 20 µg of 
Fve at day 0, 14, 28. Sera were collected weekly and used for antibodies analysis 
by ELISA. 
For E7-specific T cell immune response, C57BL/6 mice were subcutaneously 
immunized with PBS, 20 µg of E7, or 20 µg of E7 plus 20 µg of Fve at day 0 and 
14. Splenocytes were collected at day 28 for cell culture. The culture processes 
were described in section 2.2.10-13.  
2.2.10 Short-term T cell culture in vitro 
The method for single cell suspension was described in section 2.2.2.1. Cells were 
cultured with RPMI-1640 medium with 10% heat-inactivated BCS (Stem cell 
technologies, BC, Canada), 2 mM 100 U/ml penicillin, 100 μg/ml streptomycin, 2 
mM L-glutamine, and 1 mM sodium pyruvate (Hyclone Laboratories, Logan, UT), 
and 5.5 × 10-2 mM 2-mercaptothanol (life technology, Grand Island, NY). To 
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determine the cytokine production in the freshly isolated splenocytes, 100 μl of 
splenocytes (4 × 105 cells/well) were added into the 96-well U-bottom plate  
followed by 100 μl of E7 (1, 10, 20 μg/ml) diluted in culture medium. For 
E7-specific T cell immune response, the splenocytes were cultured in 6-well (2 × 
107 cells/well) or 24-well (4 × 106 cells/well) plates in the presence of E7 protein 
(10 μg/ml) for 9 days. Recombinant mouse IL-2 (Pharmingen) was added to the 
cultured cells on day 3 and day 6 to a final concentration of 10 U/ml. 
2.2.11 Separation of dead cells from short-term cultured splenocytes by 
Ficoll-Pague centrifugation 
Nine days after the primary cell culture with antigen, the cells were collected and 
suspended in 5 ml of HBSS. The cell suspension was transferred to 15 ml tube. 
Threr milliliters of Ficoll-Paque (Amersham Bioscience Corp. Piscataway, NJ) was 
added carefully to the bottom of the tube without disturbing the interface of two 
layers. The cells were then centrifuged for 20 min at 800g. After that, live cells 
were collected from the interface, washed 3 times with HBSS and suspended in the 
culture medium. To determine the cytokine production from the short-termed 
cultured T cells, 50 μl of T cells (2 × 106 cells/ml) collected after the Ficoll-Paque 
centrifugation and 50 ml of antigen presenting cells (6 × 106/ml) were added into 
the 96-well U bottom plate followed by 100 μl of E7 protein (1, 10, 20 μg/ml). 
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2.2.12 Intracytoplasmic cytokine staining  
For intracytoplasmic cytokine staining, 96-well plate was coated with 200 μl/well 
of anti-CD3 mAb (5 μg/ml) diluted in PBS and incubated at 37oC for 2 hrs. The 
well was then washed twice with 1 ml PBS. 2 × l05 of cells/well of short-term 
cultured cells were added to each well in the presence of 2 μg/ml of rat anti-mouse 
CD28 mAb for 12 hrs. Three μM of Monensine (Sigma, St. Louis, MO) was added 
6 hrs before harvesting the cells from the culture. Cells were then washed twice in 
staining buffer and stained with rat anti-mouse CD8-FITC or rat anti-mouse 
CD4-PerCP monoclonal antibody. After fixation with 1 % of formaldehyde 
solution (BDH laboratory supplies, England) containing 0.1 % of Saponin (Sigma) 
for 30 min at room temperature, the cells were washed twice with permeabilization 
buffer (staining buffer with 0.1 % Saponin) and stained with anti-IFN-γ, IL-10, 
IL-4, TNF-α for another 30 min at room temperature. The cells were then washed 
twice with permeabilization buffer and resuspended in 1% formaldehyde solution. 
Flow cytometry was performed using FACSCalibur. 
2.2.13 Stimulation of T cells by anti-CD3 and anti-CD28 mAbs 
Thirty microliter of rat anti-mouse CD3 mAb at a concentration of 10 µg/ml was 
added to 96-well U-bottom plate. The plate was incubated at 37 oC for two hrs. 
After that, each well was washed twice with 100 μl of PBS. One hundred 
microliters of cell suspension (1 × 106 cells /ml) and 100 ml of rat anti-mouse 
CD28 mAb (2 μg/ml) were added to each well.  




2.2.14.1 Mouse cytokines ELISA 
The 96-well high- binding plate (Costar) was coated with 25 μl of purified rat 
anti-mouse IFN-γ (2 μg/ml), TNF-α (0.8 μg/ml), TGF-β (2 μg/ml), IL-4 (1 μg/ml), 
IL-10 (2 μg/ml), IL-2 (1 μg/ml), IL-6 (1 μg/ml) diluted in coating buffter (0.1 M 
NaHCO3, PH 8.2) and incubated at 4oC overnight. After washing the plate with 
washing buffer (0.05% Tween 20, 1% BSA in TBS), the wells were then blocked 
with blocking buffer (PBS containing 0.05% Tween-20 and 1% BSA) at room 
temperature for 1 hr. 25 μl of cultured supernatants were added to wells and the 
plate was incubated at 4oC overnight. 25 μl of recombinant mouse IFN-γ, TNF-α, 
TGF-β, IL-4, IL-10, IL-2, IL-6 were added for quantification purpose. In the third 
day, plate was washed and 50 ml of biotinylated anti-mouse IFN-γ (2 μg/ml), 
TNF-α (0.3 μg/ml), TGF-β (2 μg/ml ), IL-4 (1.5 μg/ml), IL-10 (0.4 μg/ml), IL-2 (1 
μg/ml), IL-6 (1 μg/ml) mAbs were added to each well and incubated at room 
temperature for 1 hr. After washing, 25 μl of ExtraAvidin®- alkaline phosphatase 
(1:2000) diluted in blocking buffer were added and incubated at at room 
temperature for another 1 hr. Signal was developed by adding pNPP substrate and 
read with a microplate reader at 405 nm (Tecan, Ges.m.b.H, Austria). 
2.2.14.2 Mouse antibodies ELISA  
Mice were subcutaneously immunized with PBS, 20 µg of E7 or 20 μg of E7 plus 
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20 µg of Fve at day 0, 14, 28. Sera were collected weekly and used for antibodies 
analysis by ELISA. For IgG1 analysis, 96-well plate was coated with (5 μg of E7 
protein per well) and incubated at 4 °C overnight. The wells were then blocked 
with blocking buffer. Diluted sera were added and incubated at 4 °C overnight. 
After washing, the plate was incubated with biotin-conjugated anti-mouse IgG1 at 
room temperature for 1 hr, followed by addition of ExtrAvidin®-alkaline 
phosphatase for another 1 hr. Signal was developed by adding pNPP substrate and 
read with a microplate reader at 405 nm (Tecan, Ges.m.b.H, Austria). For IgG2c 
detection, ELISA Kit (Bethyl Laboratories, Montgomery, TX, USA) was used 
according to the manufacturer’s protocol. 
2.2.15 Murine tumor model protocol  
2.2.15.1 In vivo tumor protection assay 
Mice were subcutaneously immunized with PBS, 20 µg of E7, 20 μg of Fve, or 20 
μg of E7 plus 20 μg of Fve at day 0, 14, 28. 5 × l04 of TC-1 cells were inoculated 
into the right flank of mouse at day 30. Tumor size was measured every two days 
in two perpendicular dimensions and expressed as length × width (mm2). The 
survival was monitored. 
2.2.15.2 In vivo tumor therapeutic assay 
Mice were subcutaneously inoculated with 5 × l04 of TC-1 cells in the right flank at 
day 0. Mice were then subcutaneously immunized with PBS, 20 µg of E7, 20 μg of 
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Fve, or 20 µg of E7 plus 20 µg of Fve at day 3, 10, 17. Tumor size was measured 
every two days and survival was monitored.  
2.2.15.3 In vivo tumor metastatic assay 
For the metastasis protection assay, mice were subcutaneously immunized with 
PBS, 20 µg of E7, 20 μg of Fve, or 20 μg of E7 plus 20 μg of Fve at day 0, 14, 28. 
5 × l04 of TC-1 cells were intravenously injected into the tail vein of mice 2 days 
after the last immunization. For tumor metastasis therapeutic assay, mice were 
intravenously injected with 2 × l04 of TC-1 cells by tail vein at day 0. Mice were 
then subcutaneously immunized with PBS, 20 µg of E7, 20 μg of Fve, or 20 µg of 
E7 plus 20 µg of Fve at day 3, 10, 17. The survival was monitored. 
2.2.15.4 In Vivo depletion of CD4+, CD8+ T Cells and IFN-γ 
Mice were subcutaneously immunized with PBS, 20 µg of E7, 20 μg of Fve or 20 
µg of E7 plus Fve at day 0, 14, 28. To deplete CD4+, CD8+ T cells and IFN-γ, mice 
were intraperitoneally injected with 800 μg of anti-CD4, 500 μg of anti-CD8 and 
500 μg of anti-IFN-γ mAbs at days -4, -1, 6, 13, 20, 27, 34, 41, 48. 5 × l04 of TC-1 
cells was inoculated into the right flank at day 30. Tumor size was measured every 
two days and survival was monitored. The depletion of CD4+, CD8+ T cells was 
assessed at day 6 after the first immunization and the depletion in the spleen was 
higher than 95% as determined by flow cytometry analysis. 
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2.2.15.5 T-cell adoptive transfer 
Mice were immunized with PBS, 20 μg of E7 or 20 μg of Fve, or 20 μg E7 plus 20 
μg Fve at days 0, 14 and 28. Splenocytes were collected at day 30 and CD90+ T 
cells were isolated using CD90 microbeads (Miltenyi Biotec) for cell transfer 
experiment. The purity of T cells was above 98% determined by flow cytometry 
analysis. 8 × 106 of freshly purified CD90+ T cells were adoptively transferred into 
recipient mice at day -1, 3, 6, 9. Recipient mice were inoculated subcutaneously in 
the right flank with 5 × 104 of TC-1 cells to initiate tumors at day 0. Tumor size 
was measured every two days. 
2.2.16 Statistical analysis 
Statistical significance was determined using SPSS, Version 11.0.1 (SPSS Inc., 
Chicago, IL, USA). For all tests, p < 0.05 was considered to indicate statistical 
significance. Results for tumor sizes are given as mean ± SEM and were analyzed 
by one-way ANOVA. Antibody cytokine production between groups was analyzed 
by Student's t test. In tumor protection and therapeutic and adoptive transfer 
experiments, the tumor free and survival analysis were carried out using the 
Kaplan-Meier and the log-rank test. P < 0.05 was considered as statistically 
significant. 







Figure 2.1 Immunofluorescent staining of freshly isolated splenic DCs for CD4 
and CD8α. DC were extracted and enriched from the spleens of C57BL/6 mice 
and were stained with anti-CD11c (PE conjugate), anti-CD4 (APC conjugate), and 
anti-CD8α (Percp conjugate). Splenic DCs were separated into CD11cint and 
CD11chi populations (A) and CD11chi DCs could be further divided into CD4+, 
CD8α+ and CD4-CD8α− sub-populations (B). The cells were gated for CD11c+ cells 
with the high forward scatter of DC. The CD4 and CD8α fluorescence distribution 
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Chapter 3  




Native Fip-Fve (Fve) is an acetylated protein consisting of 114 amino acid residues 
with an estimated molecular weight of 12.7 kDa423. Its 3D- structure determined by 
x-ray crystallography revealed that it is a non-covalently linked homodimer, 
wherein each subunit of the homodimer consists of an N-terminal alpha-helix 
followed by a fibronectin III-type fold (appendix 4). Sugar–binding studies 
suggested that Fve could be a lectin with specificity for complex cell surface 
carbohydrates430. Fve has potent mitogenic stimulatory effects on both mouse 
splenocytes and hPBMCs, and enhances IL-2, IFN-γ, and TNF-α production415,423. 
Hsu et al. reported that Fve could inhibit IL-5-mediated survival of eosinophils 
through the modulation of cytokine receptor expression and apoptotic signal 
protein production. Moreover, mice fed with Fve protein-induced systemic 
production of IFN-γ and coadministration Fve with antigen could drive a strong 
Th1 skewed immune response431.  
Take together, published studies to date support the notion that Fve protein could 
activate total splenocytes mitogenically and have some immunomodulatory effects 
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on the immune system, but there is no systematic study and detailed 
immunological characterization being carried out to elucidate the effects of Fve on 
isolated immune cells such as T subsets, DCs, and NK cells. Therefore, the first 
part of this study aimed to characterize further the mitogenic effect of Fve on 
splenic T–subsets. The surface marker expression, proliferation, and cytokine 
production of T cells was assayed in vitro. 
The interaction between Fve and innate immunity also is worth exploring. DCs are 
highly specialized antigen-presenting cells that play a pivotal role in regulating the 
T cell responses. Characterizing the maturational state of the Fve-stimulated DCs is 
important because several studies indicate that immature DCs are involved in 
maintaining tolerance436-439 whereas fully mature DCs display several distinct 
features: (1) they gain the capacity to activate naïve T cells owing to their high 
expression levels of MHC antigen-presenting molecules, adhesion molecules, and 
costimulatory molecules such as CD86, CD40, CD80; (2) they are very efficient at 
presenting the antigens to T cells leading to T cell activation, differentiation, and 
polarization. In this study, murine DCs from bone marrow and spleen were 
characterized after Fve stimulation in vitro and in vivo. Besides, their maturation 
state in vivo correlated with their ability to process and present Ag to specific CD4+ 
and CD8+ T cells was also explored. 
Another important and distinct cell type in the innate arm of the immune system is 
the NK cell. NK cells and T cells share a common biopotential progenitor; NK 
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cells share a common killing mechanism with CTLs and, like CD4+ Th and CTL 
cells, NK cells secrete IFN-γ but not IL-2. The effector functions of NK cells can 
be regulated by the integrated processing of signals transduced by stimulatory or 
inhibitory cell surface ligands/receptors440. Thus, it would be interesting and 
important to explore the nature of interaction between Fve and NK cells and the 
possible immunological outcomes of such interactions.  
In summary, the main objective of this chapter is to explore and elucidate the 
immunomodulatory effects of Fve on T cells, DCs, and NK cells by in vitro and in 
vivo experimental approaches such as [3H]-thymidine uptake for cell proliferations, 
ELISA for cytokine profiles, and FACS analysis for surface marker profiles. 




3.2.1. In vitro immunological characterization of Fve-stimulated splenocytes 
and splenic T cells 
3.2.1.1 Extraction and purification of Fve from cultivated Flammulina 
velutipes 
Fve protein is the major component of the crude extract from the mushroom fruit 
bodies of Flammulina velutipes (appendix 2). A native form of Fve protein was 
extracted from the fruit bodes of the cultivated golden needle mushroom (appendix 
2). Fve protein was purified, using ion exchange chromatography as described 
(section 2.2.2.1). The yield of Fve protein was 40 mg from 1 kg wet-weight of 
fresh mushroom. The purified Fve protein was analyzed on a 7.5% SDS-PAGE and 
the molecular weight of the protein is about 12.7 kDa. (Fig. 3.1). The purified Fve 
protein was used in all the experiments described in this thesis.  
3.2.1.2 Dose-dependent proliferation of Fve-stimulated splenocytes 
To examine the mitogenic effect of Fve on mouse splenocytes, splenocytes from 
C57BL/6 mice were cultured with Fve protein at final concentrations from 0 to 20 
μg/ml for 72 hrs, and then the cell proliferation was analyzed by [3H]-thymidine 
incorporation (section 2.2.4). As shown in Figure 3.2A, Fve stimulated splenocytes’ 
proliferation in a dose-dependent manner. 
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To exclude the possibility of endotoxin LPS contamination in the Fve protein, cell 
proliferation experiments were performed using Fve protein before and after 
polymyxin B agarose treatment. As shown in Figure 3.2B, the Fve-induced 
splenocytes proliferation remained unchanged before and after the removal of LPS, 
suggesting that the proliferation of splenocytes by Fve was not induced by LPS 
contamination. 
3.2.1.3 The percentages of CD4+ T cells and CD8+ T cells in Fve-stimulated 
splenocytes 
To characterize the Fve-induced T cell proliferation, splenocytes were stimulated 
by 20 μg/ml of Fve for 24, 48, and 72 hrs, and the surface markers CD3, CD4, and 
CD8 were analyzed by flow cytometry (section 2.2.6.1). The flow cytometric data 
were summarized in Table 3. As shown in Table 3, the percentages of 
Fve-stimulated CD4+ T cells in the cultured splenocytes were 28%, 35%, and 39% 
at 24, 48 and 72 hrs respectively, higher than those of non-stimulated CD4+ T cells 
(24%, 24%, 9%) and of GST-stimulated CD4+ T cells (27%, 23%, 9%). Similarly, 
and more evidently, the percentages of Fve-stimulated CD8+ T cells in the cultured 
splenocytes were 17%, 20%, and 43% at 24, 48, and 72 hrs respectively, much 
higher than those of non-stimulated CD8+ T cells (13%, 9%, 5%) and of 
GST-stimulated CD8+ T cells (10%, 7%, 7%). These data indicate that 
non-stimulated and GST-stimulated CD4+ and CD8+ T cells might go to apoptosis 
over time, whereas Fve-stimulated CD4+ and CD8+ T cells could proliferate and 
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survival longer.  
When analyzing the ratio of CD4+ T cells and CD8+ T cells (ratio = CD4/CD8, 
Table 3), the ratios of CD4/CD8 were almost unchanged at 24 hrs and 72 hrs in a 
non-stimulated group (from 1.9 to 2.0) but decreased significantly from 1.6 to 0.9 
after Fve stimulation, indicating that Fve may have more effects on CD8+ T cells 
than on CD4+ T cells. 
3.2.1.4 Aggregations of purified CD4+ T cells and CD8+ T cells in response to 
Fve 
Since Fve induced aggregation or adhesion of hPBMC424 and purified T cells from 
hPBMC (unpublished data from our lab), it’s interesting to examine whether a 
similar phenomenon could happen in the mouse. For this purpose, purified CD4+ T 
cells and CD8+ T cells from mouse spleen were co-cultured with 20 μg/ml of Fve 
protein for 24 hrs (section 2.2.3). Microscopic visualization of stimulated cells 
revealed that CD4+ T cells (Fig. 3.3A) and CD8+ T cells (Fig. 3.3B) form large 
aggregates, whereas unstimulated cells remained in a single-cell suspension. The 
cell aggregated within 30 min after Fve stimulation and continued to expand in size 
for the duration of the culture period.     
3.2.1.5 Up-regulation of CD69, OX-40 and 4-1BB expression on 
Fve-stimulated T cells 
Purified CD90+ T cells were stimulated with/without Fve in the presence or 
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absence of BM-DCs as accessory cells (ACs) for 24 hrs, and cell surface 
expression of CD69, OX-40, and 4-1BB were analyzed by flow cytometry. As 
shown in Figure 3.4, CD69, OX-40 and 4-1BB were up-regulated on CD3+CD4+ T 
cells and CD3+CD8+ T cells after Fve stimulation in the absence of accessory cells 
as compared to those on the non-stimulated T cells. The up-regulations of these 
markers increased greatly in the presence of accessory cells. These results indicate 
Fve could activate T cells independent of accessory cells, although the magnitude 
of the surface marker expression levels was greatly enhanced in the presence of 
BM-DCs as accessory cells. Moreover, further cytometric analysis of T subsets 
revealed that OX-40 was highly expressed on CD4+ T cells as compared to those 
on CD8+ T cells.  
3.2.1.6 Accessory cell-dependent T cell proliferation in response to Fve 
stimulation 
To explore further the mitogenic effect of Fve on T cells, purified CD90+ T cells 
were stimulated with/without 20 μg/ml of GST protein, or 20 μg/ml of Fve for 72 
hrs with/without accessory cells, and the cell proliferation was assayed by 
3H-thymidine incorporation (section 2.2.6.1). As shown in Figure 3.5, in the 
absence of accessory cells, T cells slightly proliferated in response to Fve as 
compared to those in non-stimulated and GST-controls, but the level of 
proliferation was very low. In contrast, the level of Fve-stimulated T cell 
proliferation was greatly enhanced in the presence of accessory cells, 10 times 
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higher than that in Fve-stimulated T cells without accessory cells. This indicates 
that Fve induces T cell proliferation is an accessory cell-dependent manner. 
Moreover, BM-DCs (Fig. 3.6) and B cells (Fig. 3.7) both can act as accessory cells 
to induce T cell proliferation. 
To determine whether Fve-induced proliferation of CD4+ and CD8+ T cells was 
accessory cell dependent or not, splenic CD4+ and CD8+ T cells were isolated by 
AutoMACS (section 2.2.2.5) and co-cultured with 20 μg/ml of Fve for 72 hrs, and 
the cell proliferation was examined by [3H]-thymidine incorporation. GST 
protein-stimulated T cells were used as control. As shown in Fig 3.8, Fve-induced 
proliferation of both T cell subsets in an accessory cell-dependent manner. 
Moreover, the proliferation levels of CD4+ and CD8+ T cells were similar at 48 hrs 
time point. However, the level of proliferation of CD8+ T cells was higher at 72 hrs 
as compared to that of CD4+ T cells. 
3.2.1.7 The cytokine profile of Fve-stimulated T cells 
To explore the cytokine profile of Fve-stimulated T cells, T cells from the 
splenocytes of C57BL/6 mice were cultured with 20 μg/ml of Fve protein for 72 
hrs and the culture supernatants were harvested for cytokine assay by ELISA 
(section 2.2.5). As shown in Figure 3.9, Fve induced CD3+ T cells to produce IFN-γ, 
IL-2, IL-6 in the presence, but not in the absence, of the accessory cells. Production 
of IL-4, TNF-α, and IL-10 by the Fve-stimulated T cells was at basal level. 
Moreover, the kinetics study of IFN-γ and IL-2 production revealed that a high 
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level of T cell-derived IL-2 was detected at 24 hrs, and then gradually decreased 
and finally reduced to basal level by 72 hrs after Fve stimulation (Fig. 3.10B). 
Since IL-2 is the growth factor of T cells, the reduction of IL-2 with time probably 
was inversely correlated to the increased Fve-induced T cell proliferation as 
described earlier (Fig. 3.5). On the other hand, significant levels of IFN-γ were 
detectable at 24 hrs time point and then reached maximum levels at 48 hrs after Fve 
stimulation, followed by a slight decline at 72 hrs (Fig. 3.10A). 
To investigate whether the IFN-γ and IL-2 production by T cells required direct 
cell-cell contact between BM-DCs and T cells, similar experiments were set up 
using the transwell culture system. BM-DCs were placed in the lower chambers in 
the presence of Fve, while T cells were placed on the upper chambers separated by 
a porous membrane. The production of IL-2 and IFN-γ was reduced significantly in 
transwell culture at 24 hrs as compared to the normal cell culture conditions (i.e., in 
the “DC + T cell + Fve” group with cell-cell contact). Interestingly, under the 
transwell culture conditions, high level production of IFN-γ was observed only at 
48 hrs instead of 24 hrs (Fig 3.10A) , and the production of IL-2 was significantly 
attenuated (Figure 3.10B), suggesting that the direct DC-T cell contact is important 
for the T cells to be fully activated.   
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3.2.2 Phenotypic and functional analysis of Fve-stimulated DCs 
3.2.2.1 Fve failed to up-regulate MHC class II, costimulatory molecules on 
BM-DCs in vitro 
It is well known that dendritic cell maturation status is a key parameter for DC-T 
cell cognate interaction, which determines the outcome of T cell activation and 
differentiation. The DC maturation process involves a series of changes including 
reduction of antigen uptake, up-regulation of surface MHC class II, and 
co-stimulatory molecules441. In this experiment, the phenotypic changes associated 
with DC maturation were monitored by surface marker staining followed by flow 
cytometry analysis. Briefly, purified BM-DCs were stimulated with Fve at 
concentrations ranging from 10 to 100 μg/ml, or LPS at 1 μg/ml as a positive 
control for 16–18hrs, and surface marker expression on BM-DCs was analyzed by 
flow cytometry after immunofluorecent staining (section 2.2.6.2). As shown in 
Figure 3.11, BM-DCs stimulated with LPS showed up-regulation of MHC class II, 
CD86, CD80, and CD40 as compared to the non-stimulated control. However, 
up-regulation of these surface markers was not observed on DC stimulated with 
various concentrations of Fve, except that there was a slight up-regulation of MHC 
class II on DC stimulated with 100 μg/ml of Fve. The results suggest that Fve is 
incapable of inducing DC’s phenotypic maturation under in vitro culture 
conditions.   
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3.2.2.2 Fve induced splenic dendritic cells phenotypic maturation in vivo, 
licensed them for Th1 priming 
In view of the observation that Fve failed to induce phenotypic maturation of 
BM-DCs under the conventional in vitro culture conditions, the next question to be 
addressed was whether Fve could induce DC maturation in vivo. To this end, 
splenic CD11c+ DCs were enriched from spleens of BALB/c mice that were 
injected intravenously with Fve 12 hrs prior to harvest, as described in method and 
materials (section 2.2.6.2, Fig. 2.1A&B) and the surface expression of MHC class 
II and CD86 was analyzed. PBS-injected mice were served as controls. As shown 
in Figure 3.12A, the up-regulation of MHC class II and CD86 molecules can be 
seen on both CD11chi and CD11cint subsets isolated from Fve-treated mice, as 
compared to that from PBS treated-mice. Furthermore, up-regulation of MHC class 
II and CD86 was seen in all three subtypes of CD11chi DCs (Fig. 3.12B), especially 
in the CD8α+ DCs. This indicates that Fve can stimulate phenotypic maturation of 
splenic DCs in vivo.  
Functional characterization of the DCs isolated from Fve-injected mice 
subsequently was carried out using CD4+ T cells purified from OVA-specific 
TCR-transgenic DO11.10 mice . As shown in Figure 3.13A, the OVA-specific 
CD4+ T cells co-cultured with DCs derived from the Fve-injected mice had a 
higher cell proliferation as compared to that of PBS control. To further assess the 
polarization effect of these splenic DCs on CD4+ T cells, culture supernatants were 
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collected for cytokine profiling by ELISA.  As shown in Figure 3.13B, CD4+ T 
cells co-cultured with Fve-treated DCs showed increased production of the 
Th1-skewed cytokines IFN-γ and IL-2 and proinflammatory cytokine IL-6, 
whereas the signature Th2 cytokine IL-4, was not up-regulated. The data suggest 
that Fve-treated splenic DCs may preferentially drive Th1 differentiation. 
3.2.2.3 Fve preferentially enhanced antigen-specific CD8+ T cell activation to 
produce high levels of IFN-γ and IL-2  
To further confirm the in vivo effects of Fve on mouse DCs, similar experiments 
were carried out using C57BL/6 mice. Splenic CD11c+ DCs were enriched from 
spleens of C57BL/6 mice intravenously injected with Fve 12 hrs prior to harvest 
(section 2.2.2.4) and the surface expression of MHC class II and CD86 was 
analyzed by flow cytometry. PBS and LPS-injected mice served as controls. 
Consistent with the above results (Fig. 3.12) in BALB/c, the up-regulation of MHC 
class II and CD86 molecules can be seen on both CD11chi and CD11cint subsets 
isolated from Fve and LPS-treated mice, as compared to that from PBS treated 
mice (Fig. 3.14C). Besides, up-regulation of MHC class II and CD86 was seen in 
all three subtypes of CD11chi DCs (Fig. 3.14D). This further indicates that Fve 
stimulate phenotypic maturation of splenic DCs in vivo.  
To explore further whether Fve-stimulated DCs can prime antigen-specific CD4+ 
and CD8+ T cell activation, in vitro functional assays for these Fve-stimulated DCs 
were performed using OVA-specific CD8+ and CD4+ T cells from OT-I and OT-II 
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mice, respectively (section 2.2.7). Analysis of culture supernatants of OVA-specific 
CD8+ T cells co-cultured with OVA-laden DCs isolated from OVA plus Fve 
co-injected mice showed that production of IFN-γ and IL-2, IL-6 was greatly 
increased as compared to that from all the other experimental control groups (Fig. 
3.15A). Such a remarkable enhancement of IFN-γ and IL-2 production by 
OVA-specific CD4+ T cells was not observed in similar parallel functional assays 
performed using CD4+ T cells from OT-II mice (Fig. 3.15B). Besides, there was no 
increased induction of IL-4, the signature cytokine for Th2 responses, by both 
CD4+ and CD8+ OVA-specific T cells. These data suggest that Fve can efficiently 
enhance the OVA-specific CD8+ T cell immune response, probably by modifying 
the ability of DCs to present antigen.  
3.2.2.4 Fve-activated T cells helped phenotypic maturation of BM-DCs in a 
cell- cell contact dependent manner 
The data from section 3.2.3.1 revealed that DCs failed to mature in response to Fve 
stimulation in vitro. In contrast to in vitro data, results from in vivo experiments 
showed that Fve induced phenotypic and functional maturation of splenic DCs. The 
difference in the results from in vivo and in vitro experiments indicates that there 
might be some other cell types or factors involved in the DC maturation in vivo. It 
has been reported that naïve T cells activated by superantigen could help DC 
maturation in vivo442. Besides, as shown by data presented in Figures 3.5, 3.6, 3.7, 
and 3.8, Fve can stimulate T cell activation. This prompted me to explore further 
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whether Fve-induced activated T cells can help DC maturation or not. 
To this end, purified CD90+ T cells from C57BL/6 mice were cultured with 
purified CD11C+ BM-DCs in the presence of 20 μg/ml of Fve for 24 hrs. 
Expression profile of the surface markers on BM-DCs was analyzed by flow 
cytometry. As shown in Figure 3.16, the expression of MHC class II, CD86, but not 
CD40 and CD80, was significantly up-regulated on DCs co-cultured with the 
combination of Fve and T cells as compared to those in the “DC alone,” “DC + 
Fve,” and “DC + T cell” controls. Transwell experiments (section 2.2.6.3) 
subsequently were set up to determine whether cell-cell contact between DCs and T 
cells is necessary for DC maturation. As shown by Figure 3.16, there was no 
up-regulation of MHC class II and CD86 on DCs under the transwell culture 
conditions.  
Another set of experiments was performed to address further whether 
pre-activation of T cells by Fve had a similar role for DC maturation as seen in the 
above experiments. Purified CD90+ T cells were pre-activated by Fve protein for 
24 hrs, followed by extensive washings to remove Fve protein before co-cultured 
with DCs for another 24 hrs ( designated as “DC + T (Fve)” in Fig. 3.17). The 
surface markers of DCs were analyzed by flow cytometry after immunofluorecent 
staining. The cytometric analysis results revealed that DCs co-cultured with the 
Fve-preactivated T cells showed up-regulation of the MHC class II and CD86, with 
an expression profile similar to that of the “DC + T + Fve” positive control.  
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Taken together, these data suggest that Fve-activated T cells could help DC 
maturation in a cell-cell contact dependent manner.    
3.2.3 Cytokine profile of Fve-stimulated NK cells 
NK cell represents an important and distinct cell type in the innate arm of the 
immune system. A preliminary study was conducted to explore the effects of Fve 
on NK cells purified from BALB/c mice by in vitro co-culture experiments (section 
2.2.8). Titrated numbers of NK cells were co-cultured with 10 μg/ml of Fve protein 
for 24 hrs and supernatants were collected for cytokine assays by ELISA. 
Microscopic examination showed that significant cell aggregation occurred at 24 
hrs (data not shown). Cytokine profiling data revealed that Fve-stimulated NK cells 
produced significant levels of IL-6 without increased production of IFN-γ, IL-2, 
IL-4, and IL-10. The production of IL-6 without IFN-γ cytokine production profile 
is a rather unexpected observation that deserves further investigation.   











Figure 3.1 SDS-PAGE analysis of purified native Fve protein. Fve protein 
purified from Flammulina velutipes by ion exchange chromatography was analyzed 
by 7.5% of Tricine SDS-PAGE. Fve shows a single band with molecular mass of 
12.7 kD. Lane 1: molecular mass markers; lane 2: purified Fve protein from 
Flammulina velutipes (golden needle mushroom). 
















Figure 3.2 Fve stimulated mouse splencyte proliferation. Splenocytes collected 
from C57BL/6 naïve mice were resuspended in the RPMI complete medium, and 
incubated in the presence of different doses of Fve in triplicate wells of a 96-well 
plate (5 × 105 cells/well) (A). To exclude the possibility of endotoxin’s effect on 
splenocytes proliferation, splenocytes (5 × 105 cells/well) from C57BL/6 naïve 
mice were incubated with 20 μg/ml of Fve (before and after polymyxin B agarose 
treatment) (B). The cultures were pulsed for 18 hrs with [3H]-labeled thymidine. 
The cells were harvested and thymidine incorporation was measured by liquid 
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Table 3 The percentage of CD3+CD4+ T cells and CD3+CD8+ T cells in total 




CD3+CD4+ T cells 
(%) 
CD3+CD8+ T cells 



















Non-stimulation 24  24 9 13 9 5 1.9  2.7  2.0 
GST (20 μg/ml) 27  23 13 10 7 7 2.8  3.4  1.9 
Fve (20 μg/ml) 28  35 39 17 20 43 1.6  1.7  0.9 
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A. Purified CD4+ T cells 
                               Non-stimulation 










B. Purified CD8+ T cells 
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Figure 3.3 The aggregations of purified mouse CD4+ T cells and CD8+ T cells 
after Fve stimulation. CD4+ T cells and CD8+ T cells from spleen of C57BL/6 
mice were purified by AutoMACS. Purified CD4+ T cells and CD8+ T cells were 
stimulated with 20 μg/ml of Fve for 24 hrs. The morphology of the CD4+ T cells (A) 
and CD8+ T cells (B) was examined by light microscopy at 24 hrs. Non-stimulated 
CD4+ T cells and CD8+ T cells used as negative controls. 
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Figure 3.4 Fve stimulated CD69, OX-40, 4-1BB up-regulation on T cells. 
CD90+ T cells purified from the splenocytes of C57BL/6 mice were incubated for 
24 hrs either alone or with BM-DCs at a 10:1 ratio (T cell/DC) in the presence or 
absence of 20 μg/ml of Fve. The cells were stained with rat anti-mouse CD3−percp, 
CD4−APC, and anti-CD8β−FITC, CD69−PΕ, OX-40−PE or 4-1BB−PE. The cells 
were gated for CD3+CD4+ (A), CD3+CD8+ cells (B) for activation analysis by flow 
cytometry. The numbers in the histograms represent the mean fluorescence 
intensities (MFIs) of the surface markers on T cells. 
 


























Figure 3.5 Fve stimulated mouse spleen T cells proliferation in an accessory 
cell-dependent manner. For accessory cell-dependent proliferation assay, CD90+ 
T cells from splenocytes of C57BL/6 (A) or BALB/c (B) mice were purified from 
spleen cells by AutoMACS. Mitomycin C-treated splenocytes (3 × 105  cells/well) 
as accessory cells were co-cultured with purified CD90+ T cells (1 × 105 cells/well) 
with GST (20 μg/ml), or Fve (20 μg/ml) for 72 hrs. The cultures were pulsed with 
[3H]-thymidine for the last 18 hrs of the co-culture. The cells were harvested and 
thymidine incorporation was measured by liquid scintillation counting at 72 hrs. 















































   
 
 
Figure 3.6 DCs can be accessory cells in the T cell proliferation stimulated by 
Fve. Purified CD90+ T cells (1 × 105 cells/well) from C57BL/6 mice were 
co-cultured with mitomycin C-treated BM-DCs (2 × 104 cells/well) in the presence 
or absence of Fve (20 μg/ml) in triplicates using the 96-well plate. The DCs and 
CD90+ T cells alone were included for comparison. The cultures were pulsed with 
[3H]-thymidine for the last 18 hrs of the co-culture. The cells were harvested and 
thymidine incorporation was measured by liquid scintillation counting at 72 hrs. *: 
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Figure 3.7 B cells as accessory cells in the T cell proliferation stimulated by 
Fve. For accessory cell-dependent proliferation assay, mitomycin C-treated B cells 
(3 × 105 cells/well) were co-cultured with CD90+ T cells (1 × 105 cells/well) from 
C57BL/6 (A) or BALB/c mice (B) with GST (20 μg/ml), or Fve (20 μg/ml). The 
cultures were pulsed with [3H]-thymidine for the last 18 hrs of the co-culture. The 
cells were harvested and thymidine incorporation was measured by liquid 
scintillation counting at 72 hrs. B cell refers to mitomycin C-treated B cell. The 
experiments were performed three times and similar results can be observed. Data 










































Figure 3.8 Accessory cell-dependent proliferation of Fve-stimulated T cell 
subsets. Mitomycin C-treated splenocytes (3 × 105 cells/well) as APCs were 
co-cultured with purified CD4+ or CD8+ T cells (1 × 105 cells/well) from C57BL/6 
mice with GST (20 μg/ml), or Fve (10 μg/ml) for 48 hrs (A) or 72 hrs (B). The 
cells then were harvested and thymidine incorporation was measured. *ACs 
(accessory cella), refers to mitomycin C-treated splenocyte. The experiments were 
performed twice and similar results can be observed. Data are representative from 
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Figure 3.9 Profile of cytokine production by T cells stimulated with Fve in vitro. 
CD90+ T cells (2 × 106 cells/ml) from the spleen of C57BL/6 mice were incubated 
either alone or with BM-DCs at a 10:1 ratio (T cell/DC) in the presence or absence 
of 20 μg/ml of Fve for 24 hrs. The supernatants were collected and cytokine 
production by T cells was measured by ELISA. The experiments were performed 
three times and similar results can be observed. Data are representative from one of 






























Figure 3.10 Fve stimulated murine T cells to produce IFN-γ and IL-2 in 
different kinetics. CD90+ T cells (2 × 106 cells /ml) from the spleens of C57BL/6 
mice were incubated either alone or with BM-DCs at a 10:1 ratio (T cell/DC) in the 
presence or absence of 20 μg/ml of Fve for 24, 48 or 72 hrs. Transwell groups also 
were set up correspondingly. The supernatants were collected and cytokine 






























































































                                         
 
 
Figure 3.11 Immunofluorecent staining of CD11c+ DC after Fve and LPS 
treatment. BM-DCs were stimulated with different concentrations of Fve protein, 
or LPS for 16–18 hrs. The numbers in the histograms represent the mean 
fluorescence intensities (MFIs) of the surface markers on BM-DCs after 
stimulation. LPS but not Fve triggered up-regulation of MHC class II, CD86, 





































































Figure 3.12 Fve induced splenic dendritic cells phenotypic maturation in vivo. 
BALB/c mice (n = 8 mice/group) were injected intraveneously with PBS, Fve, or 
LPS 12 hrs prior to cell harvest. DCs were enriched from spleen for staining of 
MHC class II and CD86. Splenic DCs were separated into CD11cint and CD11chi 
populations (A) and CD11chi DCs could be divided further into CD4+, CD8α+ and 
CD4-CD8α− sub-populations (B). Dark line histograms represent PBS-stimulated 
DCs, filled grey histograms represent Fve-stimulated DCs. The numbers in the 































































































Figure 3.13 Fve-activated splenic DCs induced the antigen-specific CD4+ T 
cells priming. BALB/c mice (n = 8 mice/group) were injected intraveneously with 
PBS or Fve, and the DCs from the pool of eight spleens from each group of mice 
were isolated 12 hrs later. Purified DCs were pulsed with or without 0.1 µM of 
OVA323-339 peptide for 2 hrs at 37°C and washed three times before cocultured with 
CD4+ T cells from DO11.10 transgenic mice for 72 hrs. The 3H-thymidine was 
added 18 hrs before cell harvest and thymidine incorporation was measured by 
liquid scintillation counting after 72 hrs (A). Supernatants were collected and 
cytokine production was measured by ELISA (B). The experiments were 
performed three times and representative data from one of these experiments are 
presented. DC: dendritic cells alone; DC/CD4=1/10: the ratio of DCs to CD4+ T 
cells is 1 to 10.  







Figure 3.14 Fve induced splenic dendritic cells phenotypic maturation in vivo. 
C57BL/6 mice (n = 8 mice/group) were injected intraveneously with PBS, Fve, or 
LPS 12 hrs prior to cell harvest. DCs were enriched from spleen for staining of 
MHC class II and CD86. Splenic DCs were separated into CD11cint and CD11chi 
populations (A) and CD11chi DCs could be further divided into CD4+, CD8α+ and 
CD4-CD8α− sub-populations (B). MHC class II and CD86 up-regulation can be 
seen in both CD11cint and CD11chi populations (C) and the three CD11chi 
sub-populations of DCs (D) after stimulation by Fve in vivo. Dark line histograms 
represent PBS-stimulated DCs, red line histograms represent Fve-stimulated DCs, 
and green line histograms represent LPS-stimulated DCs. Data are representative of 
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Figure 3.15 Fve greatly enhanced antigen-specific responses of CD8+ T cells.  
C57BL/6 mice (n = 8 mice/group) were intraveneously injected with PBS (□), OVA 
(  ), Fve (■), or OVA plus Fve (■), and the DCs from the pool of eight spleens from 
each group of mice were isolated 24 hrs later. Purified DCs were pulsed with 1 µM 
of OVA257-264 peptide or 1 µM of OVA323-339 peptide for 2 hrs at 37°C and washed 
three times before co-cultured with CD8+ T cells from OT-I mice or CD4+ T cells 
from OT-II mice, respectively, for 72 hrs. Supernatants were collected and cytokine 
productions by CD8+ T cells (A) and CD4+ T cells (B) were measured by ELISA. 
The experiments were performed three times and representative data from one of 
these experiments are presented. DC: dendritic cells alone; DC/CD8=1/10: the ratio 
of DCs to CD8+ T cells from OT-I mice is 1 to 10; DC/CD4=1/10: the ratio of DCs 







































































Figure 3.16 T cells helped phenotype maturation of BM-DCs stimulated by 
Fve in a cell-to-cell contact manner. Purified BM-DCs were incubated alone (DC 
alone), or with CD90+ T cells at a T cell/ DC ration of 10:1; with CD90+ T cells (T 
cell/DC = 10:1) separated in trans-well in the presence or absence of Fve protein 
(20 μg/ml). MHC class II, CD86, and CD40 staining of DCs were performed and 
represented as dark line histograms. The numbers in the histograms indicates the 




























































                                              
 
Figure 3.17 Preactivated T cells can help BM-DCs to up-regulate MHC class II 
and CD86. CD90+ T cells were purified from splenocytes in C57BL/6 mice and 
stimulated with/without Fve protein (20 μg/ml) for 24 hrs. The purified BM-DCs 
were incubated with freshly purified T cells or activated T cells (T cell/DC ratio= 
10:1) for 24 hrs. The surface markers, such as MHC class II, CD86, and CD80 on 
BM-DCs were stained and analyzed. The numbers in the histograms represents the 
MFIs of the surface markers. DC respresents Bone marrow-derived dendritic cells 
(BM-DCs), T represents T cells. DC+ T (ctrl) indicates non-stimulated T cells 
co-cultured with BM-DCs. DC+ T (Fve) indicates Fve-preactivated T cells 
co-cultured with BM-DCs. DC+T+Fve indicates fresh prepared T cells co-culured 
with BM-DCs in the presence of Fve protein. 
 

















































Figure 3.18 Cytokine profile of NK cell stimulated by Fve in vitro. Different cell 
numbers of purified NK cells from BALB/c mice were stimulated with/without 10  
μg/ml Fve in vitro. After 24 hrs, supernatants were collected for cytokine assay 
using ELISA. The experiments were performed two times and representative data 
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3-D structure of Fve homodimer
 
 
Figure 3.19 Three-dimensional structure of Fve and a proposed model for the 
interactions between Fve and target cells. (A) Three-dimensional structure of 
Fve protein. Fve is a homodimer protein and each monomer consists of N-terminal 
α-helix followed by a FNIII-like domain with Ig fold. (B) In this proposed model, 
the homodimer structure of Fve protein could act as a bridge to induce cell-cell 
aggregations that occur via a stepwise manner. (1) The interaction of Fve protein 
with the cellular receptor(s) probably via binding to the receptor’s sugar 
components could represent the first step to initiate cell-cell aggregation, which 
results in the up-regulation of CD69, adhesion molecules such as ICAM-1, and 
other accessory molecules on target cells. (2) The Fve-induced adhesion molecules 
and accessory molecules expressed on activated target cells, which further 
enhanced the cell-cell interaction and aggregation. The APC-T cell bidirectional 
interaction results in: (1) full activation of the T cells for the cytokine production 
and cell proliferation; (2) the APC maturation. 
* ( ) represents the Fve homodimer; (■) represents possible sugar 
component(s) of receptor(s) constitutively expressed on target cells, including T 
cells, DCs and NK cells; ( ■, ■) represent the putative adhesion and accessory 
molecules expressed on the activated target cells. 










Figure 3.20 Proposed mechanisms by which Fve protein enhanced innate and 
adaptive immune responses via cooperative interactions between T cells, DCs 
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This chapter describes the in vitro and in vivo studies on the immunomodulatory 
effects of native Fve protein on T subsets, DCs and NK cells. In addition, the 
interactions between Fve, T and DC and the subsequent immunological outcomes 
and implications will be described and discussed. 
In this study, it was observed that total splenocytes from C57BL/6 mice co-cultured 
with graded doses of Fve protein showed dose-dependent cell proliferative 
responses (Fig. 3.2A). After 72 hrs of Fve stimulation, the percentages of CD4+ and 
CD8+ T subsets in the splenocytes were analyzed by flow cytometry. As shown by 
the cytometric data in Table 3, there was a greater percentage increase of CD8+ T 
cells than CD4+ T cells with the corresponding change of CD4/CD8 ratio from 2.0 
to 0.9 for after Fve stimulation. The results suggest that Fve can stimulate more 
CD8+ T cell proliferation than CD4+ T cell proliferation (Table 3), and such an 
intriguing preferential increase in CD8+ T cells also was observed in the in vivo 
settings, whereby mice received three subcutaneous injections of Fve protein that 
resulted in a similar increase of the percentage of CD8+ T cells in spleen and 
draining lymph nodes (unpublished data from our laboratory). The underlying 
mechanisms for this intriguing Fve-induced preferential increased proliferation of 
CD8+ T cells remain unclear and need to be explored further. 
Subsequently, the effects of Fve protein on purified CD90+ T cells, CD8+ and CD4+ 
T subsets were analyzed. Microsopic visualization of stimulated cells revealed that 
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the purified CD4+ and CD8+ T subsets aggregated 2–4 hrs after being co-cultured 
with 20 μg/ml of Fve protein (Fig. 3.3). Similar T cell aggregation by Fip proteins 
has been observed in the previous studies, which showed that hPBML aggregation 
can be induced by Lin Zhi-8424 and Fve protein415. Moreover, the data from our lab 
also indicate that Fve could induce purified human CD4+ and CD8+ T cell adhesion. 
Incidentally, such cell aggregations also were observed in Fve-stimulated purified 
CD11c+ DCs and NK cells (data not shown). Cytometric surface marker analysis of 
the Fve-stimulated purified T cells showed an up-regulation of CD69, an early 
activation marker (Fig. 3.4), and adhesion molecule ICAM-1 (data from our 
laboratory), but there was no cytokine production and cell proliferation by these T 
cells, suggesting that Fve could not fully activate purified T cells in the absence of 
accessory cells, although Fve induced the cellular aggregation. Further studies 
showed that with the help of DCs or B cells as accessory cells, T cells could be 
fully activated as reflected by further up-regulation of CD69, OX40, 4-1BB 
expression and cellular proliferation and cytokine production. The importance of 
accessory cells for T cell activation by mitogens has been reported443,444 and 
previous mechanistic studies found that soluble factors (IL-1, IL-6) and physical 
interaction with T cells of accessory cells were both required for the activation of 
human peripheral blood T cells or murine T cells445-448. 
The modes of interaction of Fve with its target cells probably could be explained 
by the unique structural and functional properties of Fve protein. A published 3D- 
structural study of Fve protein from our laboratory430 has demonstrated that native 
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Fve exists as a homodimer protein in natural conditions (Fig. 3.19A, appendix 4). 
Each monomer consists of an N-terminal α-helix and β-strand followed by a 
fibronectin type III-like domain with immunoglobulin like-fold. The N-terminal 
α-helices and the β-strands in both subunits, which run anti-parallel to each other, 
form secondary structure elements for the protein dimerization, while Ig like 
domains are responsible for the carbohydrates-binding.  
Some preliminary sugar binding studies suggested that Fve could be a unique lectin 
sharing some functional similarities with other well-known lectins such as PHA, 
ConA, and PMA, as summarized in appendix 6. Moreover, there are two predicted 
patches of residues on Fve protein that could be associated with sugar binding 
properties (430, appendix 5). On the basis of the characteristic structural features of 
Fve, A model will be proposed to explain the possible modes of interaction of Fve 
protein and its target cells, and the subsequent induction of cellular aggregation 
using the cartoon shown in Figure 3.19B. It is conceivable that Fve could bind to 
the sugar components of the constitutive expressed surface cellular receptor(s) of 
its target cells, such as T cells, leading to cellular aggregation that resulted in 
partial T cell activation. In the settings whereby T cells co-culture with Fve in the 
presence of DCs or B cells as accessory cells, a multitude cellular interactions 
could occur through the binding of Fve to all its target cells. For example, 
Fve-induced DC-DC aggregation may lead to up-regulation of additional adhesion 
molecules or counterpart ligands for molecules such as OX-40, 4-1BB expressed 
on Fve-activated T cells, resulting in further enhanced cell-cell interaction and 
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subsequent mitogenic activation of T cells. 
Generally, the activation of T lymphocytes by antigens or mitogens initiates a 
coordinated up- and down-regulation of the expression of a wide number of known 
genes during the early phase. The CD69 molecule, designated as activation inducer 
molecule (AIM)449, early activation antigen (EA-1)450, MLR-3, Leu-23451, is a 
phosphorylated disulfide-linked 27/33-kD homodimeric protein452. CD69 
expression is induced in vitro on most immune cells, especially on T lymphocytes. 
In this study, the up-regulation of CD69 on both CD4+ and CD8+ T cells was 
observed after Fve stimulation (Fig. 3.4A&B). Similar findings have been reported 
for T cell activation induced by a variety of stimuli, such as Lin Zhi-8424, 
anti-CD3/TCR453 and anti-CD2 mAbs, activators of protein kinase C454, or PHA449. 
Moreover, CD69 signal has been shown to induce synthesis of different cytokines, 
such as IL-2, TNF-α, and IFN-γ, and T cell proliferation. In the present study, 
Fve-induced T cell proliferation (Fig. 3.5), and IL-2 and IFN-γ production (Fig. 
3.9) , is an accessory cell-dependent event although CD69 was also up-regulated on 
T cells without the help of accessory cells, indicating that CD69 expression is 
insufficient to trigger full activation of T cells and that accessory cells have 
definitely an important role in helping T cell activation.  
Moreover, Fve-activated CD4+ and CD8+ T cells also showed up-regulation of 
OX-40 (CD134) and 4-1BB (CD137) (Fig. 3.4 A&B). OX-40 and 4-1BB are TNF 
superfamily molecules that are commonly expressed following T cell activation; 
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their direct effects on CD4+ and CD8+ T cells have been studied extensively455,456. 
Their counterparts, designated as OX-40L and 4-1BBL, respectively, can be 
expressed by dendritic cells, B cells, T cells and non-immune cells, such as smooth 
muscle cells and endothelial cells457,458. The signaling of OX-40 and 4-1BB 
controls the T cell immune response in two ways. First, they positively regulate the 
T cell division, proliferation, and survive by enhancing the expressions of survivin 
and aurora B kinase459, anti-apoptotic molecules (BCL-2 and BCL-XL)380,460, and 
inhibiting the expression of the pro-apoptotic molecule BIM461. The interactions 
between OX-40L and OX-40, 4-1BBL and 4-1BB can also expand the 
antigen-specific memory cell pool. Second, studies using mouse TReg cells have 
shown that ligation of the OX-40 affect these T-cell subsets462. Signaling triggered 
by OX-40 has been found to inhibit the development of FOXP3+ TReg cells from 
naive CD4+ T cells463-465 and suppress the differentiation of IL-10-producing CD4+ 
TReg cells from naive CD4+ T cells466. Furthermore, ligation of OX-40 
down-regulated FOXP3 and IL-10 expression in newly differentiated inducible 
TReg cells and consequently resulted in their conversion to effector T cells466. 
Although how signaling through 4-1BB affects the induction of peripheral TReg 
cells is not yet known, binding of 4-1BB to its ligand has been shown to block the 
suppressive activity of TReg cells in culture systems that contained both inducible 
and natural TReg cells467. Thus, ligation of OX40 and 4-1BB has a dual effect on 
promoting T-cell responses: it enhances the proliferation of effector T cells and 
concomitantly blocks the generation of inducible TReg cells or blocks their 




Besides, results from this study showed that Fve-induced production of IL-2 and  
IFN-γ by T cells followed different kinetics. IL-2 was produced very rapidly and 
reached the peak by 24 hrs, whereas the level of IFN-γ increased continuously and 
was maintained at a high level after 48 hrs (Fig. 3.10). The different kinetics of 
IL-2 and IFN-γ production may be due to sequential activation of the different 
signaling pathways in T cells and the characteristics of IL-2 and IFN-γ themselves. 
Early in vivo study indicates that production of IL-2 by activated T cells can be 
detected as early as 1–2 hrs, maximal secretion achieved within 6–8 hrs, and 
secretion undetectable by 20–24 hrs469. IL-2 production by T cells in this study is 
somewhat slower than the above in vivo study but consistent with the report in vitro 
study470. The molecular mechanism underlying the transient nature of IL-2 is less 
well understood. A classical auto-regulatory feedback loop has recently been 
described in which IL-2 inhibits its own production by activating several STAT 
transcription factors and transcriptional repressor B lymphocyte maturation 
protein-1 (Blimp-1)470,471. Moreover, it has been widely accepted that IL-2 is a 
potent mediator that stimulate the proliferation and promotes survival of activated 
T cells472,473. Lin Zhi-8, which is a homology of Fve, has been shown to induce T 
cell proliferation. Neutralizing Ab to IL-2 receptor blocks its proliferative 
response424. Based on these observations, it is reasonable to speculate that IL-2 is 
important in the Fve-induced T cell proliferation. Besides, IL-2 is able to induce 
the activation of NK cells474 and facilitates the induction of CTLs, and induces the 
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proliferation of, and immunoglobulin synthesis by, B cells148. IFN-γ has been 
regarded as a key cytokine in protecting host against microorganism infection and 
tumor formation48,62,64-67,73. The major properties of IFN-γ include stimulation of 
phagocyte bacteriacidal activity, stimulation of antigen presentation through class I 
and class II MHC molecules475, orchestration of leukocyte-endothelium 
interactions476, up-regulation of co-stimulatory molecules CD86, CD80 on 
APCs477,478, the activation of transcription factors, such as IRF-1/2479, and the 
stimulation and repression of a variety of genes476.  Based on this, induction of 
IL-2 and IFN-γ production by Fve provided the theoretical bases that led us ot 
develop Fve-based cancer immunotherapies. 
DCs are well recognized for their role in the priming and differentiation of naïve T 
cells480. DCs collect and process antigens for presentation to T cells, but there are 
many variations on this basic theme. DCs differ in the regulatory signals they 
transmit, directing T cells to different types of immune response or tolerance. The 
data from the present study showed that Fve can aggregate BM-DCs after an 
overnight stimulation (data not shown). However, the up-regulation of the 
conventional maturation markers such as MHC class II, CD86, CD80, and CD40 
on BM-DCs and the enhanced production of cytokine IL-12 and TNF-α by 
BM-DCs were not observed after in vitro co-cultured with Fve (Fig. 3.11). In 
contrast to the in vitro data, Fve induced maturation of DCs in vivo as documented 
by the up-regulation of MHC class II and CD86 (Figs. 3.12&3.14). Notably, it 
appears that Fve preferentially, although not exclusively, drives maturation of the 
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CD8+ dendritic cell subset (Figs. 3.12 & 3.14). Compatible with phenotypic 
maturation, DCs from Fve-injected mice enhanced the OVA-specific CD4+ activity 
and skewed Th1 immune response (Fig. 3.13). Moreover, in vitro functional assay 
using OVA-specific CD8+ T cells from OT-I mice clearly showed that DCs from 
mice co-immunized with Fve and OVA greatly enhanced the activation of 
antigen-specific CD8+ T cells (Fig. 3.15A). It is well known that there are at least 
three distinct subsets (CD4+CD8-, CD4-CD8+, CD4-CD8-) of DCs found in the 
mouse spleen. Previous studies have shown that these subsets exhibit intrinsic 
differential capacity to present soluble antigen and activate antigen-specific CD4+ 
and CD8+ T subsets. The CD8− subsets show the greatest ability to stimulate 
antigen-specific MHC class II-restricted CD4+ T cells, whereas the CD8+ DC are 
much more efficient at cross-presenting antigen and stimulating MHC class 
I-restricted CD8+ T cells481,482. Thus, it is tempting to speculate that Fve could 
modify the ability of DCs (for example, by up-regulating the CD8+ DC subset to 
enhance CD8+ T cells via cross presentation pathway) to generate enhanced 
Ag-specific T cell immune response in vivo.  
The differential effects of Fve on DC maturation seen in the in vivo and in vitro 
experimental settings suggest the possible roles of other cell types to help DC 
maturation. Moreover, it is well known that immune cells such as NK cells, γδ-T 
cells and activated T cells can induce DCs maturation442,483-487. The mitogenic 
effects of Fve on T cells activation prompted me to conduct to explore the helper 
role of activated T cells in DC maturation. Indeed, the data from this study revealed 
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that Fve-stimulated T cells could induce phenotypic maturation of DC in vitro a 
cell-to-cell contact dependent manner (Figs. 3.16). Similar observations have been 
reported by a number of laboratories442,485-487. McLellan et al. demonstrated that 
Ag-stimulated T cells positively regulated the expression of costimulatory 
molecules on DCs487. In another study, Muraille et al. found that activated T cells 
induced by staphylococcal superantigen or anti-CD3 mAbs were required for 
optimal DC maturation in vivo442. Collectively, these observations support the 
notion that T cells can be stimulated rapidly in vivo and initiate a cascade of events 
leading to DC maturation. However, the precise mechanisms by which Fve-induced 
DC maturation in the in vivo setting remain unclear in the present study. Therefore, 
further studies using RAG-/-, CD4-/- or CD8-/- mice can be carried out to confirm the 
helper role of T cells in DC maturation in vivo. Besides, trans-well study showed 
that T cell-DC direct interaction is a prerequisite for DC maturation. It is well 
known that CD40 stimulation is important for DC maturation and IL-12 production. 
In this study, the CD40L expression was not up-regulated in the Fve-stimulatd T 
cells, indicating CD40-CD40L interaction might not be essential for the T 
cell-mediated DC maturation. Thus, identification of the surface molecules 
involved in T-DC interaction is necessary in order to further dissect the 
mechanisms of T cell-mediated DC stimulation. 
Of note, it has been shown that interaction between NK cells and DCs can also 
induce DC maturation, mediated by NK cell-derived cytokines. Ligation of NKp30 
on NK cells by DCs promotes the secretion of TNF-α and IFN-γ, which leads to 
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DC maturation488. Another study showed that induced recruitment of NK cells into 
lymph nodes provided an early source of IFN-γ for Th1 polarization, which could 
be a mechanism by which some adjuvants facilitated Th1 responses489. Both 
studies suggested that IFN-γ secreted by NK cells play a pivotal role in the 
initiation and regulation of innate and adaptive immune responses. In this study, 
however, it was observed that Fve stimulated NK cells to produce significant levels 
of IL-6 without concomitant elevated production of IFN-γ, IL-2, IL-4, and IL-10. It 
appears that Fve-induced NK cells responses could be unique and the implications 
of such responses DC phenotypic maturation and T cell activation deserve further 
studies. 
The roles of IL-6 in innate and adaptive immunity have been an area of active 
research in recent years. In this study, it was observed that Fve-stimulated T cells 
(Fig. 3.9) and NK cells (Fig. 3.18) secreted significant levels of IL-6 that was not 
reported in other Fve-related studies. IL-6 was first found in 1977 490 and has 
multiple well-characterized functions, such as regulating T cell proliferation, 
survival, and B cell differentiation491. The mechanism for maintaining the T cell 
survival is that IL-6 rescues T cells from entering apoptosis, and protects cells from 
Fas-mediated cell death492,493. More recent studies have documented a series of 
IL-6 activities that are critical for regulating the innate immunity. For example, at 
least two in vitro studies suggested that IL-6 was involved in skewing the 
differentiation of human monocytes away from a dendritic lineage to a more 
macrophage phenotype494,495 indicating that IL-6 might have some inhibitory 
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effects on the development of dendritic cells. Moreover, another study reported that 
IL-6 inhibited NF-kB activity and suppressed CCR7 expression in dendritic cells496, 
suggesting that IL-6 may inhibit their maturation or trafficking. In contrast, Pasare 
et al. found that IL-6 secretion by dendritic cells following TLR activation blocks 
the immunosuppressive activities of regulatory T cells, indicating IL-6 is essential 
in the activation of antigen-specific adaptive immune response induced by 
dendritic cells497. The implications of Fve-induced IL-6 production by T and NK 
cells on the innate and adaptive immunological outcomes have not been addressed 
in this study. It is conceivable that IL-6, acting cooperatively with other cytokines, 
is likely to be an important regulatory and determining factor in the initiation and 
differentiation of antigen-specific immune responses. Therefore, it is an important 
area to be addressed by more studies.  
Taken together, data derived from this study indicate that Fve is a mitogen, 
targeting immune cells of both innate and adaptive immune systems. Our data also 
strongly support the notion that Fve is a potent mitogen that predominantly 
activates T cells, and the full activation of T cells is accessory cells dependent. 
Furthermore, results from in vitro and in vivo studies suggested that there is a 
dynamic cross talk and bi-directional positive feedback between DCs and T cells. It 
appears that DCs can act as accessory cells to fully activate T cells to produce IL-2, 
IFN-γ, and IL-6, and induce cellular proliferation. On the other hand, Fve-activated 
T cells can help DC subsets to acquire phenotypic and functional maturation for the 
priming and differentiation of antigen-specific CD4+ and CD8+ T cells. 
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Furthermore, Fve inducs NK cells to secrete IL-6 and probably other unidentified 
mediators that can have important immunological implications. These multitude 
interactions of Fve with T, DC, and NK cells, and their possible cooperative 
interactions and the possble immunological outcomes, are summarized in Figure 
3.20. 
As we know, successful cancer immunotherapy aims to enhance antigen-specific 
immune response not only by boosting components of the immune system that 
produce an effective and memory immune response intrinsically but also by 
inhibiting components that may induce tolerance. Information generated from this 
study prompted us to propose that Fve can be used as a potent adjuvant molecule to 
initiate and potentiate a Th1-skewed antigen-specific CD4+ T cell and CD8+ T cell 
immune response. Such adjuvant properties can be further exploited for boosting 
effectiveness of immunotherapeutic vaccines to target cancer. A classic example for 
this type of immunotherapeutic vaccines against cancer is the vaccine against 
HPV-associated cervical cancer. The proof of concept work in support of this 
notion will be described and discussed in the next chapter. 
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Chapter 4  
Enhanced antitumor immunity by coadministration of 
HPV-16 E7 protein and Fve protein 
 
4.1 Introduction 
Cancer immunotherapy is an attractive alternative for the treatment of patients with 
cancer. The side effects, when used in the absence of radiotherapy or chemotherapy, 
are lower than those of classical antitumor chemotherapeutics. Identifying and 
cloning genes encoding tumor-associated antigens recognized by T cells has 
reopened the never-ending hope of curing cancer13. Although several treatments 
using tumor-associated antigens have been approved for some types of cancers, 
their efficacies have been variable and generally not sufficient. One important 
contributory factor for the insufficient and variable responses of immunotherapy is 
the poor immunogenicity of most tumor antigens, which results in insufficient 
activation of tumor antigen-specific CD8+ T cells. 
Cervical cancer is the second largest cause of cancer deaths in women and kills 
approximately 274,000 women worldwide each year498,499. Epidemiological and 
laboratory studies strongly support a crucial role for persistent human 
papillomavirus (HPV) infection and transcription in cervical carcinogenesis500,501. 
Although more than 100 HPV genotypes have been identified, four “high-risk” 
types of HPV (types 16, 18, 31, 45) are associated with approximately 80 percent 
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of all cervical cancers502,503. Of the high risk types, HPV type 16 is the most 
common and is responsible for more than 50 percent of all cervical cancers503. 
HPV are double-stranded circular viruses of approximately 8 kb that infect basal 
and suprabasal layers of stratified epithelium. The early genes, which include E1, 
E2, E4, E5, E6, and E7, code for proteins involved in viral DNA replication, 
transcription control, and cellular transformation. Late genes encode the major viral 
capsid protein, L1 and a minor capsid protein, L2. Infection with high-risk HPV 
sometimes results in integration of the viral episome into host DNA. If the 
integration interrupts the viral E2 gene and results in the loss of E2-mediated 
transcriptional repression, the transformed cells overexpress the E6 and E7 proteins, 
initiating the malignant transformation process501,504. Thus, HPV-16 E7 has been a 
major target of many prophylactic HPV vaccines in the prevention of HPV 
infections, as well as of many therapeutic HPV vaccines for the control of existing 
HPV infections and HPV-associated lesions, such as squamous intraepithelial 
lesion and cervical cancer. However, the antigen-specific immune responses and 
antitumor effects generated by HPV-16 E7 alone are weak and insufficient to 
control tumor growth. Several strategies have been developed to increase the 
potency of HPV-16 E7 vaccine; for example, immune modulators, such as 
cytokines505,506, heat shock proteins507,508, non-toxic bacteria toxins509, or CpG270 
have been incorporated as adjuvant to enhance the HPV-16 E7-specific immunity. 
These have proven to be effective in animal models, but their potency in humans 
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has yet to be assessed, and active research to develop novel adjuvant molecules still 
is ongoing. 
Fve has been shown to have the ability to trigger the proliferation of murine T cells 
and production of IL-2, IFN-γ (from my data in chapter 3, 415,423). Moreover, Fve 
can activate the innate immunity by stimulating the DCs maturation and further 
enhance the antigen-specific CD8+ T cells activity. Previous study also found that 
coadministration of Fve with antigen could drive strong Th1-skewed immune 
responses431. Taken together, information generated from this study prompted us to 
propose that Fve could be a potent adjuvant molecule to initiate and potentiate 
Th1-skewed antigen-specific immune responses, and such adjuvant properties 
could be exploited further to boost the immunogenicity and effectiveness of 
immunotherapeutic vaccines targeted at inducing immune responses specific to the 
cancer. 
Therefore, in this chapter, the potential role of Fve as an adjuvant for cancer 
immunotherapy was explored. Using HPV type 16 E7 as a model tumor antigen 
and TC-1 cell-induced tumor model, a series of proof-of-concept studies were 
carried out to show the effectiveness of Fve as an adjuvant to enhance both 
humoral and cellular responses of the antitumor therapy in vivo.  




4.2.1 Production of recombinant E7 protein 
The recombinant E7 protein containing 98 amino acid residues of the full-length 
E7 gene was expressed and purified in E. coli as described previously510. A total 4 
mg of the recombinant E7 protein was obtained from 6L of bacterial culture. The 
predicted molecular weight of the HPV 16 E7 protein was calculated to be 11 kDa. 
However, the E7 protein migrated at 18 kDa in SDS-PAGE (Fig. 4.2A), at a higher 
molecular mass than predicted. This dissimilarity between experimental and 
theoretical molecular weight could be explained based on its amino acidic 
composition that had been reported earlier510-512. The recombinant E7 was further 
confirmed by E7-specific monoclonal antibodies using western blot (Fig. 4.2B). 
4.2.2 Co-administration of HPV-16 E7 plus Fve increased HPV-16 E7-specific 
humoral immune response 
To investigate the effects of Fve on the induction of HPV-16 E7-specific humoral 
immunity, C57BL/6 mice were either immunized with PBS, Fve, E7, or E7 plus 
Fve at day 0, 14, 28. The HPV-16 E7-specific antibodies in the sera of different 
immunized mice were measured by ELISA (section 2.2.9). As shown in Figure 4.3 
A&B, mice immunized with HPV-16 E7 plus Fve produced significantly higher 
levels of IgG1 and IgG2c as compared to those immunized with HPV-16 E7 alone. 
HPV-16 E7-specific IgG1 and IgG2c in HPV-16 E7 plus Fve immunized mice were 
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7-fold and 33-fold higher respectively than those of mice immunized with HPV-16 
E7 alone at day 28. Negligible levels of HPV-16 E7-specific IgG1 and IgG2c 
antibodies were detectable in the PBS control group over the same studied period 
(Fig. 4.3 A&B). Furthermore, the BALB/cJ mice were immunized with the same 
regimen, and the E7-specific IgG1 and IgG2a were measured by ELISA from day 0 
to day 63 after the first immunization. Consistent with the data from C57BL/6 mice, 
E7 plus Fve vaccination enhanced IgG1 and IgG2a production significantly higher 
than E7 immunizaiton alone. HPV-16 E7-specific IgG1 and IgG2a in HPV-16 E7 
plus Fve immunized mice were 4-fold and 27-fold higher respectively than those of 
mice immunized with HPV-16 E7 alone at day 35 (Fig. 4.4).  These results 
indicate that Fve could enhance strong HPV-16 E7-specific humoral immune 
responses.  
4.2.3 Coadministration of HPV-16 E7 and Fve enhanced IFN-γ production by 
E7-specific CD4+ and CD8+ T cells 
To evaluate the E7-specific T cell responses in the immunized mice, splenocytes 
from C57BL/6 immunized mice were collected and stimulated with different 
concentrations of E7 protein from 1 to 20 μg/ml in vitro (section 2.2.9). The culture 
supernatants were collected at 72 hrs and the cytokine production were measured 
by ELISA. As shown in Figure 4.5, IFN-γ production was significantly enhanced in 
splenocytes from HPV-16 E7 plus Fve immunized mice as compared to those from 
HPV-16 E7 or PBS immunized mice. There was no statistical difference for the 
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production of TNF-α, TGF-β, and IL-10 in splenocytes between E7 plus Fve 
immunized mice and E7 immunized mice. No IL-4 production was detected in the 
splenocytes of all the three groups.   
To investigate the effect of Fve on E7-specific T cell immune response in 
immunized mice, the splenocytes from immunized mice were cultured with E7 
protein and IL-2 for nine days. Then, short-cultured T cells were restimulated with 
different concentrations of E7 protein in vitro, and the cytokine production was 
measured at 72 hrs (section 2.2.10). As shown in Figure 4.6, the IFN-γ production 
was significantly enhanced in T cells from HPV-16 E7 plus Fve immunized mice as 
compared to those from HPV-16 E7 or PBS immunized mice. There was no 
statistical difference for the production of TNF-α, TGF-β, and IL-10 in T cells 
between E7 plus Fve immunized mice and E7 immunized mice. To further explore 
which subset of T cells are responsible for the enhanced IFN-γ production, 
short-cultured T cells were re-stimulated with 5 µg/ml of anti-CD3 and 2 µg/ml of 
anti-CD28 antibody for 12 hrs. IFN-γ-secreting CD4+ and CD8+ T cells were 
stained with specific monoclonal antibodies and analyzed by flow cytometry 
(section 2.2.12). Flow cytometry analysis revealed that 18.7 percent of IFN-γ+ 
producing cells within the CD4+ T subset were induced in the HPV-16 E7 plus Fve 
co-immunized mice, whereas only 4.9 percent and 5.7 percent of IFN-γ+ cells were 
produced in HPV-16 E7 and PBS mice, respectively (Fig. 4.7 upper panel). 
Similarly, 37.8 percent of IFN-γ+ cells among the CD8+ T subset were induced in 
the HPV-16 E7 plus Fve co-immunized mice whereas only 11.4 percent and 12.5 
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percent of IFN-γ+ T cells were produced in HPV-16 E7 and PBS mice, respectively 
(Fig. 4.7 lower panel).  
In summary, these results indicate that Fve could significantly increase HPV-16 
E7-specific IFN-γ secreting CD4+ and CD8+ T cells. 
4.2.4 Coadministration of HPV-16 E7 and Fve enhanced protection of mice 
against tumor growth 
Immunization with HPV-16 E7 plus Fve led to an enhanced HPV-16 E7-specific 
immunity prompted us to explore the antitumor potential of Fve in vivo. Mice 
immunized with PBS, HPV-16 E7, Fve, or HPV-16 E7 plus Fve were challenged 
with TC-1 cells subcutaneously and the tumor growth was monitored (Fig. 4.8A). 
Results showed that 60 percent of mice co-immunized with HPV-16 E7 plus Fve 
remained tumor free for up to 167 days after the tumor challenge whereas only 20 
percent of mice remained tumor free (p < 0.05) in the HPV-16 E7 immunized 
group (Fig. 4.8B). Mice immunized with PBS or Fve alone developed tumors 
rapidly within 10 and 15 days after tumor challenge, respectively (Fig. 4.8B). 
Interestingly, mice immunized with Fve alone generally showed a reduction in 
tumor sizes as compare to the PBS control mice (Fig. 4.8C&D). This suggests that 
Fve protein alone could confer partial suppression of tumor growth. However, such 
suppressive effect was insufficient to protect mice against tumor formation in the 
absence of HPV-16 E7-specific immune responses, as only mice in the group 
immunized with HPV-16 E7 plus Fve exhibited low tumor burden or had remained 
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tumor-free over the total duration of this study. 
To determine whether long-term HPV-16 E7-specific immunity could be 
established in the immunized mice, splenocytes from tumor-free mice (HPV-16 E7 
alone or HPV-16 E7 plus Fve groups) were collected and stimulated with HPV-16 
E7 protein in vitro 167 days after tumor challenge. Splenocytes from naïve mice 
were used as the negative control. Results showed that upon HPV-16 E7 antigen 
stimulation, splenocytes from HPV-16 E7 plus Fve co-immunized mice still 
produced higher levels of IFN-γ  as compared to those from HPV-16 
E7-immunized mice (Fig. 4.9). Hence, Fve enhanced HPV-16 E7-specific 
immunity persisted in the co-immunized mice and may account for the long-term 
protection against tumor formation.  
In addition, tumor protection assays were performed using the metastasis tumor 
model as described previously513. Mice pre-immunized with the same 
immunization regimen were challenged with TC-1 cells intravenously (Fig. 4.10A). 
Results showed that mice immunized with E7 plus Fve had longer survival as 
compared to mice immunized with E7, Fve, and PBS (Fig. 4.10B). 
Taken together, these data indicate that immunization with Fve plus HPV-16 E7 is 
not only more effective than immunization with HPV-16 E7 alone; it also is able to 
confer long-term protection to the mice against tumor formation and metastasis. 
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4.2.5 Therapeutic immunization of HPV-16 E7 and Fve suppressed the tumor 
growth and prolonged the survival of tumor bearing mice 
Whether coadministration of HPV-16 E7 and Fve was equally effective in 
suppressing the growth of the established tumor was further determined by 
therapeutic tumor assay. In this set of experiments, TC-1 cells were inoculated in 
the left flank of mice three days prior to regular treatments with PBS, HPV-16 E7, 
Fve, and HPV-16 E7 plus Fve, respectively (Fig. 4.11A). Results showed that mice 
treated with HPV-16 E7 plus Fve had the longest survival (Fig. 4.11A).  
Further investigations then were carried out in a tumor metastasis model 
established by injecting TC-1 cells intraveneously into the tail vein of each mouse 
at day 0. Mice then were treated with same regimens (Fig. 4.12A). As shown in 
Figure 4.12B, all the mice in the groups immunized with PBS, Fve, or HPV-16 E7 
alone did not survive beyond 55 days, while mice treated with HPV-16 E7 plus Fve 
showed significantly prolonged survival for up to 120 days. These results indicate 
that Fve could significantly enhance the HPV-16 E7-specific antitumor activity 
therapeutically. 
In summary, the results from these series of proof-of-principle experiments 
strongly support the notion that Fve could enhance an antigen-specific immune 
response that not only confers long-term protection against tumor growth but also 
retards tumor growth at the early and advanced stages of tumor development. 
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4.2.6 Both CD4+ and CD8+ T cell subsets and IFN-γ were essential for the 
tumor protection 
Since Fve significantly increased IFN-γ-secreting T cells and enhanced HPV-16 
E7-specific antitumor immunity, in vivo antibody depletion assay was performed to 
determine the roles of the T cell subsets and IFN-γ in the antitumor effects induced 
by combined vaccination (Fig. 4.13A). As expected, 60 percent of the HPV-16 E7 
plus Fve co-immunized mice without any depletions remained tumor free 
throughout the duration of this part of the study (Fig. 4.13B), while the tumors 
developed in the remaining 40 percent of these mice were dramatically reduced in 
size (Fig. 4.13B). In contrast, all the mice depleted of CD4+, CD8+ T cells, or IFN-γ 
developed tumors within 27 days. Interestingly, mice depleted of CD8+ T cells had 
similar tumor size as PBS control, whereas tumor growth was retarded in the mice 
depleted of CD4+ T cells and of IFN-γ (Fig. 4.13C). These data suggested that 
while CD8+ T cells, CD4+ T cells, and IFN-γ are essential for the antitumor 
protection generated in mice co-immunized with HPV-16 E7 plus Fve; CD8+ T 
subset plays a more dominant role in these antitumor effects. 
4.2.7 Adoptively transfer T cells from co-immunized mice retarded the tumor 
growth 
To investigate further the roles of T cells in the antitumor effects seen in the 
HPV-16 E7 plus Fve co-immunized mice, a T cell-adoptive transfer experiment 
was set up. The immunization and tumor challenge regimen was as detailed in 
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Figure 4.14A. Mice received T cells from co-immunized mice showed significant 
reduction in tumor growth (Fig. 4.14B) as compared to those adoptively transferred 
with T cells from donor mice immunized with HPV-16 E7, Fve and PBS, 
respectively. These data support the notion that T cells play a pivotal role in the 
therapeutic antitumor effects and such effects probably are directly correlated to the 
efficacy and magnitude of the HPV-16 E7-specific T cell responses as 
demonstrated in Figure 4.5-7. 












Figure 4.1 The schematic diagram showing the strategy for HPV related 
cancer immunotherapy using Fve as adjuvant. 
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Figure 4.2 Analysis of recombinant E7 protein by SDS-PAGE and western blot. 
The recombinant GST-E7 proteins were expressed in E. coli and purified using 
GST-affinity column. After thrombin cut, E7 protein was eluted and run at 18 kDa 
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Figure 4.3 Fve enhanced E7-specific antibodies production in C57BL/6 mice. 
Mice (n = 5 per group) were subcutaneously immunized with PBS (♦), 20 µg of E7 
(■) or 20 µg of E7 plus 20 µg of Fve (▲) at day 0, 14 and 28. Sera were collected 
weekly for measurement of E7-specific IgG1 (A) and IgG2c (B) by ELISA. Data 
are representative of three independent experiments. Bars represent means ±SEM, 














































Figure 4.4 Fve enhanced E7-specific antibodies production in BALB/cJ mice.  
BALB/cJ mice (n = 5 per group) were subcutaneously immunized with 20 µg of E7 
(■) or 20 µg of E7 plus 20 µg of Fve (▲) at day 0, 14 and 28. Sera were collected 
weekly for measurement of E7-specific IgG1 (A) and IgG2a (B) by ELISA. Data 
are representative of two independent experiments. Bars, SEM. *, p < 0.05 (E7 vs 



















































Figure 4.5 Cytokine profile by splenocytes from immunized C57BL/6 mice.  
Mice (n = 5 per group) were subcutaneously immunized with PBS (□), 20 µg of E7 
(■), and 20 µg of E7 plus 20 µg of Fve (■) at day 0 and 14. Splenocytes were 
collected at day 28 and cultured with 1, 10, or 20 µg/ml of E7. Supernatants were 




























































Figure 4.6 Cytokine profile by short-term cultured T lymphocytes from 
immunized C57BL/6 mice. Mice (n = 5 per group) were subcutaneously 
immunized with PBS (□), 20 µg of E7 (■), and 20 µg of E7 plus 20 µg of Fve (■) 
at day 0 and 14. Splenocytes were collected from immunized mice at day 28 and 
then cultured with E7 protein and IL-2 for 9 days. Short-term cultured T cells were 
then stimulated with 1, 10 or 20 µg/ml of E7 for 72 hrs. Culture supernatants were 
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Figure 4.7 ICCS analysis of short-term cultured T lymphocytes from 
immunized C57BL/6 mice. Mice (n = 5 per group) were subcutaneously 
immunized with PBS, 20 µg of E7, and 20 µg of E7 plus 20 µg of Fve at day 0 and 
14. Splenocytes were collected at day 28 and then cultured with E7 protein and 
IL-2 for 9 days. For intracellular staining, short-term cultured T cells were 
stimulated with anti-CD3 and anti-CD28 antibodies for 12 hrs. Cytokine-secreting 
CD4+ T cells and CD8+ T cells were then analyzed by flow cytometry. The 
numbers in the dot plots indicate the percentages of CD4+IFN-γ+ T cells and 
CD8+IFN-γ+ T cells in the total T cells. 
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Figure 4.8 Co-immunization of E7 and Fve enhanced protection against the 
growth of TC-1 tumors. Mice (n = 10 per group) were immunized with PBS (♦), 
20 µg of E7 (■), 20 µg of Fve (×) or 20 µg of E7 plus 20 µg of Fve (▲) at day 0, 
14, 28 and then inoculated subcutaneously with TC-1 cells at day 30 (A). The mice 
were monitored daily for tumor growth by palpation (B) and the tumor size was 
measured every two days (D). Mean tumor size was calculated (C). Data are 
representative of two independent experiments. Bars represent means±SEM.. 
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Figure 4.9 IFN-γ production by splenocytes in tumor-free mice of day167 after 
tumor challenge. Mice (n = 10 per group) were immunized with PBS (♦), 20 µg 
of E7 (■), 20 µg of Fve (×) or 20 µg of E7 plus 20 µg of Fve (▲) at day 0, 14, 28 
and then inoculated subcutaneously with TC-1 cells at day 30. One hundred and 
sixty-seven days after the tumor challenge, spleens were collected from the 
tumor-free mice and cultured with 20 μg/ml of E7 protein in vitro. Supernatants 
were collected at 72 hrs and IFN-γ levels were analyzed. Bars represent means±
SEM.  








Figure 4.10 E7 plus Fve co-immunization extended the survival of mice in 
metastatic prevention tumor model. Mice (n = 10 per group) were immunized 
with PBS (♦), 20 µg of E7 (■), 20 µg of Fve (×) or 20 µg of E7 plus 20 µg of Fve 
(▲) at day 0, 14, 28 and then were intravenously injected with TC-1 cells at day 30 
(A). The survival of mice was monitored and the survival curves were analyzed by 
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Figure 4.11 E7 plus Fve co-immunization therapeutically reduced tumor 
growth. Mice (n = 10 per group) were inoculated subcutaneously with TC-1 cells 
on day 0 and then treated with PBS (♦); 20 µg of E7 (■), 20 µg of Fve (×) or 20 µg 
of E7 plus 20 µg of Fve (▲) at day 3, 10, 17 (A). The tumor size was measured 
every two days (D) and the survival was monitored daily (B). The mean tumor size 
was calculated (C).The survival curves were analyzed by log-rank test. Data are 
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Figure 4.12 E7 plus Fve co-immunization extended the survival of mice in 
metastatic therapeutic tumor model. Mice (n = 5 per group) were intravenously 
injected with TC-1 cells on day 0 and then treated with PBS (♦); 20 µg of E7 (■), 
20 µg of Fve (×) or 20 µg of E7 plus 20 µg of Fve (▲) at day 3, 10, 17 (A). The 
survival of mice was monitored and the survival curves (B) were analyzed by 
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Figure 4.13 CD4+, CD8+ T cells and IFN-γ were essential for the tumor 
protection in E7 plus Fve immunized mice. Mice (n = 10 per group) were 
immunized with PBS or 20 µg of E7 plus 20 µg of Fve at day 0, 14, 28. 5 × l04 of 
TC-1 cells were inoculated subcutaneously into the right flank at day 30. To deplete 
the CD4+ (■), CD8+ (×) T cells or IFN-γ (−), E7 plus Fve immunized mice were 
injected intraperitoneally with α-CD4, α-CD8, α-IFN- γ mAbs respectively at day 
-4, -1, 6, 13, 20, 27, 34, 41, 48. PBS (♦) and E7 plus Fve immunized mice without 
depletion (▲) were control groups (A). The mice were monitored daily for tumor 
growth by palpation (B). Tumor size was measured every two days (C) and the 
mean tumor size of each groups was calculated (C). Bars, SEM.  
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Figure 4.14 Adoptive transfer of T cells from the E7 plus Fve immunized mice 
retarded tumor growth. Eight million of T cells purified from the mice 
immunized with PBS (♦), HPV-16 E7 (■), Fve (×) or HPV-16 E7 plus Fve (▲) 
were adoptively transferred to recipient mice at days -1, 3, 6, and 9. Recipient mice 
(n = 10 per group) were inoculated subcutaneously with 5 × 104 of TC-1 cells at 
day 0 (A). Ten days after the tumor challenge, the size of the tumor formed was 
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Figure 4.15 Proposed mechanisms by which Fve protein facilitates innate and 
adaptive immune responses for tumor immunotherapy. Fve protein stimulates 
mouse dendritic cells in vivo, activating the innate immune response to form a 
foundation on which antigen-specific adaptive immunity is based. In particular, by 
improving the function of professional APCs, Fve facilitate the generation of Th1 
humoral and cellular antigen-specific immunity. Moreover, it is speculated that Fve 
could enhance the antigen-specific CD8+ T cell immunity through 
cross-presentation by stimulating the CD8+ DCs. These enhanced antigen-specific 
immune responses play key roles in the tumor immunotherapy. Besides, the 
cytokine productions (such as IFN-γ  and IL-6) secreted from Fve-stimulated T 
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Antigen-specific immunotherapy is a promising strategy to eradicate systemic 
tumors at multiple sites while conferring the advantage of specific discrimination 
between neoplastic and non-neoplastic cells. However, a major hurdle for the 
development of such vaccines for treatment and prevention of cancer is the poor 
immunogenicity of tumor-associated antigens. An attractive strategy to overcome 
this problem is the use of an immune modulator as an adjuvant to boost the antigen 
specific immunity and enhance the efficacy of tumor vaccines514. 
Our in vivo tumor protection results showed that 60 percent of the mice remained 
tumor free from the HPV-16 E7 plus Fve co-immunization after tumor challenge as 
compared to only 20 percent of mice immunized with HPV-16 E7 (Fig. 4.8B). 
More importantly, the enhanced antitumor effects induced by HPV-16 E7 plus Fve 
co-immunization were also observed in therapeutic tumor model (Fig. 4.11). These 
data indicate that HPV-16 E7 plus Fve co-immunization is more efficacious to 
protect mice against tumor challenge and to eradicate established tumors. It is 
conceivable that enhancing HPV-16 E7-specific T cell immunity and IFN-γ 
production may contribute, at least in part, to the Fve augmentation of antitumor 
effects observed in this study. 
It is well known that antigen-specific T cell immunity plays a critical role in tumor 
immunotherapy515. Investigators using other adjuvants such as heat shock protein 
65507, bacteria exotoxin509, IL-12505, CpG270, or MPL mixed with QS1516 had found 
Chapter 4 Enhanced antitumor immunity by coadministration of HPV-16 E7 protein and Fve protein 
 
 187
that CD4+ and/or CD8+ cells play major roles in protecting animals from challenge 
with HPV-16 E7-expressing TC-1 cells. In this study, by depletion of CD4+ and 
CD8+ T cells, we showed that both T cell subsets are essential for the inhibition of 
tumor growth, and CD8+ T cells appear to play a more dominant role in tumor 
protection. These results concur with the conventional dogma that CD8+ T cells are 
pivotal and highly specialized for cytolytic function and thus have been the main 
focus in cancer immunotherapy, whereas CD4+ T cells confer helper functions in 
antitumor effect by providing activation signals to CD8+ T cells517,518 and 
contributing to the survival maintenance of CD8+ T memory cells519-523. Recent 
studies, however, found that tumor-specific CD4+ T cells are able to eliminate a 
wide variety of tumors that were resistant to CD8-mediated rejection524,525, 
providing new supporting evidence for the hypothesis that CD4+ T cells may play a 
broader role in antitumor responses. Moreover, the HPV-16 E7 plus Fve 
immunization-protected tumor-free mice recalled higher levels of IFN-γ production 
at 167 days after tumor inoculation (Fig. 4.9), indicating that Fve can enhance 
HPV-16 E7-specific memory immunity to protect mice against tumor growth. 
These findings are important because the capacity to elicit an effective long-term 
memory immune response is essential to the success of a vaccination strategy526-528. 
To further address the importance of T cells in mediating the antitumor effects seen 
in this study, total T cells from HPV-16 E7 plus Fve immunized mice were 
adoptively transferred into tumor-bearing recipient mice. Results indicated that T 
cells from HPV-16 E7 plus Fve immunized mice were more efficacious in 
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suppressing tumor growth as compared to those from HPV-16 E7 immunized mice 
(Fig. 4.14B). This enhanced efficacy correlated with the increased number of 
HPV-16 E7-specific effector T cells induced by co-immunization. However, other 
possibilities such as increased HPV-16 E7-specific T cell avidity cannot be 
excluded as antigen-specific CD8+ T cells with high avidity are known to produce 
stronger antitumor effects in vaccinated mice than low-avidity CD8+ T cells529,530. 
In recent years, adoptive transfer of antigen-specific T cells into patients has 
emerged as a promising new approach to cancer treatments198,531,532. T cell transfer 
data from this study suggest that Fve protein could be a good immunotherapeutic 
vaccine adjuvant to enhance the antitumor immunity mediated by tumor 
antigen-specific T cells, thereby providing a promising new strategy to improve the 
efficacy of the adoptive cell therapy approach. 
Besides, HPV-16 E7 plus Fve co-immunization could significantly up-regulate the 
HPV-16 E7-specific antibodies especially IgG2c in C57BL/6 (Fig. 4.3B) and IgG2a 
in BALB/cJ mice (Fig. 4.4B), which was consistent with previous finding that Fve 
can increase the Th1 skewed humoral OVA-specific immune response431. Previous 
reported studies using NY-ESO-1 tumor antigen as model antigen have shown that 
antigen-specific IgG2a antibodies contribute to DC maturation and cross-priming 
of CD8+ T cells, probably through a mechanism mediated by antigen-antibody 
immune complexes533,534. Although there is no direct evidence showing that 
antibody-mediated responses play an important role in controlling HPV-associated 
malignancies, the possible role of higher production of HPV-16 E7-specific 
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antibody in improving the antitumor activity cannot be ruled out and deserves more 
studies. 
IFN-γ has been shown to inhibit tumor growth in vivo by up-regulation of MHC 
class I, inducing inflammation at tumor site as well as eliciting an angiostatic 
effect48,73,476,535-537. This study also demonstrated that IFN-γ was critical for 
generating potent antitumor effects against TC-1 tumor challenge. The data showed 
that the tumor protection effect of HPV-16 E7 plus Fve vaccine was significantly 
attenuated in IFN-γ-depleted mice (Fig. 4.13B&C). These results are consistent 
with previous studies demonstrating the important role of IFN-γ in the antitumor 
effect48,63,536,538. Interestingly, It was found that the mean tumor size of HPV-16 E7 
plus Fve immunized mice with IFN-γ-depletion was smaller than that of PBS 
immunized mice (Fig. 4.13C), suggesting that additional IFN-γ independent 
mechanisms may also contribute towards the suppression of tumor growth 
observed. 
It is worth noting that Fve protein alone conferred some antitumor effects as 
compared to those treated with PBS (Fig. 4.8C&D). This interesting observation 
could be explained by the fact that Fve protein mitogenically expands T cell pool 
and induces high levels production of IFN-γ  (Fig. 3.9), creating a positive and 
conducive microenvironment to confer partial antitumor effects. This may also 
represent an additional beneficial effect of using Fve as an adjuvant for antitumor 
immunotherapeutic vaccines. 
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In summary, this study has demonstrated that an immunomodulatory protein Fve 
exhibited effective adjuvant effects in enhancing robust and long-lasting adaptive 
antigen-specific immune responses that conferred strong prophylactic and 
therapeutic antitumor effects. Notably, it appears that by targeting at DCs, Fve 
could effectively enhance antigen-specific CD8+ T cell immune responses. 
Prophylactic vaccines aiming to induce neutralizing antibodies have been 
successfully translated into clinical applications for HPV associated malignancies 
539,540. However, the future challenge is to combine prophylactic approach together 
with a therapeutic immunization, for example, combining E7 to HPV capsid 
protein L1 or L2 to develop chimeric vaccines541-543. Overall, Fve could potentially 
be an effective adjuvant for such HPV chimeric vaccine. It could also be exploited 
to develop other anti-cancer and anti-viral vaccines. 
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Chapter 5  
Conclusions and future perspectives 
 
5.1 Conclusions 
A group of fungal proteins defined by amino acid sequence similarity and their 
actions on immunological responses are classified into a distinct family, fungal 
immunomodulatory protein (Fip). The molecular masses of Fips were estimated to 
be approx. 15 kDa by SDS-PAGE and their major biological activities resembled 
the mitogenic activity of lectins towards mouse spleen cells and hPBMCs. In the 
present study, Fve, a fungal immunomodulatory protein isolated from edible 
mushroom Flammulina velutipes, was shown to induce adhesion/aggregation, 
activation and proliferation of mouse lymphocytes. This protein stimulated partial 
activation of both purified CD4+ and CD8+ T cells by up-regulating the expression 
of CD69, OX-40 and 4-1BB in the absence of accessory cells. In the presence of 
accessory cells, the CD4+ T cells and CD8+ T cells were fully activated to 
proliferate and secrete high levels of IL-2, IFN-γ, and IL-6 accompanied by further 
up-regulation of CD69, OX-40 and 4-1BB. Transwell studies showed that 
accessory cell-T cell direct interaction was important to the full activation of T cells. 
Production of IFN-γ and IL-2 but not IL-4 by Fve-stimulated T cells suggests that a 
type I development and differentiation process of T cells occurred after Fve 
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stimulation. Moreover, 3H-thymidine cell proliferation assay showed that B cells 
and dendritic cells both can act as accessory cells for Fve-stimulated T cell activity. 
Besides, Fve could stimulate NK aggregation and produce high level of IL-6 but 
not comcomitant elevated production of IFN-γ. It appears that Fve-induced NK cell 
responses could be unique and the implications of such responses to DC 
phenotypic maturation and T cell activation deserve further studies. 
In vitro co-culture experiments showed that Fve failed to induce BM-DC 
phenotypic maturation. In contrast, in vivo studies in wild type mice revealed 
intraveneously injected Fve could drive splenic DCs to full maturation as shown by 
the up-regulation of MHC class II molecules and CD86 expression on DCs. 
Functional assays using DO11.10 and OT-II mice showed that such Fve-stimulated 
splenic DCs could polarize T cells to antigen-specific Th1 cells. Furthermore, 
splenic DCs isolated from OVA plus Fve proteins co-injected C57BL/6 mice 
co-cultured with T cells from OT-1, showed that Fve enhanced the production of 
IL-2 and IFN-γ by antigen-specific CD8+ T cells. The differential in vitro and in 
vivo effects of Fve on DC maturation imply that the Fve-induced DC maturation in 
vivo may involve accessory help by other cell types. Indeed, it was found that Fve- 
activated T cells could help to induce phenotypic maturation of DC in cell 
contact-dependent manner.  
Taken together, my data demonstrated that Fve can drive Th1-skewed polarization 
and enhance CD8+ T cells activity in antigen-specific manner. In view of this, it 
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was hypothesized that Fve could act as a vaccine adjuvant which can enhance the 
immunogenicity of the co-administered antigens. To verify this hypothesis, the 
proof-of-concept experiments were carried out with HPV type 16 E7 protein as a 
model antigen in tumor animal models induced by the cervical cancer-related 
E7-expressing TC-1 tumor cells.  
Mice co-administered with Fve plus E7 proteins showed enhanced E7-specific 
antibody production as well as E7-specific IFN-γ-producing CD4+ and CD8+ T 
cells as compared to that in mice immunized with E7 alone. Tumor protection 
assays showed that 60 percent of mice co-immunized with E7 plus Fve remained 
tumor free for up to 167 days after tumor cells challenge compared to only 20 
percent of the E7-immunized group. Tumor therapeutic assays showed that E7 plus 
Fve treatment significantly prolonged the survival of tumor bearing mice as 
compared to those treated by E7 alone. In vivo cell depletion assay and adoptive 
transfer of T cells illustrated that the CD4+, CD8+ T cells and IFN-γ play critical 
roles in conferring the antitumor effects.  
In summary, this study has demonstrated that fungal immunomodulatory 
protein-Fve, a homodimer with immunoglobulin superfamily-like fold, has strong 
mitogenic stimulatory effects on predominantly CD4+ and CD8+ T cells. Moreover, 
activated T cells helped DC maturation. In addition, Fve could drive Th1-skewed T 
cell polarization and enhance CD8+ T cells activity in an antigen-specific manner. 
Tumor model studies demonstrated that Fve enhanced robust and long-lasting 
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adaptive antigen-specific immune responses that mediated the strong prophylactic 
and therapeutic antitumor effects.  
5.2 Future perspectives 
Based on the current study, several aspects require further investigation: 
5.2.1 Delineation of the proposed carbohydrate binding site of the Fve protein 
Fve is structurally predicted to be a saccharide-binding protein. The 3-D structural 
analysis indicates that Fve has two potential carbohydrat-binding pockets430. The 
first patch, consisting of residues Tyr11, Arg50, Asp57, Phe94, Glu104, Glu105, 
Tyr106 and Glu110 is found on the same side of the dimer (Appendix 5A). The 
second patch, continuous with the first, consists of Tyr11, Trp24, Arg26, Asp87, 
Glu110 and Trp111. This patch lies on opposite sides of the dimmer (Appendix 5B). 
In addition, microscopic visualization in this study found that purified CD4+ T cells, 
CD8+ T cells, DCs, and NK cells can aggregate after Fve stimulation indicating 
Fve is probably a lectin with specificity for cell surface carbohydrates binding. 
Therefore, it is worthwhile to delineate the carbohydrate binding site on Fve by 
further studies. PCR-based site-directed mutagenesis will be used to generate a 
panel of Fve point mutants. Functional screening of these point mutants will be 
performed by the assays as follows: glycan binding assay, cytokine production 
profiling by ELISA, and cell proliferation assay by [3H]-thymidine uptake. 
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5.2.2 Identification of cellular receptor (s) involved in Fve interaction 
The signal transduction pathways involved in Fve-induced cellular activation still 
need to be elucidated at the molecular levels. It is necessary to identify the cellular 
receptor (s) involved in Fve interaction. The 3D- structure of Fve protein showed 
that Fve is a homodimer, each monomer consists of an N-terminal α-helix and 
β-strand followed by a fibronectin type III-like domain with immunoglobulin 
like-fold structure (Appendix 4). The swapping of N-terminal α-helix links with 
hydrogen bonding and this α-helical pair is essential for protein dimerization and 
stabilization430. The presence of FNIII-like domain (immunoglobulin 
superfamily-like domain, also the first FNIII domain found in products of fungal 
origin) indicates that Fve shares structural similarity with human fibronectin 
domain, which is known to be involved in integrin binding. Therefore, it is 
speculated that Fve may interact with integrin-like proteins or with the proteins of 
the immunglobulin superfamily, which are involved in cell adhesion, costimulation, 
and activation544-546. The preliminary data from our lab showed that Fve-stimulated 
proliferation of hPBMC was greatly inhibited in the presence of blocking 
antibodies for CD2 or LFA-1. To examine whether there is a direct interaction 
between Fve to CD2 and LFA-1, in vitro pull-down assay can be performed. 
Moreover, co-immunoprecipitation will be performed to identify the potential 
receptors for Fve in the target cells such as T cells and DCs. 
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5.2.3 Functional characterization of Fve-induced OX-40 and 4-1BB expressing 
T cells.  
OX-40 and 4-1BB were inducible in the Fve-activated murine T cells. As discussed 
in chapter 3, the signaling of OX-40 and 4-1BB controls T cell immune response 
by: (a) enhancing the expression of anti-apoptotic molecules; (b) inhibiting the 
development and activation of TReg cells. Further studies are required to confirm 
whether Fve-induced OX-40 and 4-1BB exhibit such regulatory functions to 
enhance T cell immune response.  
Moreover, in the context of cancer immunotherapy as described in chapter 4, the 
expansion of antigen-specific effector T cell and inhibition of Treg cells are 
important antitumor mechanisms. Therefore it is worthwhile to investigate whether 
mice co-immunized with tumor antigens such as E7 antigen with Fve protein could 
up-regulate the expression of OX-40 and 4-1BB on antigen-specific T cells and 
increase T cell functions.  
5.2.4 Clarification of the underlying mechanisms of Fve-activated T 
cell-dependent DC maturation 
DCs are professional antigen-presenting cells with the unique ability to take up and 
process antigens in the peripheral blood and tissue. Immature DCs are particularly 
efficiant in ingestion and processing antigen to activate T cells. DCs must undergo 
maturation to to fully activated DCs, which express high levels of cell surface 
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MHC class I/II and costimulatory molecules. Data from this study revealed that 
Fve can induce DCs phenotypic and functional maturation under in vivo but not in 
vitro settings, but the underlying mechanism is unclear. In vitro co-culture studies 
showed that Fve-induced DC phenotypic maturation is activated T cell-dependent 
indicating that Fve-activated T cells may constitute a novel form of immune signal, 
functionally linked to DC maturation. Therefore, further studies using RAG-/-, 
CD4-/- or CD8-/- mice can be carried out to confirm the helper role of T cells in DC 
maturation in vivo. Besides, trans-well study showed that T cell-DC direct 
interaction is a prerequisite for DC maturation. Identification of the surface 
molecules involved in such interaction is necessary in order to further dissect the 
signaling pathway for DC maturation. Furthermore, soluble mediator(s) responsible 
for T cell-dependent DC maturation cannot be ruled out. To this end, blocking 
experiments with mAbs against TNF-α, IFN-γ, IL-6, OX-40, 4-1BB or CD40 
should be performed.  
5.2.5 Further studies on the function of Fve-induced splenic CD8+ DC subsets. 
In vivo data from the current study showed that Fve preferentially drive maturation 
of splenic CD8+ DCs. It has been well documented the CD8+ DC are much more 
efficient in activating MHC class I - restricted CD8+ T cells by cross-priming481,482 
whereas the CD8− subsets preferentially stimulate MHC class II-restricted CD4+ T 
cells. Further functional studies should be performed using TAP-1 knockout mice 
to determine whether the Fve-induced CD8+ DC subsets are responsible for the 
Chapter 5 Conclusions and future perspectives 
 
 198
cross-priming of antigen-specific CD8+ T cells.    
5.2.6 Exploration of the potential effects of Fve on NK cells  
NK cells share a common biopotential progenitor with T cells and share a common 
killing mechanism with cytotoxic T cells. Previous in vivo studies from our 
laboratory revealed that with Fve treatment increased NK cells in the spleen from 
0.85 percent to about 4 percent (unpublished data), suggesting that Fve may have 
direct or indirect effects on NK cells in vivo leading to an expansion of this cell 
type. NK cells are effector cells of innate resistance that are able to lyse tumor and 
virus-infected cells spontaneously in the absence of Ag-specific recognition and 
clonal expansion547. Furthermore, the cytolytic activity of NK cells can be 
augmented by IL-2 and IFN-γ. In view of this, it is possible that Fve-induced 
production of IL-2 and IFN-γ could enhance the cytolytic functions of NK cells in 
vivo, this warrant more research work to test this hypothesis. Taken together, the 
data suggest that it will be worthwhile to explore the use of Fve to expand the NK 
cells population and to increase NK cell functions to treat cancer and viral 
infections. 
5.2.7 Characterization of the possible interaction between Fve and other 
immune cells. 
B cells and macrophages are important cells in both innate and adaptive 
immunities548-550. B cells can act as APC for T cell activation or tolerance. 
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Macrophages are known to be involved in angiogenesis by producing a series of 
cytokines/growth factors551,552. Moreover, macrophages facilitate B cell activation 
in vivo by collecting and displaying native antigen549,553. Thus, the 
immunomodulatory effects of Fve on these cells should not be overlooked and 
therefore deserve further exploration. 
5.2.8 Optimization strategies to enhance the adjuvant effects of Fve for cancer 
immunotherapy. 
The proof of study described in chapter 4 demonstrated the potential use of Fve as 
an adjuvant in cancer immunotherapy.  The results showed that Fve was capable 
of increasing the immunogenicity of a tumor antigen, which is a promising strategy 
to induce specific antitumor response. However, that the use of Fve significantly 
inhibited tumor cell growth but did not completely eradicate tumor from host. It 
could be due to limited efficacy of the vaccines against tumor cells. To optimize the 
effects of Fve may increase the efficacy of the vaccine. To increase the numbers of 
immunizations and T regulatory cells depletion should be explored  
5.2.9 Safety of Fve for human use. 
Several safety concerns may be raised when Fve is prepared for clinical use. These 
include the possibility that Fve protein might (1) enhance the immunogenicity of 
self antigens, thereby triggering the development of organ specific or systemic 
autoimmune disease, or (2) increase susceptibility of the host to pathogenic agents 
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that cause toxic shock. To clarify the magnitude of these safety concerns, in vivo 
experiments should be carried out in which mice are repeatedly injected with 
different doses of Fve protein. The histochemical staining of lymphoid tissue and 
organs should be done. And morbidities and mortality of the Fve-treated animals 
should be evaluated. 
Lastly, I conclude this study by citing the following quote: 
“With science having largely demystified the ‘witchcraft’ of immune response, 
immunologists are turning to the next challenge: putting their new knowledge to 
clinical use in taming pathological immune responses. Successes are still mostly on 
the horizon.”           
— Annual Review of Immunology, Vol. 23: 1-2
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Appendix 1: Fungal immunomodulatory protein (FIP) family.  
A family of fungal immunomodulatory proteins (Fips) which include Fip-Fve (A), 
Fip-LZ-8 (B), Fip-Gts (C), and Fip-Vvo (D) purified from Flammulina velutipes, 

























Appendix 2: Wild type and cultivated form of Flammulina velutipes. 
Wild type flammulina velutipes are often found in clusters on hardwood stumps in 
forest, frequently in the winter season (A). Cultivated form of Flammulina velutipes 
(also known as golden needle mushroom) shows whitish-yellow color and 


















Appendix 3: Alignment of amino acid sequences of Fip-Fve, Fip-Gts, Fip-LZ-8, 
and Fip-Vvo, immunomodulatory proteins.  
Identical amino acids are represented with [*], while partial identical amino acids are 











Appendix 4: The overall three dimensional structure of Fve dimer solved by SAD 
of a NaBr-soaked Fve crystal.  
Each monomer consists of an FNIII-like domain with an N-terminal α-helix and 
β-strand. The α-helices (HA and HB in red color) interact via hydrophobic 
interactions while the β-strands (SA and SB in blue color) form a β-sheet. The FNIII 
domain consists of a sandwich of two sheets, I and II, formed by β-strands E-B-A and 
G-F-C-C’, respectively. The Br atoms are colored green. The Fve ID in protein data 















Appendix 5: Potential carbohydrate-binding sites of Fve.  
All residues with strong propensity to be in the carbohydrate-binding site of proteins 
(see the text) are shown in red. Among these, there are two pairs of contiguous 
surfaces, which could potentially bind sugars. (a) The first pair (colored blue), 
consisting of Tyr11, Arg50, Asp57, Phe94, Glu104, Glu105, Tyr106 and Glu110 are 
found on the same side of the dimmer (A). The second patch (colored green), which is 
continuous with the first (and hence shares common residues), consists of Tyr11, 
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Appendix 7: Schematic representation of the human papillomavirus 16 (HPV-16) 
genome showing the arrangement of the major non-structural and capsid genes.  
The three circles correspond to the three reading frames in which the sense strand can 
be translated. There are no known gene products produced from the antisense strand. 
Viral protein early 4 (E4) is encoded by a messenger RNA transcript that includes the 
initial amino acids of the E1 gene. The region between late 1 (L1) and E6 is an 
important transcriptional regulatory region — the mRNAs encoding most 
nonstructural (E6, E7, E1, E2, E4 and E5) and capsid (L1 and L2) genes originate in 























Coadministration of the fungal immunomodulatory protein FIP-Fve
and a tumour-associated antigen enhanced antitumour immunity
Introduction
Cancer immunotherapy is an attractive alternative for the
treatment of patients with cancer. When immunotherapy
is used in the absence of radiotherapy or chemotherapy,
there are fewer side effects than found with classical anti-
tumour chemotherapeutics. The identification and clon-
ing of genes encoding tumour-associated antigens
recognized by T cells have renewed hopes that it may be
possible to develop cures for some cancers.1 Although
several treatments using tumour-associated antigens have
been approved for some types of cancer, their efficacies
have been variable and generally insufficient. One
important factor contributing to insufficient and variable
responses to immunotherapy is the poor immunogenicity
of most tumour antigens, which results in insufficient
activation of tumour antigen-specific CD8+ T cells.
Cervical cancer is the second highest cause of cancer
deaths in women and kills approximately 274 000 women
worldwide each year.2,3 Epidemiological and laboratory
studies strongly support a crucial role for persistent human
papillomavirus (HPV) infection and transcription in cervi-
cal carcinogenesis.4,5 Among over 100 HPV genotypes,
HPV type 16 is the most common and is responsible for
more than 50% of all cervical cancers.6 HPV-16 E7, one
of its oncoproteins, is essential for the induction and
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Summary
Fve is a fungal protein isolated from the golden needle mushroom Flam-
mulina velutipes and has previously been reported to trigger immunologi-
cal responses in both mouse and human lymphocytes. In this study, we
evaluated the potential application of Fve as an adjuvant for tumour
immunotherapy and examined the underlying mechanism(s). When the
human papillomavirus (HPV)-16 E7 oncoprotein was used as a model
antigen, mice coimmunized with HPV-16 E7 and Fve showed enhanced
production of HPV-16 E7-specific antibodies as well as expansion of
HPV-16 E7-specific interferon (IFN)-c-producing CD4+ and CD8+ T cells
as compared with mice immunized with HPV-16 E7 alone. Tumour pro-
tection assays showed that 60% of mice coimmunized with HPV-16 E7
plus Fve, as compared with 20% of those immunized only with HPV-16
E7, remained tumour-free for up to 167 days after challenge with the
tumour cells. Tumour therapeutic assays showed that HPV-16 E7 plus
Fve treatment significantly prolonged the survival of tumour-bearing mice
as compared with those treated only with HPV-16 E7. In vivo cell deple-
tion and adoptive T-cell transfer assays showed that CD4+ and CD8+ T
cells and IFN-c played critical roles in conferring the antitumour effects.
Interestingly, Fve could stimulate the maturation of splenic dendritic cells
in vivo and induce antigen-specific CD8+ T-cell immune responses. In
summary, Fve has potent adjuvant properties that enhance T helper type
1 antigen-specific humoral and cellular immune responses which confer
strong antitumour effects. The use of Fve as an adjuvant could be
an attractive alternative to the current vaccination strategy for cancer
immunotherapy.
Keywords: adjuvant; dendritic cells; fungal immunomodulatory protein
Fve; human papillomavirus-16 E7; immunotherapy
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maintenance of cellular transformation.5 Thus, HPV-16 E7
has been a major target of many prophylactic HPV vaccines
for the prevention of HPV infections as well as many
therapeutic HPV vaccines for the control of existing HPV
infections and HPV-associated lesions, such as squamous
intraepithelial lesions and cervical cancer. However, the
antigen-specific immune responses and antitumour effects
generated by HPV-16 E7 alone are weak and insufficient
to control tumour growth. Several strategies have been
developed to increase the potency of the HPV-16 E7
vaccine; for example, various immune modulators, such as
cytokines,7,8 heat shock proteins,9,10 non-toxic bacterial
toxins,11 and CpG12 have been incorporated as adjuvants to
enhance HPV-16 E7-specific immunity. These have proved
to be effective in animal models, but their potency in
humans has yet to be assessed and active research to
develop novel adjuvant molecules is still ongoing.
Fve, or fungal immunomodulatory protein (FIP)-fve, is
a major fruiting body protein isolated from the edible
golden needle mushroom, Flammulina velutipes.13–15 It
belongs to an FIP family, sharing sequence similarity with
LinZhi-8 from Ganoderma lucidum,16 Fip-gts from Gano-
derma tsugae17 and Fip-vvo from Volvariella volvacea.18
The Fve protein is an acetylated protein consisting of 114
amino acid residues with an estimated molecular weight
of 12.7 kDa.13 Fve has been shown to have the ability to
trigger the proliferation of mouse splenocytes and human
peripheral mononuclear cells and to enhance the produc-
tion of interleukin (IL)-2, IFN-c and tumour necrosis fac-
tor (TNF)-a.13,19 Moreover, it has been suggested that
coadministration of Fve with antigen may drive strong T
helper type 1 (Th1)-skewed immune responses.20
In this study we explored the potential role of Fve as
an adjuvant for cancer immunotherapy. Using HPV type
16 E7 as a model tumour antigen and the TC-1 cell-
induced tumour model, we carried out a series of proof-
of-concept studies to show the effectiveness of Fve as an
adjuvant to enhance both humoral and cellular responses
to antitumour therapy in vivo.
Materials and methods
Mice and the tumour cell line
Six- to eight-week-old female C57BL/6 mice were pur-
chased from the Laboratory Animal Center (Sembawang,
Singapore). Breeding pairs of OT-I and OT-II mice with
transgenic Va2Vb5 T-cell receptors (TCRs) specific for
the ovalbumin (OVA)257–264 epitope in the context of
H-2Kb and the OVA323–339 epitope in the context of I-A
b
were originally acquired from The Jackson Laboratory
(Bar Harbor, ME) and were maintained and bred in
the Animal Holding Unit of the National University of
Singapore. All animal procedures were performed accord-
ing to approved protocols and in accordance with the
Institutional Animal Care and Use Committee of The
National University of Singapore. The maintenance of
TC-1 cells (kindly provided by Dr T. C. Wu, Johns
Hopkins University, Baltimore, MD) has been described
previously.21 On the day of tumour challenge, TC-1 cells
were harvested by trypsinization and washed three times
with phosphate-buffered saline (PBS), and the designated
numbers of cells for tumour inoculation were resus-
pended in 200 ll of PBS.
Reagents
All antibodies were purchased from BD PharMingen (San
Diego, CA) unless otherwise stated. For the detection of
antigen-specific immunoglobulin G1 (IgG1) in mouse sera,
the rat anti-mouse Igj light chain (clone 187.1) and biotin-
conjugated rat anti-mouse IgG1 monoclonal antibody
(mAb) (clone LO-MG1-2; Serotec Ltd., Oxford, UK) were
used. The purified mouse IgG1 (clone 107.3) was used as
the standard. For the cytokine enzyme-linked immunosor-
bent assay (ELISA), mAbs of rat anti-mouse IFN-c (clone
R4-6A2), biotin-conjugated rat anti-mouse IFN-c (clone
XMG1.2), rat anti-mouse IL-2 (clone JES6-IA20), biotin-
conjugated rat anti-mouse IL-2 (JES6-5H4), rat anti-mouse
IL-4 (clone, BVD6-24G2) and biotin-conjugated rat anti-
mouse IL-4 (clone BVD4-1D11) were used. Rat anti-mouse
TNF-a (clone AF-410-NA) and biotinylated rat anti-mouse
TNF-a (clone BAF410) were purchased from R&D Systems
(Minneapolis, MN). Rat anti-mouse CD3e (clone 145-
2C11) and CD28 (clone 37.51) mAbs and recombinant
mouse IL-2 were used for stimulation of T cells in vitro.
Fluorescein isothiocyanate (FITC)-conjugated rat anti-
mouse CD8b (clone 53-5.8), biotin-conjugated rat anti-
mouse CD4 (clone GK1.5), streptavidin-PerCP and
allophycocyanin (APC)-conjugated rat-anti-mouse IFN-c
(clone XMG-2.1) were used for intracellular cytokine
staining. Rat anti-mouse CD16/CD32 (clone D34-485),
biotin-conjugated rat anti-mouse CD8a (clone 53-6.7),
APC-conjugated rat anti-mouse CD4 (clone, RM4-5),
PE-conjugated rat anti-mouse CD11c (clone HL3), FITC-
conjugated anti-I-Ab (clone AF6-120.1), FITC-conjugated
anti-CD86 (clone GL1) and streptavidin-conjugated PerCP
were used for surface marker staining for splenic dendritic
cells (DCs).
Monoclonal anti-CD4 (clone, GK1.5), anti-CD8 (clone,
2.43) and anti-IFN-c (clone, R4-6A2) antibodies for the
in vivo depletion experiment were purified from the
supernatants of hybridoma cells (American Type Culture
Collection, Bethesa, MD) by passage through protein G
columns (Amersham Biosciences AB, Uppsala, Sweden).
Production of Fve and recombinant HPV-16 E7 proteins
The purification of Fve protein from crude extracts of
F. velutipes (golden needle mushroom) has been described
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previously.13,15 The purified Fve was treated with the
polymyxin B agarose and the endotoxin level of the Fve
protein was determined using the LAL assay kit according
to the manufacturer’s instructions (BioWhittaker, Walk-
ersville, MD). There was no detectable level of endotoxin
in the purified Fve protein.
The cDNA of HPV-16 E7 (a gift kindly provided by Dr
S. W. Chan, Institute of Molecular and Cellular Biology,
ASTAR, Singapore) was subcloned into the pGEX-4T1
expression vector (Amersham Biosciences AB). The open
reading frame of HPV-16 E7 was amplified by poly-
merase chain reaction using a set of primers: E7-F
50-TTGTTGGATCCCATGGAGATACACCTACATTG-30
and E7-R 50-TTACTGAATTCTTATGGTTTCTGAGAAC
AGATG-30. The amplified DNA was digested with BamHI
and EcoRI, and the resulting fragment was then cloned
into the BamHI and EcoRI sites of the pGEX-4T1 vector.
The pGEX-HPV-16 E7 recombinant plasmid was trans-
formed into Escherichia coli TG-1 for protein expression.
The HPV-16 E7 protein was purified from GST-HPV-16
E7 fusion proteins after thrombin treatment.
Preparation of DCs
Bone marrow-derived dendritic cells (BM-DCs) were gen-
erated with granulocyte–macrophage colony-stimulating
factor (GM-CSF) according to a method previously
described.22 In brief, bone marrow cells were harvested
from femurs and tibias of normal C57BL/6 mice and
washed with PBS. The cells (4 · 106 to 6 · 106) were
resuspended in complete RPMI-1640 medium containing
recombinant mouse GM-CSF (20 ng/ml; BD PharMin-
gen) and cultured in 100-mm-diameter Petri dishes. On
day 3 of culture, half of the medium was replaced with
fresh medium supplemented with GM-CSF (10 ng/ml).
On day 5 of culture, immature DCs were harvested for
purification.
The splenic DCs were purified as previously
described23 with some modifications. Spleens (from eight
mice) were minced with scissors and digested in 10 ml
of Hanks’ balanced salt solution (HBSS) with Ca2+ and
Mg2+ (Sigma-Aldrich, St Louis, MO) containing collage-
nase D (400 U/ml; Roche Molecular Biochemicals,
Mannheim, Germany) for 30 min at 37. Next, 1 ml of
0.1 M ethylenediaminetetraacetic acid (EDTA) was added
at room temperature for 5 min to disrupt cell adhesion.
The digested tissue samples were filtered through a 40-
lm nylon mesh to remove undigested fibrous material.
All subsequent steps were performed at room
temperature using HBSS without Ca2+ and Mg2+
(Sigma-Aldrich). Cells in the filtrates were recovered by
centrifugation, resuspended in 1068 g/cm3 OptiPrep
density gradient medium (Sigma-Aldrich) and centri-
fuged at 600 g for 15 min. The low-density fraction was
collected (2–4% of the total) and resuspended in mag-
netic antibody cell sorting (MACS) running buffer [PBS
with 0.5% bovine serum albumin (BSA) and 2 mM
EDTA] for subsequent purification.
Purification of DCs and T cells
CD11c (N418), CD90.2 (Thy1.2), CD4 (L3T4) and CD8
(Ly-2) microbeads were used for the isolation of the sple-
nic DCs, BM-DCs from cell cultures, Thy1.2+ T cells, and
CD4+ and CD8+ T cells from spleens, respectively,
according to the manufacturer’s instructions (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany). Briefly, cells
were labelled with 10 ll of microbeads per 1 · 107 cells
at 4 for 20 min and washed twice. The labelled cells were
subsequently separated using an autoMACS separator
(Miltenyi Biotec GmbH). The purities of the various cell
populations were determined by flow cytometry analysis.
The purity of DCs and Thy1.2+ T cells was above 97%
and 98%, respectively. The purity of OT-II CD4+ T cells
and OT-I CD8+ T cells was above 95% and 85%, respec-
tively (data not shown).
In vitro cell proliferation and cytokine production
assays
Thy1.2+ T cells were purified from spleen cells of
C57BL/6 mice by magnetic cell sorting. The purity of
Thy1.2+ T cells was above 95%. The purified Thy1.2+ T
cells were seeded in triplicate (1 · 105 per well) into a
96-well U-bottom plate in the presence or absence of
2 · 104 BM-DCs treated with mitomycin C (Roche Diag-
nostics GmbH, Mannherim, Germany). BM-DCs alone
were used as a control. All cells were treated with or
without Fve (20 lg/ml) and pulsed with [3H]-labelled
thymidine for the last 18 hr of cultures. The cells were
harvested and [3H]thymidine incorporation was mea-
sured by liquid scintillation counting at 72 hr. Super-
natants were collected and cytokine production was
measured by ELISA.
ELISA for anti-HPV-16 E7 antibodies
Mice were subcutaneously immunized with PBS, 20 lg of
HPV-16 E7 or 20 lg of HPV-16 E7 plus 20 lg of Fve at
days 0, 14 and 28. Sera were collected weekly for antibody
analysis by ELISA. For IgG1 analysis, a 96-well plate was
coated with HPV-16 E7 protein (5 lg per well) and incu-
bated at 4 overnight. The wells were then blocked with
blocking buffer (PBS containing 0.05% Tween-20 and 1%
BSA). Diluted sera were added and incubated at 4 over-
night. The plate was then incubated with biotin-conju-
gated anti-mouse IgG1 for 1 hr, followed by the addition
of ExtrAvidin-alkaline phosphatase (Sigma-Aldrich) for
another hour. The signal was developed by adding
p-nitrophenyphosphate substrate (Sigma-Aldrich) and read
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with a microplate reader at 405 nm (Tecan Group Ltd,
Ma¨nnedorf, Switzerland). It has been well established that
C57BL/6 mice express the Igh1-b gene, which encodes the
IgG2c isotype rather than IgG2a.24 Thus, the levels of
antigen-specific IgG2c in the mouse sera were detected
using an ELISA kit (Bethyl Laboratories, Montgomery,
TX) according to the manufacturer’s protocol.
Intracellular IFN-c production in T cells of
Fve-immunized mice
To investigate the HPV-16 E7-specific cellular immune
response, mice were subcutaneously immunized with
PBS, 20 lg of HPV-16 E7, or 20 lg of HPV-16 E7 plus
20 lg of Fve at days 0 and 14 and splenocytes were col-
lected at day 28. To determine the cytokine production
profiles of splenocytes in primary cultures, 5 · 105
splenocytes per well were stimulated with HPV-16 E7
protein for 72 hr and culture supernatants were collected
for cytokine assays by ELISA. To determine the cytokine
production profiles of T subsets by intracellular staining,
splenocytes were first cultured with 10 lg/ml HPV-16 E7
for 9 days, followed by secondary stimulation with anti-
CD3 and anti-CD28 antibodies prior to intracellular
staining with cytokine-specific antibodies. Recombinant
mouse IL-2 was added to the primary splenocyte cultures
at days 3 and 6 to a final concentration of 10 U/ml to
maintain the cells up to 9 days; these cultured cells from
mice within the same group were then pooled to set up
secondary cultures. Briefly, 2 · l05 cells were restimulated
with 5 lg/ml anti-mouse CD3 and 2 lg/ml anti-mouse
CD28 mAbs for 12 hr. Monensin (Sigma-Aldrich) was
added 6 hr before harvesting. Cells were surface-stained
with anti-CD8b and anti-CD4 mAbs, fixed with parafor-
maldehyde, permeabilized with saponin (Sigma-Aldrich)
and then stained intracellularly with anti-mouse IFN-c
mAb. Flow cytometric analysis was performed using a
FACSCalibur with CELL QUEST software (BD Biosciences,
San Jose, CA).
In vivo tumour protection and depletion assays
Mice were subcutaneously immunized with PBS, 20 lg of
HPV-16 E7, 20 lg of Fve, or 20 lg of HPV-16 E7 plus
20 lg of Fve at days 0, 14 and 28. TC-1 cells (5 · l04)
were inoculated into the right flank of a mice at day 30.
To deplete CD4+ T cells, CD8+ T cells or IFN-c, mice
were intraperitoneally injected with 800 lg of anti-CD4,
500 lg of anti-CD8 or 500 lg of anti-IFN-c mAbs respec-
tively at days )4, )1, 6, 13, 20, 27, 34, 41 and 48.
Tumour size was measured every 2 days in two perpen-
dicular dimensions and expressed as length · width
(mm2) and the survival was monitored. The depletion of
CD4+ and CD8+ T cells was assessed at day 6 after the
first immunization, and the depletion in the spleen was
> 95% as determined by flow cytometric analysis. Scien-
tists performing the analyses of tumour size and survival
rates were blinded to the treatments.
In vivo tumour therapeutic assay
Mice were subcutaneously inoculated with 5 · l04 TC-1
cells in the right flank at day 0. Mice were then subcuta-
neously immunized with PBS, 20 lg of HPV-16 E7,
20 lg of Fve, or 20 lg of HPV-16 E7 plus 20 lg of Fve
at days 3, 10 and 17. For tumour metastasis therapeutic
assay, mice were intravenously injected with 2 · l04 TC-1
cells in the tail vein at day 0. Mice were then subcutane-
ously immunized with the same regimen at days 3, 10
and 17. The survival rates were monitored daily.
T-cell adoptive transfer
Splenocytes from immunized mice were collected and
Thy 1.2+ T cells were isolated using Thy1.2 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) for cell
transfer experiments. The purity of T cells was above
98% as determined by flow cytometric analysis. Freshly
purified Thy1.2+ T cells (8 · 106) were adoptively
transferred into recipient mice at days )1, 3, 6 and 9.
Recipient mice were inoculated subcutaneously in the
right flank with 5 · 104 TC-1 cells at day 0. The
tumour size was measured on alternate days from day
10 onwards.
Analysis of in vivo activation of DCs
Mice were intravenously injected with PBS or 20 lg of
Fve. Twelve hours later, enriched splenic DCs (1 · 106
cells in 100 ll) were blocked with anti-CD16/CD32 mAb
at 4 for 20 min prior to incubation with mAbs against
CD4, CD8, CD11c and I-Ab and with mAbs against CD4,
CD8, CD11c and CD86 at 4 for 25 min. Flow cytometric
analysis was performed using a FACSCalibur with CELL
QUEST software (BD Biosciences).
Analysis of DC-directed CD4+ and CD8+ T-cell
activation
Naı¨ve C57 BL/6 mice were intravenously injected with
PBS, 100 lg of ovalbumin (OVA), 20 lg of Fve, or OVA
(100 lg) plus Fve (20 lg) 24 hr prior to isolation of the
CD11c+ DCs. Purified CD11c+ DCs were pulsed with
1 lM of OVA323–339 peptide or 1 lM of OVA257–264 pep-
tide, respectively (AnaSpec, Inc., San Jose, CA), for 2 hr
at 37 and then washed extensively. Naı¨ve CD4+ and
CD8+ cells were purified from OT-II and OT-I transgenic
mice, respectively. DCs (5 · 103 cells) were incubated
with 5 · 104 CD4+ T cells or 5 · 104 CD8+ T cells,
respectively, in U-bottom 96-well plates in 200 ll of
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complete RPMI-1640 medium in triplicate for 72 hr.
Supernatants were collected and cytokine production was
determined by ELISA.
Statistical analysis
Results for tumour sizes are presented as mean ± stan-
dard error of the mean (SEM) and were analysed by
one-way analysis of variance (ANOVA). Differences in
antibody and cytokine production between groups were
analysed by Student’s t-test. In tumour protection, thera-
peutic and adoptive transfer experiments, the tumour-free
and survival analyses were carried out using the Kaplan–
Meier analysis and the log-rank test. P < 005 was consid-
ered as statistically significant.
Results
Fve stimulated mouse T-cell proliferation and IFN-c
production in vitro
To examine the immunostimulatory effect of Fve in vitro,
mouse splenocytes were cultured in the presence of
increasing concentrations of the Fve protein. As shown in
Fig. S1(a and b), Fve induced the proliferation of spleno-
cytes in a dose-dependent manner and significant produc-
tion of IFN-c and TNF-a. Fve predominately stimulated
the proliferation of T cells in the splenocytes as cellular
proliferation was drastically reduced in T-cell-depleted
splenocytes (data not shown). Fve-induced T-cell prolifer-
ation and IFN-c production were accessory-cell-depen-
dent (Fig. 1 and Fig. S1c).
Coadministration of HPV-16 E7 plus Fve increased
HPV-16 E7-specific B-cell and T-cell activities
We next investigated the effects of Fve on the induction
of HPV-16 E7-specific immunity. Firstly, we measured
HPV-16 E7-specific antibodies in the sera of the various
groups of differentially immunized mice. As shown in
Fig. 2a,b, mice immunized with HPV-16 E7 plus Fve pro-
duced significantly higher levels of IgG1 and IgG2c as
compared with those immunized with HPV-16 E7 alone.
HPV-16 E7-specific IgG1 and IgG2c in mice immunized
with HPV-16 E7 plus Fve were 7-fold and 33-fold higher,
respectively, than those of mice immunized with HPV-16
E7 alone at day 28 (Fig. 2a,b). These results indicate that
Fve could enhance strong HPV-16 E7-specific humoral
immune responses.
Consistently, IFN-c production was significantly enhan-
ced in splenocytes from mice immunized with HPV-16 E7
plus Fve as compared with those from mice immunized
with HPV-16 E7 or PBS (Fig. 2c and Fig. S3). In order to
elucidate the IFN-c-producing T subsets, the HPV-16 E7
cultured primary cells were restimulated with anti-CD3
and anti-CD28 antibodies for 12 hr and cytokine produc-
tion was examined by intracellular staining. Flow cytometry
analysis revealed that 187% of IFN-c-producing cells
within the CD4+ T subset were induced in the HPV-16 E7
plus Fve co-immunized mice, whereas only 49% and 57%
of IFN-c+ cells were induced in HPV-16 E7 and PBS mice,
respectively (Fig. 2d, upper panel). Similarly, 378% of the
CD8+ T cells in the HPV-16 E7 plus Fve co-immunized
mice were IFN-c+ cells, whereas only 114% and 125% of
IFN-c+ CD8+ T cells were detected in HPV-16 E7 and PBS
mice, respectively (Fig. 2d, lower panel). These results
indicate that Fve could significantly increase HPV-16
E7-specific IFN-c-secreting CD4+ and CD8+ T cells.
Coadministration of HPV-16 E7 and Fve enhanced
protection of mice against tumour growth
The finding that immunization with HPV-16 E7 plus Fve
led to enhanced HPV-16 E7-specific immunity prompted
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Figure 1. Fve stimulates mouse splenic T-cell activation in an acces-
sory-cell-dependent manner. Purified CD90+ T cells (1 · 105 cells/
well) were co-cultured with mitomycin C-treated bone marrow-
derived dendritic cells (BM-DCs) (2 · 104 cells/well) in the presence
or absence of Fve (20 lg/ml) in triplicate using the 96-well plate.
The DCs and CD90+ T cells alone were included for comparison.
The cultures were pulsed with [3H]thymidine for the last 18 hr of
the co-culture. The cells were harvested and thymidine incorporation
was measured by liquid scintillation counting at 72 hr (a). The cul-
ture supernatants were collected at 72 hr and interferon (IFN)-c pro-
duction was measured by enzyme-linked immunosorbent assay
(ELISA) (b). *P < 005. c.p.m., counts per minute.
 2009 Blackwell Publishing Ltd, Immunology, 128, e881–e894 e885
Coadministration of FIP-Fve and HPV-16 E7 proteins enhanced antitumour immunity
nization regimen in vivo. Mice immunized with PBS,
HPV-16 E7, Fve, or HPV-16 E7 plus Fve were challenged
with TC-1 cells subcutaneously and tumour growth was
monitored. Results showed that 60% of mice co-immu-
nized with HPV-16 E7 plus Fve remained tumour-free for
up to 167 days after the tumour challenge, whereas only
20% of mice remained tumour-free (P < 005) in the
group immunized with HPV-16 E7 (Fig. 3a). Mice immu-
nized with PBS or Fve alone developed tumours rapidly
within 10 and 15 days after tumour challenge, respectively
(Fig. 3a). Interestingly, mice immunized with Fve alone
generally showed a reduction in tumour size as compared
with the PBS control mice (Fig. 3b). This suggests that
Fve protein alone could confer partial suppression of
tumour growth. However, such a suppressive effect was
insufficient to protect mice against tumour formation in
the absence of HPV-16 E7-specific immune responses as
only mice in the group immunized with HPV-16 E7 plus
Fve exhibited a low tumour burden or remained tumour-
free over the total duration of this study.
To determine whether long-term HPV-16 E7-specific
immunity could be established in the immunized mice,
splenocytes from tumour-free mice (HPV-16 E7 alone or
HPV-16 E7 plus Fve groups) were collected and stimu-
lated with HPV-16 E7 protein in vitro 167 days after
tumour challenge. Splenocytes from naı¨ve mice were used
as the negative control. Results showed that, upon HPV-
16 E7 antigen stimulation, splenocytes from HPV-16 E7
plus Fve co-immunized mice still produced higher levels
of IFN-c as compared with those from HPV-16 E7-
immunized mice (Fig. 3c). Hence, Fve-enhanced HPV-16
E7-specific immunity persisted in the co-immunized mice
and may account for the long-term protection against
tumour formation. Taken together, these data indicate
that immunization with Fve plus HPV-16 E7 is not only
more effective than immunization with HPV-16 E7 alone;
it is also able to confer long-term protection against
tumour formation in the co-immunized mice.
Therapeutic immunization of HPV-16 E7 and Fve
suppressed tumour growth and prolonged the survival
of tumour-bearing mice
We also determined whether coadministration of HPV-16
E7 and Fve was equally effective at suppressing the
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Figure 2. Fve enhanced human papillomavirus (HPV)-16 E7-specific antibody production and up-regulated interferon (IFN)-c production of
in vitro HPV-16 E7-stimulated T cells. For the HPV-16 E7-specific humoral immune response, mice (n = 5 per group) were immunized with
phosphate-buffered saline (PBS) (r), HPV-16 E7 ( ) or HPV-16 E7 plus Fve ( ) at days 0, 14 and 28. Sera were collected weekly for the mea-
surement of HPV-16 E7-specific (a) immunoglobulin G1 (IgG1) and (b) IgG2c by enzyme-linked immunosorbent assay (ELISA). For the T-cell
immune response, mice (n = 5 per group) were immunized with PBS (r), HPV-16 E7 ( ), and HPV-16 E7 plus Fve ( ) at days 0 and 14.
Splenocytes were collected at day 28 and cultured with 1, 10 or 20 lg/ml HPV-16 E7. Supernatants were collected at 72 hr and IFN-c levels were
measured by ELISA (c). For intracellular staining, the HPV-16 E7 cultured primary T cells were restimulated with anti-CD3 and anti-CD28 anti-
bodies for 12 hr. The numbers in the upper right quadrant indicate the percentage of IFN-c+ cells among the gated CD4+ cells and CD8+ cells,
respectively (d). Data are representative of three independent experiments. Error bars represent the standard error of the mean. *P < 005.
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experiments, TC-1 cells were inoculated into the left
flanks of mice 3 days prior to regular treatments with
PBS, HPV-16 E7, Fve, and HPV-16 E7 plus Fve, respec-
tively. Results showed that mice treated with HPV-16 E7
plus Fve had the highest tumour survival rate (Fig. 4a).
Further investigations were then carried out in a
tumour metastasis model established by injecting TC-1
cells intraveneously into the tail vein of each mouse at
day 0. Mice were then treated with same regimens. As
shown in Fig. 4b, none of the mice in the groups immu-
nized with PBS, Fve or HPV-16 E7 alone survived beyond
55 days, while mice treated with HPV-16 E7 plus Fve
showed significantly prolonged survival for up to
120 days. These results indicate that Fve could signifi-
cantly enhance HPV-16 E7-specific antitumour activity
therapeutically.
In summary, the results of these series of proof-of-prin-
ciple experiments strongly support the notion that Fve
could enhance an antigen-specific immune response that
not only confers long-term protection against tumour
growth but also retards tumour growth at the early and
advanced stages of tumour development.
Both CD4+ and CD8+ T-cell subsets and IFN-c were
essential for protection against tumours
As Fve significantly increased IFN-c-secreting T cells and
enhanced HPV-16 E7-specific antitumour immunity, we
next performed in vivo antibody depletion assays to deter-
mine the roles of the T-cell subsets and IFN-c in the anti-
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Figure 3. Co-immunization with human papillomavirus (HPV)-16
E7 and Fve enhanced protection against the growth of TC-1
tumours. Mice (n = 10 per group) were immunized with phosphate-
buffered saline (PBS) (r), 20 lg of HPV-16 E7 ( ), 20 lg of Fve
(·) or 20 lg of HPV-16 E7 plus 20 lg of Fve ( ) at days 0, 14 and
28 and then inoculated subcutaneously with TC-1 cells at day 30.
The mice were monitored daily for tumour growth by palpation (a)
and the tumour size was measured every 2 days (b). One hundred
and sixty-seven days after tumour challenge, splenocytes were col-
lected from the tumour-free mice and cultured with HPV-16 E7 pro-
tein in vitro. Supernatants were collected at 72 hr and interferon
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Figure 4. Human papillomavirus (HPV)-16 E7 plus Fve co-immuni-
zation therapeutically extended the survival of tumour-bearing mice.
For the therapeutic assay (a), mice (n = 10 per group) were inocu-
lated subcutaneously with TC-1 cells on day 0 and then treated with
phosphate-buffered saline (PBS) (r), HPV-16 E7 ( ), Fve (·) or
HPV-16 E7 plus Fve ( ) at days 3, 10 and 17. For the therapeutic
metastasis assay (b), mice (n = 5 per group) were intravenously
injected with TC-1 cells. Their survival was monitored and analysed
by log-rank test.
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expected, 60% of the HPV-16 E7 plus Fve co-immunized
mice without any depletions remained tumour-free
throughout the duration of this part of the study (Fig. 5a),
while the tumours that developed in the remaining 40% of
these mice were dramatically reduced in size (Fig. 5b). In
contrast, all the mice depleted of CD4+ T cells, CD8+ T cells
or IFN-c developed tumours within 27 days. Interestingly,
mice depleted of CD8+ T cells had similar tumour sizes to
the PBS control, whereas tumour growth was retarded in
the mice depleted of CD4+ T cells and of IFN-c (Fig. 5b).
These data suggested that, while CD8+ T cells, CD4+ T cells
and IFN-c are essential for the antitumour protection gen-
erated in mice co-immunized with HPV-16 E7 plus Fve,
the CD8+ T subset plays a more dominant role in these
antitumour effects.
To further investigate the roles of T cells in the anti-
tumour effects seen in the HPV-16 E7 plus Fve co-
immunized mice, a T-cell adoptive transfer experiment
was set up. The immunization and tumour challenge regi-
men was as detailed in Fig. 6a. Mice that received T cells
from co-immunized mice showed a significant reduction
in tumour growth (Fig. 6b) compared with those receiv-
ing T cells adoptively transferred from donor mice immu-
nized with HPV-16 E7, Fve and PBS, respectively. These
data support the notion that T cells play a pivotal role in
therapeutic antitumour effects and such effects are proba-
bly directly correlated to the efficacy and magnitude of
the HPV-16 E7-specific T-cell responses, as demonstrated
in Fig. 2c,d.
Fve stimulated phenotypic maturation of splenic DCs
in vivo and enhanced CD8+ T-cell activation
To elucidate the mechanism of the adjuvant action of
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Figure 5. CD4+ and CD8+ T cells and interferon (IFN)-c were essen-
tial for protection against tumours in mice immunized with human
papillomavirus (HPV)-16 E7 plus Fve. Mice (n = 10 per group) were
immunized with phosphate-buffered saline (PBS) or 20 lg of HPV-
16 E7 plus 20 lg of Fve at days 0, 14 and 28. TC-1 cells (5 · l04)
were inoculated subcutaneously into the right flanks of mice at day
30. To deplete CD4+ T cells ( ), CD8+ T cells (·) or IFN-c (-), mice
immunized with HPV-16 E7 plus Fve were injected intraperitoneally
with anti-CD4, anti-CD8, or anti-IFN-c monoclonal antibodies
(mAbs), respectively, at days )4, )1, 6, 13, 20, 27, 34, 41 and 48.
Mice immunized with PBS (r) and HPV-16 E7 plus Fve ( ) with-
out depletion were included as the control groups. The mice were
monitored daily for tumour growth by palpation (a) and the tumour
size was measured every 2 days (b). Error bars represent the standard
error of the mean.
s.c. TC-1 
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Figure 6. Adoptive transfer of T cells from mice immunized with
human papillomavirus (HPV)-16 E7 plus Fve retarded tumour
growth and prolonged survival. Eight million T cells purified from
mice immunized with phosphate-buffered saline (PBS) (r), HPV-16
E7 ( ), Fve (·) or HPV-16 E7 plus Fve ( ) were adoptively trans-
ferred to recipient mice at days )1, 3, 6 and 9. Recipient mice
(n = 10 per group) were inoculated subcutaneously with 5 · 104
TC-1 cells at day 0 (a). Ten days after the tumour challenge, the size
of the tumour formed was measured on alternate days. Data are pre-
sented as mean ± standard error of the mean (b).
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are responsible for the priming of the specific immune
response.25,26 To this end, splenic CD11c+ DCs were
enriched from spleens of mice which were intravenously
injected with Fve prior to harvest and analysed for surface
expression of major histocompatibility complex (MHC)
class II and CD86. As shown in Fig. 7c, DCs isolated
from Fve-treated mice up-regulated MHC-II and CD86
molecules in both CD11chi and CD11cint subsets as com-
pared with those from control mice. CD11chi DCs can be
further subdivided into CD4+, CD8a+ and CD4) CD8a)
subtypes (Fig. 7b). Up-regulation of MHC-II and CD86
was seen in all three subtypes of CD11chi DCs (Fig. 7d),
especially in the CD8a+ DCs. This indicates that Fve stim-
ulates phenotypic maturation of splenic DCs in vivo. Sub-
sequently, the in vitro functional assays for these Fve-
stimulated DCs were performed using OVA-specific CD8+
and CD4+ T cells from OT-I and OT-II mice, respec-
tively. Analysis of culture supernatants of OVA-specific
CD8+ T cells co-cultured with OVA-laden DCs isolated
from OVA plus Fve co-injected mice showed that produc-
tion of IFN-c and IL-2 was greatly increased compared
with those from all the other experimental control groups
(Fig. 8a). Such a marked enhancement of IFN-c and IL-2
production by OVA-specific CD4+ T cells was not
observed in similar parallel functional assays performed
using CD4+ T cells from OT-II mice (Fig. 8b). There was
no increased induction of IL-4, the signature cytokine for
Th2 responses, by either CD4+ or CD8+ OVA-specific T
cells. These data suggest that Fve can efficiently enhance
the OVA-specific CD8+ T-cell immune response, probably
by modifying the ability of DCs to present antigen.
Discussion
Antigen-specific immunotherapy is a promising strategy
to eradicate systemic tumours at multiple sites while con-
ferring the advantage of specific discrimination between
neoplastic and non-neoplastic cells. However, a major
hurdle for the development of such vaccines for treatment
and prevention of cancer is the poor immunogenicity of
tumour-associated antigens. An attractive strategy to
overcome this problem is the use of an immune modula-
tor as an adjuvant to boost antigen-specific immunity
and enhance the efficacy of tumour vaccines.27
Our in vivo tumour protection results showed that 60%
of the mice co-immunized with HPV-16 E7 plus Fve
remained tumour-free after tumour challenge as com-
pared with only 20% of mice immunized with HPV-16
E7 alone (Fig. 3). More importantly, the enhanced anti-
tumour effects induced by HPV-16 E7 plus Fve co-immu-
nization were also observed in the therapeutic tumour
model (Fig. 4). These data indicate that HPV-16 E7 plus
Fve co-immunization is more efficacious for the protec-
tion of mice against tumour challenge and the eradication
of established tumours, and that Fve enhances antitumour
effects. It is conceivable that the enhanced HPV-16 E7-
specific T-cell immunity and increased IFN-c production

































Figure 7. Fve induced splenic dendritic cell
(DC) phenotypic maturation in vivo. Mice
(n = 8 mice/group) were intraveneously
injected with phosphate-buffered saline (PBS)
or Fve 12 hr prior to cell harvest. DCs were
enriched from spleens for staining of major
histocompatibility complex (MHC) class II and
CD86. Splenic DCs were separated into
CD11cint and CD11chi populations (a) and
CD11chi DCs were further divided into CD4+,
CD8a+ and CD4) CD8a) subpopulations (b).
MHC class II and CD86 up-regulation could
be seen in both CD11cint and CD11chi popula-
tions (c) and the three CD11chi subpopulations
of DCs (d) after stimulation with Fve in vivo.
Open histograms delineated with a dark line
represent PBS-stimulated DCs, and filled grey
histograms represent Fve-stimulated DCs. The
numbers in the histograms indicate the mean
fluorescent intensities (MFIs) of DCs stimu-
lated with PBS (upper number) and Fve (lower
number), respectively.
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in part, to the enhanced antitumour effects observed in
this study.
It is well known that antigen-specific T-cell immunity
plays a critical role in tumour immunotherapy.28 Previous
studies using other adjuvants such as heat shock protein
65,9 bacteria exotoxin,11 IL-12,7 CpG12 and 3-O-deacylated
monophosphoryl lipid A (MPL) mixed with a purified
Quillala saponaria saponin immunologic adjuvant
(QS21)29 found that CD4+ and/or CD8+ cells play major
roles in protecting animals from challenge with HPV-16
E7-expressing TC-1 cells. In this study, we performed
in vivo T-cell subset depletion assays to elucidate the
contribution of CD4+ and CD8+ T cells to antitumour
activity. We found that both T-cell subsets are essential
for the inhibition of tumour growth and CD8+ T cells
appear to play a more dominant role in protection against
tumours. These results concur well with the conventional
dogma that CD8+ T cells are pivotal and highly specialized
for cytolytic function and thus have been the main focus
of cancer immunotherapy, whereas CD4+ T cells confer
helper functions in the antitumour effect by providing
activation signals to CD8+ T cells30,31 and contributing to
the survival maintenance of CD8+ T memory cells.32–36
Recent studies, however, found that tumour-specific CD4+
T cell were able to eliminate a wide variety of tumours
that were resistant to CD8-mediated rejection,37,38 provid-
ing new supporting evidence for the hypothesis that CD4+
T cells may play a broader role in antitumour responses.
Moreover, we found that tumour-free mice protected by
immunization with HPV-16 E7 plus Fve had higher levels
of IFN-c production at 167 days after tumour inoculation
(Fig. 3c), indicating that Fve enhances HPV-16 E7-specific
memory immunity to protect mice against tumour
growth. These findings are important because the capacity
to elicit an effective long-term memory immune response
is essential for the success of a vaccination strategy.39–41
We also adoptively transferred total T cells from HPV-
16 E7 plus Fve immunized mice into tumour-bearing
recipient mice to address the importance of T cells in
mediating the antitumour effects seen in our study.
Results indicated that T cells from mice immunized with
HPV-16 E7 plus Fve were more efficacious in suppressing
tumour growth than those from mice immunized with
HPV-16 E7 alone (Fig. 6b). This enhanced efficacy was
probably correlated to the increased number of HPV-16
E7-specific effector T cells induced by co-immunization.
However, other possibilities, such as increased HPV-16
E7-specific T-cell avidity, cannot be excluded as antigen-
specific CD8+ T cells with high avidity are known to pro-
duce stronger antitumour effects in vaccinated mice than
low-avidity CD8+ T cells.42,43 In recent years, adoptive
transfer of antigen-specific T cells into patients has
emerged as a promising new approach to cancer treat-
ment.44–46 Our T-cell transfer data suggest that the Fve
protein may be a good immunotherapeutic vaccine adju-
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Figure 8. Fve greatly enhanced antigen-specific responses of CD8+ T cells. Mice (n = 8 mice/group) were intraveneously injected with phos-
phate-buffered saline (PBS), ovalbumin (OVA), Fve or OVA plus Fve and the dendritic cells (DCs) were isolated from the pool of eight spleens
harvested from each group of mice 24 hr later. Purified DCs were pulsed with 1 lm OVA257–264 peptide or 1 lm OVA323–367 peptide for 2 hr at
37 and washed three times before co-culturing with CD8+ T cells from OT-I mice or CD4+ T cells from OT-II mice, respectively, for 72 hr.
Supernatants were collected for cytokine assays by enzyme-linked immunosorbent assay (ELISA). The experiments were performed three times
and representative data from one of these experiments are presented. DC, dendritic cells alone; DC:CD8 = 1 : 10, the ratio of DCs to CD8+ T
cells from OT-I mice is 1 : 10; DC:CD4 = 1 : 10, the ratio of DCs to CD4+ T cells from OT-II mice is 1 : 10.
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tumour antigen-specific T cells, thereby providing a
promising new strategy to improve the efficacy of the
adoptive cell therapy approach.
In addition, we found that HPV-16 E7 plus Fve
co-immunization significantly up-regulated HPV-16 E7-
specific IgG1 and IgG2c. The enhanced production of
IgG2c in C57BL/6 (Fig. 2b) and IgG2a in BALB/cJ mice
(Fig. S2b) was consistent with the previous finding that
Fve can increase the Th1-skewed humoral OVA-specific
immune response.20 Previous studies using the NY-ESO-1
tumour antigen as a model antigen have shown that anti-
gen-specific IgG2a antibodies contribute to DC matura-
tion and cross-priming of CD8+ T cells, probably through
a mechanism mediated by antigen–antibody immune
complexes.47,48 Although there is no direct evidence that
antibody-mediated responses play an important role in
controlling HPV-associated malignancies, a possible role
of increased production of HPV-16 E7-specific antibody,
which may improve antitumour activity, cannot be ruled
out and warrants further study.
IFN-c has been shown to inhibit tumour growth in vivo
by up-regulation of MHC class I molecules, inducing
inflammation at tumour sites as well as eliciting an angio-
static effect.49–54 Our study also demonstrated that IFN-c
was critical for generating potent antitumour effects
against TC-1 tumour challenge. We found that the
tumour protection effect of the HPV-16 E7 plus Fve vac-
cine was significantly attenuated in IFN-c-depleted mice
(Fig. 5). These results are consistent with previous studies
demonstrating the important role of IFN-c in the anti-
tumour effect.51,53,55,56 Interestingly, we found that the
mean tumour size of HPV-16 E7 plus Fve-immunized
mice with IFN-c depletion was smaller than that of PBS-
immunized mice (Fig. 5b), suggesting that additional
IFN-c-independent mechanisms may also contribute to
the suppression of tumour growth found.
It is worth noting that the Fve protein alone conferred
some antitumour effects compared with the effects of PBS
(Fig. 3b). This interesting observation may be explained
by the fact that the Fve protein mitogenically expands the
T-cell pool and induces high levels of IFN-c production
(Fig. 1), creating a microenvironment to confer partial
antitumour effects. This may also represent an additional
beneficial effect of using Fve as an adjuvant for antitu-
mour immunotherapeutic vaccines.
It is well known that activation of innate immunity is a
prerequisite for an adjuvant function.57 The roles of DCs in
the priming and differentiation of naı¨ve T cells are well
recognized.26 The majority of adjuvants are microbial
products that activate innate responses through pattern
recognition receptors, such as Toll-like receptors (TLRs) on
DCs. For example, monophosphoryl lipid A, imiquimod
and CpG motifs, which are agonists for TLR4, TLR7 and
TLR9, respectively, have been developed as vaccine adju-
vants for the treatment of cancer.58,59 In this study, we
found that Fve induced maturation of DCs in vivo and,
notably, it appears that Fve preferentially, although not
exclusively, drives maturation of the CD8+ DC subset.
Moreover, in vitro functional assays using OVA-specific
CD8+ T cells from OT-I mice clearly showed that DCs from
mice co-immunized with Fve and OVA greatly enhanced
the activation of antigen-specific CD8+ T cells (Fig. 8a). It
is well known that there are at least three distinct subsets
(CD4+ CD8), CD4) CD8+ and CD4) CD8)) of DCs found
in the mouse spleen. Previous studies have shown that these
subsets exhibit intrinsic differential capacities to present
soluble antigen and activate antigen-specific CD4+ and
CD8+ T subsets. The CD8) subsets show the greatest ability
to stimulate antigen-specific MHC class II-restricted CD4+
T cells, whereas the CD8+ DCs are much more efficient at
cross-presenting antigen and stimulating MHC class
I-restricted CD8+ T cells.60,61 Taking these findings
together, it is reasonable to propose that Fve modifies the
ability of DCs (for example, by up-regulating the CD8+ DC
subset to enhance CD8+ T cells via the cross-presentation
pathway) to generate robust and long-lasting HPV-16
E7-specific CD8+ T-cell immune responses for antitumour
effects. This may be a unique feature of the adjuvant effects
of Fve and therefore further work is warranted to validate
this notion. Thus, our future research will focus on elucida-
tion of the effects of Fve on the various DC subsets and
the subsequent priming and polarization of antigen-specific
T-cell subsets.
In summary, our study has demonstrated for the first
time that an immunomodulatory protein, Fve, exhibited
effective adjuvant effects to enhance robust and long-lasting
adaptive antigen-specific immune responses that conferred
strong prophylactic and therapeutic antitumour effects.
Notably, it appears that, by targeting CD8+ DCs, Fve can
effectively enhance antigen-specific CD8+ T-cell immune
responses. For HPV-associated malignancies, prophylactic
vaccines which aim to induce neutralizing antibodies have
been successfully used in clinical applications.62,63 How-
ever, the challenge for the future is to combine the prophy-
lactic approach with therapeutic immunization, for
example, combining E7 with the HPV capsid protein L1 or
L2 to develop chimeric vaccines.64–66 We envisage that Fve
could potentially be an effective adjuvant not only for such
HPV chimeric vaccines; it could also be generally exploited
to develop other efficacious anticancer or antiviral vaccines.
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